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   Loss-­‐of-­‐function	  mutations	  in	  the	  filaggrin	  gene	  (FLG)	  have	  recently	  been	  
shown	  to	  be	  strongly	  associated	  with	  atopic	  dermatitis	  (AD).	  The	  overall	  aim	  of	  
this	  study	  was	  to	  explore	  the	  role	  of	  filaggrin	  in	  skin	  barrier	  function	  and	  AD.	  	  
	  
	   There	  were	   two	  main	   focuses	   in	   this	   study.	   The	   first	   was	   a	   functional	  
study	  whose	   primary	   objective	  was	   to	   determine	   if	  FLG	  mutations	   correlated	  
with	  skin	  barrier	  dysfunction	  in	  AD.	  Fifty-­‐five	  mild	  to	  moderate	  AD	  individuals	  
were	   recruited,	   genotyped	   and	   had	   their	   skin	   barrier	   assessed	   using	   three	  
different	  measures	   -­‐	   transepidermal	  water	   loss	   (TEWL),	   skin	   capacitance	   and	  
the	  number	  of	  tape	  strips	  required	  to	  abrogate	  skin	  barrier.	  A	  secondary	  aim	  of	  
this	   functional	   study	   was	   to	   test	   the	   hypothesis	   that	   corneocytes	   were	   less	  
adherent	  to	  one	  another	  in	  filaggrin-­‐related	  AD	  compared	  to	  wild-­‐type	  AD	  skin.	  	  
	  
	   The	   second	   main	   focus	   of	   this	   thesis	   was	   a	   structural	   study	   aimed	   at	  
interrogating	   the	   structure-­‐function	   relationship	   of	   filaggrin.	   Filaggrin	   protein	  
was	   extracted	   and	   purified	   from	   a	   total	   of	   21	   AD	   and	   non-­‐AD	   subjects	   and	  
analysed	   using	   mass	   spectrometric	   techniques.	   Specifically,	   matrix	   assisted	  
laser	   desorption/ionisation	   time-­‐of-­‐flight	   (MALDI-­‐TOF)	   mass	   spectrometry	  
(MS)	   and	   nano	   liquid	   chromatography	   tandem	  MS	   (LC-­‐MS/MS)	  were	   utilised.	  
Part	   of	   this	   structural	   study	   also	   involved	   developing	   and	   optimising	   the	  
extraction	   and	   purification	   of	   filaggrin	   protein,	   including	   a	   novel	   way	   of	  
extracting	  filaggrin	  from	  skin	  using	  tape	  stripping.	  In	  addition,	  a	  novel	  filaggrin-­‐
specific	   enzyme-­‐linked	   immunosorbant	   assay	   (ELISA)	   was	   also	   developed,	  
which	  could	  serve	  as	  a	  useful	  screening	  test	  for	  the	  protein.	  
	  
	   In	  this	  study,	  FLG	  mutations	  were	  found	  to	  correlate	  with	  higher	  TEWL	  
and	  fewer	  number	  of	  tape	  strips	  required	  to	  abrogate	  skin	  barrier,	  but	  not	  with	  
skin	   capacitance.	   FLG	   mutations	   were	   also	   not	   shown	   to	   correlate	   with	   AD	  
severity.	  The	  mean	  amount	  of	  protein	  extracted	  from	  filaggrin-­‐related	  AD	  skin	  
vi	  
was	   also	   significantly	   higher	   compared	   to	   wild-­‐type	   AD	   skin,	   supporting	   the	  
hypothesis	  that	  corneocytes	  were	  less	  adherent	  to	  one	  another	  (and	  therefore,	  
densely	  packed)	  in	  filaggrin-­‐related	  AD	  skin.	  MS	  analysis	  of	  filaggrin	  confirmed	  
the	   heterogeneic	   nature	   of	   filaggrin	   protein,	   even	   within	   a	   single	   individual.	  
Interestingly,	   this	   structural	   study	   also	   showed	   that	   filaggrin	   was	   only	  
minimally	  expressed	  in	  the	  skin	  of	  all	  the	  AD	  individuals	  studied,	  whether	  or	  not	  
they	   possessed	   any	   FLG	   mutation.	   Due	   to	   the	   limited	   amount	   of	   filaggrin	  
extracted	   from	  AD	  skin,	   it	  was	  not	  possible	   to	  conduct	   comparative	  structural	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1.0	   INTRODUCTION	  
	  
	   The	   skin	   is	   one	   of	   the	   largest	   organs	   in	   the	   human	   body,	   and	   serves	  
multiple	   functions.	   As	   it	   is	   the	  main	   interface	   between	   an	   individual	   and	   the	  
environment,	   its	   primary	   role	   is	   that	   of	   a	   protective	   barrier	   between	   the	  
environment	  and	   the	   internal	  milieu,	  minimising	  water	   loss	  outwards	   (inside-­‐
outside	   barrier)	   while	   preventing	   entry	   of	   allergens,	   irritants	   and	   pathogens	  
(outside-­‐inside	  barrier).	  During	  terminal	  differentiation,	  the	  keratinocytes	  (the	  
predominant	   cell	   type	   of	   the	   epidermis)	   undergo	   a	   series	   of	   well-­‐defined	  
morphological	   and	   biochemical	   changes	   during	   which	   actively	   dividing	   basal	  
cells	   differentiate	   through	   the	   spinous	   and	   granular	   cell	   layers	   to	   eventually	  
form	  the	  uppermost	  (cornified)	  layer	  of	  the	  epidermis,	  or	  stratum	  corneum	  (SC)	  
[1].	   This	   layer	   consists	   of	   anucleated	   squame	   cells,	   and	   together	   with	   lipid-­‐
enriched	   intercellular	  domain,	   form	   the	  main	  permeability	  barrier	  of	   the	   skin.	  
(Figure	  1.1)	  
	  
	   Diseases	  of	  the	  skin	  are	  very	  common,	  with	  atopic	  dermatitis	  (AD)	  being	  
one	   of	   the	   commonest	   in	   developed	   countries.	   AD	   is	   a	   chronic	   skin	   disease	  
characterised	   by	   pruritus	   and	   inflammation.	   It	   affects	   up	   to	   20	  %	   of	   children	  
and	  up	  to	  10	  %	  of	  adults	  [2]	  and	  therefore	  represents	  an	  enormous	  burden	  on	  
health	  care,	  particularly	  when	  its	  prevalence	  appears	  to	  be	  increasing	  in	  recent	  
decades	  [3].	  
	  
	   The	  predisposition	  of	  AD	  is	  known	  to	  be	  highly	  heritable,	  as	  evidenced	  by	  
twin	   studies	   showing	   concordance	   rates	   of	   0.72-­‐0.86	   for	  monozygotic	   versus	  
0.21-­‐0.23	   for	  dizygotic	   twins	   [4-­‐7].	  AD,	   as	  well	   as	   the	  other	   features	  of	   atopy,	  
also	  shows	  clustering	  within	  families	  [8].	  Genome-­‐wide	  association	  studies	  have	  
identified	   several	   hot	   spots,	   but	   due	   to	   poor	   replication	   of	   these	   studies,	   it	   is	  
believed	  that	  a	  complex	  interplay	  for	  different	  genes	  and	  environmental	  stimuli	  
underlies	   the	   disease	   [9].	   Nonetheless,	   Cookson	   et	   al	   identified	   statistically	  
significant	   genetic	   linkage	   with	   polymorphic	   markers	   within	   the	   epidermal	  
3	  




Figure 1.1 Diagram showing keratinocytes through the different stages of epidermal 
differentiation. Actively proliferating keratinocytes in the stratum basale differentiate and 
move upwards through the spinous and granular layers to eventually form the anucleated 
squame cells of the stratum corneum.	  
	  
	  
	   A	   consistent	   feature	  of	  AD	   is	   a	  TH2-­‐dominated	   cytokine	  milieu	   [11-­‐13].	  
As	   such,	  particularly	   in	  view	  of	   the	  marked	   inflammation	  of	   the	  disease,	  most	  
studies	   on	  AD	  pathogenesis	   have	   focused	   on	   the	   putative	   role	   of	   the	   immune	  
response.	  At	   the	   same	   time,	   there	   is	   evidence	   for	  many	   years	   that	   a	   defective	  
skin	   barrier	   is	   present	   in	   AD.	   Evidence	   of	   this	   is	   shown	   in	   increased	  
transepidermal	   water	   loss	   [14-­‐16],	   increased	   permeability	   to	   exogenous	  
substances	   [17-­‐19]	   and	   decreased	   skin	   hydration	   [15,	   20,	   21].	   However,	   the	  
most	   important	   evidence	   for	   barrier	   dysfunction	   having	   a	   role	   in	   AD	  
4	  
pathogenesis	  came	  in	  2006,	  when	  McLean’s	  group	  at	  the	  University	  of	  Dundee	  
showed	  a	  strong	  association	  of	  loss-­‐of-­‐function	  mutations	  in	  the	  gene	  encoding	  
filaggrin	  with	   AD	   [22,	   23].	   The	   group	   had	   initially	   studied	   ichthyosis	   vulgaris	  
(IV),	   and	   showed	   that	   this	   relatively	   common	   genodermatosis	   affecting	  
approximately	   one	   in	   250	   people	  was	   caused	   by	  mutation	   in	   the	   profilaggrin	  
gene,	  FLG.	  A	  link	  between	  IV	  and	  profilaggrin	  has	  long	  been	  suspected	  [24],	  but	  
the	  FLG	   gene	  had	  been	   technically	   too	  difficult	   to	  sequence	  until	   the	  McLean’s	  
group’s	  success	  in	  comprehensively	  analysing	  the	  gene.	  They	  showed	  that	  IV	  is	  
caused	   by	   two	   loss-­‐of-­‐function	   mutations	   in	   the	   FLG	   gene	   (R501X	   and	  
2282del4).	  The	  first	  is	  a	  nonsense	  mutation	  (where	  an	  arginine	  was	  replaced	  by	  
a	   stop	   codon),	   while	   the	   second	   is	   a	   frameshift	   mutation	   with	   a	   4-­‐base	   pair	  
deletion	  at	  position	  2282	  resulting	  in	  a	  premature	  stop	  codon	  [25].	  Due	  to	  the	  
semi-­‐dominant	   inheritance	   pattern	   of	   the	   gene,	   individuals	   who	   are	   either	  
homozygous	  or	  compound	  heterozygous	  for	  the	  gene	  fail	  to	  express	  detectable	  
filaggrin	   protein	   in	   the	   epidermis,	   while	   single	   heterozygotes	   will	   express	   a	  
reduced	  amount	  of	  the	  protein.	  	  Given	  the	  common	  co-­‐occurrence	  of	  IV	  with	  AD,	  
the	   group	   also	   subsequently	   showed	   that	   FLG	   gene	   mutations	   are	   a	   major	  
predisposing	  factor	  for	  AD,	  as	  well	  as	  asthma	  developing	  in	  association	  with	  AD	  
[22].	  
	  
	   The	  McLean	  group	  initially	  studied	  a	  cohort	  of	  Irish	  children	  with	  AD	  and	  
found	  that	  the	  combined	  allele	  frequency	  for	  the	  two	  prevalent	  loss-­‐of-­‐function	  
FLG	  mutations	  (R501X	  and	  2282del4)	  in	  the	  AD	  subgroup	  was	  0.330	  compared	  
to	  0.042	  in	  an	  unselected	  Irish	  control	  population.	  The	  LOD	  score	  (to	  the	  base	  
10)	   was	   estimated	   to	   be	   3.08	   –	   3.27	   [22].	   This	   association	   has	   since	   been	  
independently	   reproduced	   in	   more	   than	   25	   studies	   in	   European	   populations	  
[23,	  26-­‐35],	  with	  odds	  ratios	  between	  2.8	  and	  13.4.	  Only	  one	  Italian	  study	  had	  
so	   far	   fail	   to	   show	   an	   association,	   but	   the	   cohort	   studied	   had	   unusually	   low	  
frequencies	  of	  FLG	  mutations,	   thereby	   limiting	   it	  statistical	  power	  to	  detect	  an	  
association	  [36].	  To	  date,	  more	  than	  20	  loss-­‐of-­‐function	  FLG	  mutations	  (Figure	  






Figure 1.2 Schematic representation of the profilaggrin molecule illustrating the N-terminal 
domain, two partial filaggrin repeat domains flanking 10 almost identical filaggrin repeat 
domains, as well as the C-terminal domain. The locations of the loss-of-function FLG 
mutations identified to date are shown, all of which are either nonsense or out-of-frame 
deletion mutations. Variants highlighted in green are prevalent in European populations, 
while those in orange are common in individuals of Oriental ancestry [30].  
	  
	  
	   Reviewing	   the	   original	   Irish	   AD	   cohort	   in	   light	   of	   these	   additional	  
mutations	  showed	  that	  47%	  carried	  a	  filaggrin	  null	  allele	  [38].	  In	  cohorts	  where	  
eczema	  was	  milder,	   there	  was	  evidence	  that	  although	  the	  association	  was	   less	  
strong,	  FLG	  gene	  mutations	  were	  still	  a	  significant	  risk	  factor	  [42-­‐44].	  Therefore,	  
it	  appeared	  that	  filaggrin-­‐related	  AD	  had	  an	  earlier	  onset,	  was	  more	  persistent,	  
and	  was	  strongly	  associated	  with	  atopic	  features	  such	  as	  asthma	  [31,	  35,	  45].	  
	  
	   Non-­‐European	  populations	  had	  also	  been	  shown	  to	  carry	  FLG	  mutations,	  
although	   these	  were	  different	   variants	   to	   the	   common	  European	  ones	   (Figure	  
1.2).	   Studies	   looking	   at	   these	   populations	   similarly	   showed	   significant	  





1.1 Profilaggrin	  structure	  and	  function	  
	  
	   The	  EDC	  on	   chromosome	  1q21	   consists	   of	   three	   gene	   families	   that	   are	  
expressed	  late	  in	  human	  epidermal	  differentiation	  [48].	  They	  encode	  precursor	  
proteins	   of	   the	   cornified	   cell	   envelope	   (CE),	   calcium-­‐binding	   proteins	   and	  
intermediate	   filament-­‐associated	   proteins	   [49,	   50].	   	   Profilaggrin	   is	   one	   of	   the	  
intermediate	   filament-­‐associated	   precursor	   proteins	   [24,	   51,	   52],	   and	   is	   the	  
main	  constituent	  of	  the	  keratohyalin	  granules	  in	  the	  epidermis	  [53-­‐56].	  The	  FLG	  
gene,	  together	  with	  genes	  encoding	  trichohyalin,	  repetin	  and	  hornerin,	  belongs	  
to	   the	   ‘fused’	   gene	   family	   which	   characteristically	   have	   variable	   number	   of	  
internal	  tandem	  repeats.	  
	  
	   The	  FLG	  gene	  (Figure	  1.3)	  comprises	  of	  three	  exons	  and	  two	  introns	  [57,	  
58],	  with	  the	  initiation	  codon	  for	  translation	  located	  in	  Exon	  2	  while	  most	  of	  the	  






Figure 1.3 Schematic representation of the FLG gene showing the N-terminal domain (that 
contains a calcium-binding A-domain and a B-domain), two partial filaggrin repeats flanking 
10 almost identical filaggrin repeat (joined by short linker segments), and a C-terminal 
domain. The number of filaggrin repeat domains varies from 10 to 12 between individuals 
(with duplication of the 8th or 10th domain, or both). Each filaggrin repeat in humans is 




	   Profilaggrin	   is	   a	   large	   (around	   400	   kDa),	   highly	   phosphorylated,	  
insoluble	  protein	  consisting	  of	  10	  -­‐	  12	  filaggrin	  units	  in	  humans	  (20	  or	  more	  in	  
rodents).	  There	  are	  no	  introns	  within	  the	  filaggrin	  portion	  of	  the	  coding	  region	  
although	  the	   filaggrin	  repeats	  are	   joined	  by	  short	   linker	  segments	   [57,	  59-­‐62].	  
Each	  filaggrin	  repeat	  in	  humans	  is	  324	  amino-­‐acid	  long	  (972	  bp),	  each	  identical	  
in	  size	  but	  polymorphic	  in	  sequence	  [59,	  61].	  The	  length	  of	  tandemly-­‐arranged	  
filaggrin	  repeats	  are	  flanked	  by	  two	  partial	  filaggrin	  repeats	  and	  an	  amino-­‐	  and	  
carboxyl-­‐terminal	   domains.	   Subsequent	   to	   profilaggrin	   synthesis	   in	   the	  
epidermal	   granular	   layer,	   it	   is	   rapidly	   phosphorylated	   and	   accumulates	   in	  
keratohyalin	   granules	   [53-­‐56].	   It	   is	   believed	   that	   this	   sequestration	   of	   the	  
phosphoprotein	   prevents	   premature	   and	   hence	   deleterious	   aggregation	  
between	  filaggrin	  and	  keratin	  [63-­‐65].	  
	  
	  
1.1.1	   Profilaggrin	  amino-­terminal	  domain	  
	  
	   The	  profilaggrin	  N-­‐terminal	  domain	  is	  293	  amino-­‐acid	  long	  and	  consists	  
of	   a	   conserved	   A-­‐domain	   (81	   amino-­‐acid	   long)	   and	   less	   conserved	   cationic	   B	  
domain	  (212	  amino-­‐acid	  long)	  [57,	  58,	  66].	  The	  A-­‐domain	  contains	  two	  calcium-­‐
binding	   S100-­‐like	   EF-­‐hands	   that	   each	   binds	   a	   Ca2+	   ion	   [67].	   Like	   other	   S100	  
proteins,	   calcium	   binding	   brings	   about	   a	   conformational	   change	   to	   the	   N-­‐
terminal	   domain	   [67],	   suggesting	   that	   calcium	  plays	   a	   key	   role	   in	  profilaggrin	  
processing.	  
	  
	   The	   B-­‐domain	   contains	   functional	   bipartite	   nuclear	   localisation	  
sequences	   (bNLSs)	   that	   facilitate	   nuclear	   translocation	   of	   the	   N-­‐terminal	  
domain	   [68,	   69].	   At	   the	   nucleus,	   Ishida-­‐Yamamoto	   et	   al	  proposed	   that	   the	   N-­‐
terminal	  domain	  promotes	  keratinocyte	  denucleation	  [68].	  
	  
	   It	  is	  postulated	  that	  the	  first	  N-­‐terminal	  processing	  event	  during	  terminal	  
differentiation	   involves	   the	   release	   of	   a	   peptide	   (50	   kDa)	   containing	   the	   N-­‐
terminal	   domain	   and	   a	   partial	   filaggrin	   repeat.	   Further	   calcium-­‐dependent	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processing	   frees	   the	   N-­‐terminal	   domain	   (32	   kDa)	   [70].	   This	   two-­‐stage	  
mechanism	  is	  thought	  to	  allow	  for	  fine	  control	  of	  filaggrin	  functions:	  cleavage	  of	  
the	   N-­‐terminal	   filaggrin	   peptide,	   coupled	   with	   dephosphorylation,	   leaves	   the	  
polyfilaggrin	  region	  available	  for	  proteolytic	  processing	  to	  filaggrin	  monomers;	  
while	   subsequent	   removal	   of	   the	   partial	   filaggrin	   repeat	   frees	   the	   N-­‐terminal	  
domain	  to	  translocate	  to	  the	  nucleus.	  	  
	  
	   In	   summary,	   the	  N-­‐terminal	  domain	   is	   thought	   to	  have	   two	  main	  roles.	  
First,	  it	  regulates	  profilaggrin-­‐filaggrin	  processing	  (which	  is	  likely	  to	  be	  calcium-­‐
dependent)	  and	  hence	  regulates	  the	  keratin-­‐aggregation	  of	   filaggrin.	  Second,	   it	  




1.1.2	   Profilaggrin	  carboxyl-­terminal	  domain	  
	  
	   The	  C-­‐terminal	  domain,	   like	  the	  N-­‐terminal	  domain,	  has	   little	  homology	  
with	  the	  filaggrin	  repeats	  (only	  around	  17%).	  There	  is	   limited	  literature	  on	  its	  
structure	   and	   function.	  There	   is	   considerable	   species	   variation	   in	   length,	  with	  
humans	  having	  a	  157	  amino	  acid-­‐long	  domain,	  but	  rats	  and	  mice	  having	  23	  and	  
26	  respectively	  [71,	  72].	  Nonetheless,	  the	  last	  15	  amino	  acids	  of	  all	  three	  species	  
share	  53-­‐60%	  sequence	  identity	  [57].	  	  
	  
	   Although	   the	   function	   of	   the	   C-­‐terminal	   domain	   is	   thus	   far	   uncertain,	  
Sandilands	  et	  al	  showed	  that	  in	  humans	  who	  carry	  FLG	  mutations	  that	  express	  a	  
truncated	   profilaggrin	   species	   (up	   to	   10	   filaggrin	   repeats	   but	   not	   the	   C-­‐
terminus)	   are	   unable	   to	   process	   these	   into	   filaggrin	   monomers	   [23].	   This	  
suggests	   that	   the	   C-­‐terminal	   domain	   plays	   an	   essential	   role	   in	   profilaggrin	   to	  
filaggrin	  processing.	  Further	  evidence	  to	  support	   this	   is	  seen	   in	  studies	  on	  the	  
flaky	  tail	  mouse	  which	  showed	  that	  a	  similarly	  truncated	  profilaggrin	  does	  not	  
form	   normal	   keratohyalin	   granules,	   is	   present	   only	   at	   low	   levels	   in	   the	  
epidermis,	  and	  is	  not	  subsequently	  processed	  to	  filaggrin	  [73].	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   In	   summary,	   it	   appears	   that	   the	   C-­‐terminal	   domain	   plays	   a	   role	   in	  




1.1.3	   Processing	  of	  profilaggrin	  to	  filaggrin	  
	  
1.1.3.1	   Dephosphorylation	  
	  
	   Profilaggrin	   is	   extensively	   phosphorylated	   following	   its	   synthesis,	   and	  
since	  only	  dephosphorylated	  filaggrin	  monomers	  are	  able	  to	  aggregate	  keratin	  1	  
and	  10	  and	  other	  intermediate	  filaments,	  it	  is	  believed	  that	  this	  phosphorylation	  
process	  is	  to	  control	  premature	  aggregation	  [74].	  
	  
	   The	   processing	   of	   profilaggrin	   into	   individual	   filaggrin	   monomers	   is	   a	  
highly	   regulated	   process	   involving	   multiple	   molecular	   events	   (Fig	   1.4).	   This	  
process	   is	   better	   understood	   in	   rodents,	   although	   it	   is	   believed	   to	   be	   very	  
similar	   in	   humans.	   Dephosphorylation	   has	   been	   shown	   to	   be	   an	   early	  
processing	   step	   (preceding	   proteolysis)	   as	   no	   phosphorylated	   intermediate	  
species	   are	   detected	   [75].	   Several	   protein	   phosphatases	   (PPase)	   have	   been	  
shown	  to	  possibly	  play	  a	  role,	  such	  as	  the	  protein	  phosphatase	  PP2A	  (a	  member	  
of	  the	  protein	  phosphatase	  2A	  family)	  [76]	  and	  another	  phosphatase	  purified	  by	  
Ohno	   et	   al	   called	   PPase:	   EC	   3.1.3.2	   [77].	  Work	   done	   on	   the	   former	   showed	   a	  
reverse	  relationship	  between	  the	  phosphatase	  activity	  and	  NaCl	  concentration,	  
which	   suggests	   that	   the	   reduction	   in	   sodium	   concentration	   characteristically	  
found	  in	  granular	  cells	  may	  be	  a	  regulatory	  mechanism	  for	  this	  enzyme.	  Other	  
possible	  regulatory	  mechanisms	  postulated	  for	  this	  dephosphorylation	  process	  
are	  the	  release	  of	  highly	  basic	  histones	  as	  granular	  cells	  degranulate,	  enhancing	  
the	   activity	   of	   PPases	   and	   filaggrin	   (which	   is	   also	   highly	   basic)	   and	   activating	  






Figure 1.4 Model of profilaggrin and filaggrin processing. During terminal differentiation, the 
phosphorylated profilaggrin is dephosphorylated (probably involving the activity of one or 
more PPases) and then proteolytically cleaved to individual filaggrin monomers. Several 
proteases such as PEP1 and matriptase are thought to be involved in the proteolysis 
process. The cleaved N-terminal domain is then translocated to the nucleus. Within the SC, 
the filaggrin monomers aggregate and align keratin filaments to form macrofibrils. This 
results in compaction of the cytoskeleton and cross-linking of keratin intermediate filaments 
by transglutaminases and modification by peptidylarginine deiminases (PADs) to form a 
highly insoluble keratin matrix (a major component of the SC). The filaggrin monomers are 
subsequently degraded by various proteases into hydrophilic amino acids and derivatives, 
which are the natural moisturising factor (NMF) that contributes to skin hydration.	  
	  
	  
1.1.3.2	   Proteolytic	  cleavage	  
	  
	   Once	   again,	   the	   proteolytic	   processing	   of	   profilaggrin	   is	   best	  
characterised	  in	  mouse	  profilaggrin.	  Resing	  et	  al	  studied	  this	  process	  in	  C57/Bl6	  
mice	   and	   identified	   two	   types	  of	   linker	   segments	   that	  differed	   in	   the	   residues	  
following	   the	   carboxyl	   terminus	   of	   filaggrin	   [75].	   One	   type	   has	   Tyr-­‐Tyr-­‐Tyr	  
(Type	  A),	  while	  the	  other	  has	  Phe-­‐Tyr-­‐Pro-­‐Val-­‐	  Tyr-­‐Tyr-­‐Tyr	  (Type	  B).	  Hence,	  it	  
was	  predicted	  that	  two	  different	  proteases	  cleaved	  the	  different	  linker	  segment	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types.	   A	   previous	   study	   by	   the	   same	   group	   found	   two	   transient	   profilaggrin	  
intermediates	  (containing	  two	  and	  three	  filaggrin	  domains)	  during	  processing,	  
and	   these	  were	   subsequently	   found	   to	   only	   have	  Type	  B	   linker	   segment	   [75].	  
Hence	   the	   authors	   proposed	   that	   profilaggrin	   processing	   occurred	   in	   two	  
distinct	  stages.	  The	  first	  stage	  involved	  the	  cleaving	  of	  Type	  A	  linker	  segment	  by	  
one	   protease,	   while	   the	   second	   stage	   involved	   the	   cleaving	   of	   Type	   B	   linker	  
segment	  by	  another	  protease	  to	  release	  individual	  filaggrin	  monomers.	  
	  
	   In	   addition	   to	   mice,	   transient	   profilaggrin	   intermediates	   are	   also	  
observed	  in	  other	  species,	  such	  as	  humans	  [56],	  rabbit	  [79],	  rat	  and	  guinea	  pig	  
[80].	   This	   suggests	   a	   common	   multi-­‐stage	   processing	   mechanism	   in	   all	  
mammals.	  However,	  an	  important	  difference	  in	  humans	  profilaggrin	  compared	  
to	  other	  mammals	  studied	   is	   the	  presence	  of	  only	  one	  type	  of	   linker	  segments	  
[59].	   Therefore,	   it	   is	   presently	   uncertain	   if	   human	   profilaggrin	   is	   similarly	  
processed.	  
	  
	   Several	   proteases	   are	   thought	   to	   possibly	   play	   a	   role	   in	   proteolytically	  
cleaving	   profilaggrin	   into	   filaggrin	   monomers.	   These	   include	   profilaggrin	  
endopeptidase	   1	   (PEP1)	   which	   is	   a	   chymotrypsin-­‐like	   protease	   [81],	   the	  
proprotein	   convertases	   furin	   and	   PACE4	   [82,	   83]	   and	   µ-­‐calpain	   [84,	   85].	   In	  
addition,	  studies	  on	  mouse	  knockout	  models	  have	  also	  uncovered	  other	  possible	  
enzymes	   involved	   in	   profilaggrin	   processing,	   such	   as	   the	   serine	   proteases	  
matriptase	  [86],	  prostasin	  [87],	  inhibitors	  such	  as	  lympho-­‐epithelial	  Kazal	  type	  
inhibitor	   (LEKTI),	   which	   is	   encoded	   by	   the	   Spink5	   gene	   [88,	   89]	   and	   12R	  
lipoxygenase	   (a	   dioxygenase	   that	   is	   preferentially	   expressed	   in	   the	   epidermis	  








1.2	   Filaggrin	  structure	  and	  function	  
	  
1.2.1	   Filaggrin	  processing	  	  
	  
	   As	   seen	   in	  Figure	  1.4,	   the	  proteolytic	   cleavage	  of	  profilaggrin	   results	   in	  
individual	  filaggrin	  monomers.	  Filaggrin	  has	  been	  shown,	   in	  vitro,	   to	  aggregate	  
keratin	   filaments	   into	   macrofibrils,	   hence	   its	   name	   (filament	   aggregating	  
protein)	  [74,	  92].	  Under	  in	  vitro	  conditions,	  when	  keratin	  filaments	  and	  filaggrin	  
were	   combined,	   they	   were	   shown	   to	   form	   a	   characteristic	   structural	   form	  
similar	   to	   the	   ‘keratin	  pattern’	   of	   SC	   cells	   [92-­‐94].	   Support	   of	   this	   role	   in	   vivo	  
came	  from	  a	  study	  using	  immuno-­‐electron	  microscopy	  on	  affected	  epidermis	  of	  
ichthyosis	  vulgaris	  patients.	  This	  showed	  that	   localisation	  of	   filaggrin	   in	   lower	  
cornified	   cells	   (albeit	   greatly	   reduced	   in	   IV	   compared	   to	   normal	   epidermis)	  
correlated	  precisely	  with	   the	   formation	  of	   aggregated	  keratin	   filaments,	  while	  
the	   absence	   of	   filaggrin	   in	   upper	   cornified	   cells	   correlated	   with	   disarrayed	  
keratin	  filaments	  [55].	  	  As	  filaggrin	  binds	  to	  keratin	  filaments	  with	  simple	  ionic	  
and/or	   hydrogen-­‐bonding	   interactions	   (the	   'ionic	   zipper	   hypothesis')	   [95],	  
these	   aggregate	   into	   macrofibrils	   which	   results	   in	   compaction	   of	   the	  
cytoskeleton	   and	   cross-­‐linking	   of	   keratin	   intermediate	   filaments	   by	  
transglutaminases	   and	  modification	  by	  peptidylarginine	  deiminases	   (PADs)	   to	  
form	  a	  highly	  insoluble	  keratin	  matrix.	  Together	  with	  lipids	  and	  other	  cornified	  
envelope	  proteins,	   this	  protein	   scaffolding	   forms	   the	  SC,	  which	   is	   the	  primary	  
skin	   barrier.	   Specifically,	   filaggrin	   aggregates	   keratin	   1,	   keratin	   10	   and	   other	  
intermediate	  filaments	  [55],	  and	  this	  collapses	  the	  keratin	  cytoskeleton	  during	  
cornification	  and	  a	  form	  of	  programmed	  cell	  death	  [96].	  A	  study	  by	  Presland	  et	  
al	   also	  provided	  evidence	   that	   filaggrin	   is	   a	  major	   component	  of	   the	   cornified	  
cell	  envelope	  [97].	  
	  	  
	   Finally,	   within	   the	   SC,	   the	   filaggrin	   monomers	   are	   progressively	  
degraded	  into	  hydrophilic	  amino	  acids	  and	  derivatives,	  including	  urocanic	  acid	  
and	  pyrrolidone	  carboxylic	  acid.	  These	  make	  up	  the	  natural	  moisturising	  factor	  
(NMF)	  which	  contributes	  to	  skin	  hydration	  [98].	  The	  degradation	  of	  filaggrin	  is	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fairly	   rapid	   –	   its	   half-­‐life	   is	   estimated	   to	  be	   about	  6	  h	   [75].	  However,	   this	   has	  
been	  shown	  to	  be	  variable,	  being	  dependent	  on	   the	  SC	  hydration	  and	  external	  
humidity	   [80,	   98,	   99].	   Post-­‐translational	   enzymes	   are	   involved	   in	   this	  
degradation	  process,	   including	  peptidylarginine	  deiminases	  (PAD1	  and	  PAD3),	  
which	   are	   thought	   to	   be	   involved	   in	   the	   deimination	   of	   filaggrin	   [100-­‐102].	  
Ishida-­‐Yamamoto	  et	  al	  postulated	  that	  as	   the	  deimination	  of	   filaggrin	  converts	  
its	   net	   charge	   from	   basic	   to	   almost	   neutral,	   this	   disturbs	   the	   ionic	   binding	  
between	   filaggrin	   and	   keratin	   and	   hence	   encourages	   further	   filaggrin	  
degradation	   [103].	   Enzymes	   shown	   to	   cleave	   deiminated	   filaggrin	   monomers	  
include	  caspase-­‐14,	  an	  aspartate-­‐specific	  proteinase	  whose	  expression	  is	  almost	  
entirely	   restricted	   to	   the	   upper	   epidermis	   [104],	   calpain	   1	   and	   bleomycin	  
hydrolase	  [105].	  	  
	  
	   NMF	  compounds	  are	  abundant	  within	  corneocytes	  and	  represents	  up	  to	  
30%	  of	  the	  dry	  weight	  of	  the	  SC	  [105].	  It	  is	  highly	  hygroscopic	  and	  is	  important	  
in	   maintaining	   hydration	   of	   the	   skin,	   particularly	   in	   dry	   environmental	  
conditions	   [98].	   In	   addition,	   NMF	   is	   also	   thought	   to	   facilitate	   important	  
biochemical	   events	   within	   the	   SC	   such	   as	   regulating	   protease	   activity	   and	  




1.2.2	   Heterogeneity	  of	  filaggrin	  
	  
	   Filaggrin	  monomers	  are	   found	   to	  be	  polymorphic.	  Even	  within	  a	   single	  
individual,	   functional	   filaggrin	   consists	   of	   a	   heterogeneous	   population	   of	  
molecules.	   Although	   all	  monomers	   are	   of	   the	   same	   length	   (324	   amino	   acids),	  
there	   is	   considerable	   variation	   in	   charge	   and	   sequence,	  with	   adjacent	   repeats	  
showing	  as	  much	  as	  20	  %	  sequence	  variation	  [59,	  61].	  In	  the	  study	  by	  Gan	  et	  al,	  
the	   authors	   found	   that	   most	   of	   the	   identified	   variations	   merely	   resulted	   in	  
conservative	   changes	   to	   the	   molecule	   [59],	   thereby	   leaving	   the	   structural	  
properties	  of	  the	  protein	  largely	  unaltered.	  Thus,	  the	  human	  filaggrin	  system	  is	  
14	  
doubly	   polymorphic:	   profilaggrin	   contains	   a	   variable	   numbers	   of	   filaggrin	  
repeats,	  with	  functional	  filaggrin	  monomers	  showing	  sequence	  heterogeneity.	  
	  
	   In	   contrast	   to	   human	   filaggrin	   monomers,	   mouse	   and	   rat	   filaggrin	  
sequences	  seem	  to	  be	  highly	  conserved	  although	  this	  could	  merely	  be	  due	  to	  the	  
rodent	  protein	  being	  obtained	  from	  inbred	  strains	  [62,	  84].	  
	  
	  
1.2.3	   Filaggrin	  mutations	  
	  
	   As	   mentioned	   previously,	   there	   are	   more	   than	   20	   loss-­‐of-­‐function	  
mutations	   found	  within	   the	  FLG	   gene	   to	   date.	   Five	   are	   prevalent	   in	   European	  
populations	   with	   non-­‐European	   populations	   having	   other	   population-­‐specific	  
mutations	   [38].	   All	   these	   mutations	   are	   nonsense	   or	   frameshift	   mutations,	  
resulting	   in	   a	   truncated	   form	  of	   profilaggrin	   protein.	   Sandilands	   et	   al	   showed	  
that	  none	  of	  these	  truncated	  profilaggrin	  species	  can	  be	  processed	  properly	  into	  
functional	  filaggrin	  monomers	  [23].	  Hence,	  the	  effect	  of	  a	  mutation	  near	  the	  N-­‐
terminal	   domain	   of	   profilaggrin	   is	   similar	   to	   that	   of	   a	   mutation	   near	   the	   C-­‐
terminal	   domain,	   with	   both	   resulting	   in	   a	   reduction	   or	   complete	   absence	   of	  
filaggrin	   [45].	   Due	   to	   this	   equivalence	   of	   effect,	   several	   studies	   have	   used	   a	  
‘combined	  null	  genotype’	   in	   their	  statistical	  analysis,	  which	  groups	   individuals	  
with	   any	   one	   or	   any	   combination	   of	   two	   FLG	   mutations	   instead	   of	   analysing	  
each	  mutation	  separately	  [107].	  
	  
	   A	  noteworthy	  observation	  arising	  from	  genetic	  studies	  of	  the	  FLG	  gene	  is	  
that	   the	   loss-­‐of-­‐function	   mutations	   are	   extremely	   common	   in	   the	   general	  
population,	  with	   the	  R501X	   and	  2282del4	  mutations	   being	   carried	   by	   around	  
9%	   of	   the	   Irish	   population	   [22].	   This	   high	   prevalence	   suggests	   a	   possible	  
evolutionary	   heterozygote	   advantage.	   Irvine	   and	  McLean	   postulated	   that	   this	  
mildly	   perturbed	   skin	   barrier	   in	   heterozygotes	   might	   be	   a	   form	   of	   'natural	  
vaccination'	   against	   bacterial	   antigens,	   conferring	   some	   survival	   advantage	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during	   the	   great	   plagues	   and	   other	   ancient	   epidemics	   [29].	   It	   is	   presently	  
unknown	  when	  these	  FLG	  mutations	  arose	  in	  human	  history.	  
	  
	  
1.3	   Relevance	  of	  filaggrin	  to	  human	  diseases	  
	  
	   The	   recent	   discovery	   of	   filaggrin	   mutation	   as	   the	   cause	   of	   IV,	   and	   in	  
particular	   the	   subsequent	   discovery	   of	   its	   strong	   association	   with	   AD,	   has	  
renewed	  interest	  in	  this	  gene.	  In	  addition	  to	  these	  two	  common	  skin	  conditions,	  
FLG	  genetics	   is	  also	  generating	  new	   insight	   into	  AD-­‐related	  asthma,	  as	  well	  as	  
providing	  possible	  disease	  mechanisms	  for	  systemic	  allergies.	  
	  
	  
1.3.1	   Ichthyosis	  vulgaris	  
	  
	   IV	  is	  a	  very	  common	  autosomal	  dominant	  skin	  disease,	  with	  an	  incidence	  
of	   one	   in	   250	   people	   [108].	   It	   is	   characterised	   by	   generalised	   xerosis	   with	  
scaling	   particularly	   on	   the	   lower	   legs,	   keratosis	   pilaris	   and	   palmar	  
hyperlinearity.	   There	   is	   also	   an	   association	  with	   atopy.	   Early	   clues	   suggested	  
filaggrin’s	   role	   in	   IV;	   for	   example,	   histopathological	   studies	   of	   IV	   had	   shown	  
abnormal	   keratohyalin	   granules	   within	   the	   granular	   layer,	   and	   reduced	   or	  
absent	  expression	  of	   filaggrin	   in	  patients’	   skin	   [24,	  109,	  110].	  Zhong	  et	  al	   also	  
mapped	   several	   pedigrees	   of	   IV	   to	   the	   EDC	   on	   chromosome	   1q21,	   providing	  
further	  evidence	  of	  filaggrin's	  role	  [111].	  	  
	  
	   Previous	   attempts	   to	   sequence	   the	   FLG	   gene	   were	   hampered	   by	   the	  
repetitive	   nature	   of	   the	   sequence,	   due	  primarily	   to	   the	   tandem	   repeats	   of	   the	  
filaggrin	   domains.	   However,	   recent	   improvements	   in	   sequencing	   technology	  
and	   the	   use	   of	   single	   nucleotide	   polymorphisms	   to	   aid	   sequence-­‐specific	   PCR	  
amplification	  have	   finally	  enabled	  the	  comprehensive	  analysis	  of	   the	  FLG	  gene	  
[23].	  This	  allowed	  Smith	  et	  al	  to	  study	  15	  pedigrees	  of	  IV	  and	  ascertain	  that	  IV	  is	  
caused	   by	   loss-­‐of-­‐function	   mutations	   in	   the	   FLG	   gene	   [25].	   They	   determined	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that	   IV	   is	   inherited	   in	   a	   semi-­‐dominant	   manner	   with	   incomplete	   penetrance	  
(around	   90	  %	   in	   homozygotes).	   Therefore,	   heterozygotes	   display	   mild	   or	   no	  
phenotype,	   whereas	   homozygotes	   or	   compound	   heterozygotes	   have	   a	   severe	  
form	  of	  IV.	  
	  
	   Initially,	   two	   premature	   termination	   codon-­‐causing	   mutations,	   R501X	  
and	   2282del4,	   were	   identified.	   Subsequently,	   other	   novel	   mutations	   were	  
demonstrated	  both	  in	  European	  and	  non-­‐European	  populations	  [23,	  26,	  37,	  38,	  
40,	  46,	  47,	  112].	  
	  
	  
1.3.2	   Atopic	  dermatitis	  
	  
	   The	   clinical	   association	   between	   IV	   and	   AD	   is	   well	   recognised.	   As	  
mentioned	   previously,	   AD	   is	   a	   genetically	   complex	   disease	   with	   a	   strong	  
environmental	   component.	   Previous	   studies	   have	   provided	   some	   evidence	   of	  
filaggrin’s	   role	   in	   the	   genetic	   susceptibility	   of	   AD.	   For	   instance,	   Seguchi	   et	   al	  
demonstrated	  that	  filaggrin	  expression	  is	  suppressed	  in	  the	  skin	  of	  AD	  patients	  
[113].	  Additionally,	  previous	  genome-­‐wide	  association	  studies	  had	  linked	  AD	  to	  
a	   locus	   on	   1q21	   [10],	   and	   an	   association	   had	   also	   been	   reported	   between	  
specific	   profilaggrin	   allelotypes	   and	   dry	   skin	   [114].	   Thus,	   it	   was	   perhaps	   not	  
entirely	   surprising	   that	   having	   ascertained	   filaggrin's	   role	   in	   IV,	   Palmer	   et	   al	  
subsequently	  demonstrated	  the	  strong	  association	  between	  FLG	  gene	  mutations	  
with	  AD.	  	  What	  was	  surprising,	  however,	  was	  the	  strength	  of	  this	  association.	  In	  
a	   trait	  as	  complex	  as	  AD,	  an	  estimated	  LOD	  score	  of	  3.08	  –	  3.27	   [22]	   (with	  an	  
LOD	  score	  ≥	  3	  indicating	  significant	  linkage)	  was	  remarkable.	  
	  
	   Despite	   this	  strong	  association,	   it	   is	  certain	  the	  FLG	  mutations	  alone	  do	  
not	  account	  for	  all	  cases	  of	  AD.	  Only	  up	  to	  half	  of	  all	  AD	  cases	  can	  be	  explained	  
by	   the	  presence	  of	  at	   least	  one	  FLG	  null	  allele.	   It	   is	  known	  that	  AD	   is	   typically	  
associated	  with	  increased	  expression	  of	  TH2	  cytokines	  (such	  as	  IL-­‐4	  and	  IL-­‐13),	  
both	  of	  which	  have	  been	  shown	  to	  reduce	  filaggrin	  gene	  and	  protein	  expression	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[115].	  It	  is	  likely,	  therefore,	  that	  a	  defect	  in	  filaggrin	  expression	  may	  be	  acquired	  




1.3.3	   Asthma	  
	  
	   Asthma	   is	   part	   of	   the	   atopic	   disease	   complex,	   together	   with	   AD	   and	  
allergic	   rhinitis.	   As	  mentioned	   earlier,	   FLG	   mutations	   have	   been	   shown	   to	   be	  
associated	  with	  asthma,	  but	  only	  with	  asthma	  that	  is	  coexistent	  with	  AD	  and	  not	  
asthma	  alone	  [22,	  29,	  117].	  This	  suggests	  a	  casual	  relationship	  between	  AD	  and	  
asthma.	  This	  has	  led	  to	  the	  hypothesis	  that	  asthma	  present	  in	  AD	  individuals	  is	  
due	   to	   a	   primary	   defect	   in	   the	   epidermal	   barrier	   which	   allows	   allergens	   to	  
penetrate	   the	   skin	   to	   make	   contact	   with	   Langerhans	   cells	   (the	   antigen-­‐
presenting	   cells	   in	   the	   skin)	   [118]	   leading	   to	   sensitisation	   and	   asthma	   [116].	  
There	  are	  several	  lines	  of	  evidence	  for	  this.	  These	  include	  the	  lack	  of	  filaggrin	  in	  
bronchial	  mucosa	  [119],	  the	  association	  of	  FLG-­‐positive	  AD	  with	  high	  serum	  IgE	  
and	  allergic	  sensitisation	  [120],	  and	  the	  association	  between	  FLG	  mutations	  and	  
greater	  asthma	  severity	  [117].	  
	  
	  
1.3.4	   Genetic	  modifier	  in	  other	  diseases	  	  
	  
	   Recently,	   FLG	   mutations	   are	   emerging	   as	   a	   genetic	  modifier	   in	   certain	  
dermatological	  conditions.	  One	  of	  these	  conditions	  is	  alopecia	  areata	  (AA).	  This	  
condition,	   which	   affects	   nearly	   2	   %	   of	   the	   population	   [121],	   presents	   with	  
patchy	  hair	  loss	  and	  is	  thought	  be	  to	  a	  autoimmune	  disease	  directed	  against	  the	  
hair	   follicle.	   An	   association	   of	   AA	   with	   atopic	   disease	   had	   been	   reported	  
previously	  [122-­‐125]	  and	  hence	  it	  was	  reasonable	  to	  search	  for	  a	  possible	  role	  
of	  filaggrin	  in	  AA.	  Betz	  et	  al	  analysed	  a	  large	  cohort	  of	  AD	  patients	  and	  found	  no	  
significant	  association	  between	  the	  two	  commonest	  null	  FLG	  mutations	  (R501X	  
and	   2282del4)	   with	   AA	   [126].	   However,	   these	   mutations	   were	   significantly	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associated	  with	  AA	   in	   those	   patients	  who	   also	   had	  AD.	   In	   addition,	   the	   group	  
found	  that	  AA	  with	  concomitant	  FLG-­‐associated	  AD	  was	  more	  likely	  to	  be	  more	  
severe.	  
	  
	   Another	  condition	  that	  FLG	  mutations	  may	  act	  as	  genetic	  modifiers	  is	  X-­‐
linked	   ichthyosis	   (XLI),	   which	   is	   caused	   by	  mutations	   in	   the	   steroid	   sulfatase	  
gene	  (STS)	  located	  on	  the	  X	  chromosome	  [127].	  Liao	  et	  al	  studied	  two	  brothers	  
with	   the	   condition.	   One	   had	   a	   mild	   phenotype	   with	   fine	   scales,	   whereas	   the	  
other	  was	  more	  severely	  affected.	  Both	  carried	  the	  same	  STS	  missense	  mutation	  
T165I	  but	  the	  more	  severely	  affected	  brother	  was	  also	  a	  heterozygous	  carrier	  of	  
FLG	   mutation	   R501X.	   This	   suggests	   that	   the	   degree	   of	   filaggrin	   expression	   is	  
possibly	   a	   genetic	   modifier	   in	   XLI.	   It	   also	   suggests	   that	   especially	   in	  
genodermatoses	   with	   known	   defects	   in	   epidermal	   differentiation,	   FLG	  
mutations	  may	  similarly	  act	  as	  genetic	  modifiers	  [127].	  
	  
	  
1.4	   Biophysical	  measures	  of	  skin	  barrier	  function	  
	  
	   Several	  non-­‐invasive	  biophysical	  measures	  have	  been	  used	  in	  cutaneous	  
research	   to	  assess	   the	   function	  of	   the	  skin	  barrier.	  Of	   these,	   three	  of	   the	  most	  
commonly	  used	  measures	  are	  transepidermal	  water	  loss	  (TEWL),	  SC	  hydration,	  
and	  the	  number	  of	   tape	  strips	  required	  to	   induce	  a	  predefined	   level	  of	  barrier	  
disruption.	  
	  
	   TEWL	  is	  one	  of	  the	  most	  important	  parameters	  in	  the	  assessment	  of	  skin	  
barrier	   function,	   and	   is	   particularly	   sensitive	   in	   assessing	   irritant	   effect	   on	  
barrier	   function	   [128].	   It	   is	   a	   measure	   of	   water	   evaporation	   from	   the	   skin	  
surface,	  thus	  a	  measure	  of	  how	  'leaky'	  the	  skin	  barrier	  is.	  Intact	  skin,	  therefore,	  
has	  a	  low	  TEWL	  [129],	  while	  an	  impaired	  skin	  barrier	  characteristically	  shows	  
increased	  TEWL	  [130,	  131].	  Its	  use	  as	  a	  reliable	  measure	  of	  skin	  barrier	  function	  
has	  been	  extensively	  validated	  [129,	  132-­‐136].	  Although	   it	   is	  a	  very	  quick	  and	  
easy	  parameter	  to	  measure	  experimentally,	  there	  have	  been	  concerns	  about	  the	  
19	  
standardisation	  and	  reproducibility	  of	  TEWL	  measurements,	   since	   it	   is	  known	  
that	  factors	  such	  as	  the	  type	  of	  instrument	  used,	  site	  and	  environmental	  factors	  
affect	   TEWL	   measurements	   [137-­‐139].	   Hence,	   it	   is	   important	   during	   TEWL	  
measurements	  to	  note	  these	  factors	  and	  keep	  them	  constant.	  
	  
	   Skin	   barrier	   function	   can	   also	   be	   assessed	   by	   measuring	   the	   water	  
content	   of	   the	   SC.	   SC	   hydration	   has	   been	   shown	   to	   affect	   permeability	   and	  
flexibility,	   as	  well	   as	   the	   enzymatic	   activity	   of	   normal	   SC	   desquamation	   [140,	  
141].	   Hence,	   impaired	   skin	   barrier	   is	   associated	  with	   low	   SC	   hydration	   [142,	  
143].	   There	   are	   many	   techniques	   to	   measure	   SC	   hydration,	   with	   the	   most	  
common	   being	   an	   indirect	   measurement	   of	   SC	   hydration	   by	   measuring	   skin	  
capacitance.	   Skin	   capacitance	   is	   determined	   by	   the	   dielectric	   nature	   of	   the	  
epidermis,	   which	   varies	   depending	   on	   the	   amount	   of	   moisture	   in	   the	   skin.	  
Therefore,	  skin	  with	  different	  amount	  of	  hydration	  will	  have	  different	  dielectric	  
constants,	   thus	   giving	   different	   capacitance	   values.	   Factors	   that	   affect	   TEWL	  
measurements	  also	  affect	  skin	  hydration.	  Hence,	  these	  need	  to	  be	  kept	  constant	  
for	  accurate	  comparison	  [144].	  
	  
	   In	   addition	   to	   TEWL	   and	   skin	   capacitance,	   another	   measure	   of	   skin	  
barrier	   function	   is	   by	   using	   tape	   stripping,	   which	   is	   a	   technique	   further	  
described	   in	   Chapter	   1.5.	   Specifically,	   the	   number	   of	   tape	   strips	   required	   to	  
achieve	  TEWL	  >	  20	  g/m2/h	  (which	  is	  generally	  accepted	  as	  the	  level	  where	  the	  
SC	  is	  abrogated)	  can	  be	  used	  as	  a	  functional	  measure	  of	  skin	  barrier	  [145-­‐147].	  
Therefore,	  in	  skin	  with	  an	  impaired	  barrier,	  fewer	  number	  of	  tape	  strips	  will	  be	  
required	  to	  achieve	  TEWL	  >	  20	  g/m2/h.	  	  
	  
	  
1.5	   Tape	  stripping	  in	  skin	  research	  
	  
	   Since	   it	  was	   first	   described	   by	  Pinkus	   in	   1951,	   adhesive	   tape	   stripping	  
has	  become	  a	  widely	  used	  technique	  in	  dermatological	  research	  [148-­‐158].	  It	  is	  
a	  simple,	  validated,	  minimally	  invasive	  method	  and	  is	  used	  in	  a	  broad	  range	  of	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applications.	   These	   include	   evaluating	   the	   bioavailability	   and	  
dermatopharmacokinetics	   of	   topically-­‐applied	   drugs	   [159-­‐162],	   obtaining	   SC	  
cells	  for	  analysis	  [146,	  163,	  164],	  studying	  various	  aspects	  of	  skin	  permeability	  
[165-­‐170],	  and	  analysing	  skin	  barrier	  function	  [146,	  156,	  171].	  
	  
	   There	  are	  several	  commercially	  available	  adhesive	   tapes	  used,	  with	   the	  
D-­‐Squame	   tape	   strips	   (Cuderm	   Corporation)	   being	   the	  most	   commonly	   used.	  
The	   technique	   itself	   is	   easy	   to	   perform	   [172].	   Pieces	   of	   tape	   strips	   are	  
consecutively	   pressed	   onto	   the	   surface	   of	   the	   skin	   and	   then	   removed.	   The	  
superficial	  layers	  of	  the	  SC	  will	  adhere	  to	  the	  tapes	  and	  are	  available	  for	  further	  
analysis.	   If	   necessary,	   the	   amount	   of	   SC	   collected	   can	   either	   be	   determined	  
gravimetrically	   (that	   is,	  weighing	   the	   tape	   strips)	  or	  by	  protein	  determination	  
[149,	  173,	  174].	  
	  
	   It	   is,	  however,	  well	  documented	   that	  many	   factors	  affect	   the	  amount	  of	  
SC	  removed,	  including	  the	  anatomical	  site	  [175,	  176],	  intensity	  and	  duration	  of	  
the	  pressure	  applied	   [174,	  175],	   sex	  and	  age	   [176],	  material	  of	   the	   tapes	  used	  
[175],	   ambient	   temperature	   [177,	   178],	   and	   skin	   hydration	   [179].	  Hence,	   it	   is	  
important	  that	  these	  test	  conditions	  are	  well	  defined	  for	  standardisation.	  
	  
	  
1.6	   Mass	  spectrometry	  
	  
	   Mass	  spectrometry	  (MS)	  is	  an	  analytical	  tool	  used	  to	  measure	  the	  mass	  of	  
molecules	   and	   atoms	   expressed	   as	   their	   mass-­‐charge	   (m/z)	   ratio.	   There	   are	  
numerous	   types	   of	   mass	   spectrometers	   but	   all	   consist	   of	   three	   fundamental	  
parts:	  an	   ion	  source,	  a	  mass	  analyser,	  and	  a	  detector	  (Figure	  1.5).	   In	  order	   for	  
MS	  analysis,	  the	  sample	  molecules	  need	  to	  be	  converted	  by	  the	  ion	  source	  into	  
gas-­‐phase	   ionic	   species.	  These	   ionic	  analytes	  are	   then	  extracted	   into	   the	  mass	  
analyser	  where	  they	  are	  separated	  according	  to	  their	  m/z	  ratios.	  Finally,	  the	  ion	  
current	   due	   to	   the	   separated	   ionic	   analytes	   is	   detected	   by	   a	   suitable	   detector	  






Figure 1.5 Diagram of a generic mass spectrometer. There are three fundamental parts: an 
ion source that converts sample molecules into gas-phase ionic species, a mass analyser 
that separates the ions according to the m/z ratios, and finally a detector that detects the 
separated ionic analytes. 
	  
	  
	   Over	   the	   last	   20	   years,	   biological	  MS	   has	  made	   huge	   advances,	   largely	  
due	  to	  the	  development	  in	  the	  1980s	  of	  ‘soft	  ionisation’	  methods	  -­‐	  electrospray	  
ionisation	   (ESI)	   [180-­‐182]	   and	   matrix	   assisted	   laser	   desorption/ionisation	  
(MALDI)	   [183].	  These	  methods	  allow	   for	   the	  routine	  and	  general	   formation	  of	  
molecular	   ions	   of	   intact	   biomolecules,	   and	   are	   instrumental	   in	   driving	   the	  
design	   and	   manufacture	   of	   smaller	   and	   cheaper	   instruments	   with	   increased	  
mass	  range,	  higher	  routine	  resolution	  and	  mass	  accuracy	  [184].	  Today,	  MS	  is	  the	  
most	   sensitive	   method	   for	   structural	   characterisation	   of	   biomolecules.	   For	  
instance,	  proteins	  that	  are	  separated	  by	  gel	  electrophoresis	  can	  be	  identified	  at	  
the	   picomole	   level	   and	   below	   [185,	   186],	   while	   neuropeptides	   can	   even	   be	  
detected	  at	  the	  zeptomole	  (10-­‐21)	  level	  [187].	  
	  
	  
1.6.1	   Ionisation	  methods	  
	  
	   In	  order	   to	  allow	   for	  MS	  analysis,	   the	   sample	  must	   first	  be	   ionised	  and	  
vaporised.	  Until	  the	  development	  of	  the	  ‘soft	  ionisation’	  methods,	  samples	  were	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usually	   ionised	   by	   electron-­‐impact	   (EI)	   or	   chemical-­‐ionisation	   (CI)	   methods,	  
both	   of	   which	   require	   a	   vaporised	   sample.	   Hence,	   for	   a	   long	   time,	   MS	   was	  
restricted	   to	   small	   and	   thermostable	   compounds.	   This	   was	   because	   most	  
biomolecules,	   being	   polar	   and	   thermally	   labile,	   would	   be	   excessively	  
fragmented	   by	   EI	   and	   CI	  methods.	   The	   ‘soft	   ionisation’	   methods	   (MALDI	   and	  
ESI),	   on	   the	   other	   hand,	   allow	   for	   the	   ionised	   biomolecules	   to	   be	   transferred	  
from	  the	  condensed	  phase	   into	  the	  gas	  phase	  without	  excessive	  fragmentation	  
[188].	  In	  this	  thesis,	  both	  MALDI	  and	  ESI	  are	  employed.	  
	  
	  
1.6.1.1	   Matrix-­assisted	  laser	  desorption/ionisation	  
	  
	   The	  term	  matrix-­‐assisted	  laser	  desorption	  ionisation	  was	  first	  coined	  in	  
1985	  by	  Franz	  Hillenkamp,	  Michael	  Karas	  and	  their	  colleagues	  [189].	  There	  are	  
essentially	   two	   steps	   in	   MALDI.	   First,	   the	   sample	   is	   pre-­‐mixed	   with	   a	   highly	  
absorbing	  matrix	  compound.	  This	  mixture	  is	  dried,	  resulting	  in	  a	  ‘solid	  solution’	  
with	  the	  analyte	  molecules	  isolated	  and	  embedded	  throughout	  the	  matrix.	  The	  
second	   step	   occurs	   in	   a	   vacuum	  within	   the	   source	   of	   the	  mass	   spectrometer,	  
where	   portions	   of	   the	   solid	   solution	   are	   bombarded	  with	   a	   high-­‐energy	   laser	  
over	  a	   short	  duration.	  Although	   the	  exact	  mechanism	  of	   the	  MALDI	  process	   is	  
still	  not	  completely	  understood	  [190,	  191],	  it	  is	  generally	  thought	  that	  the	  rapid	  	  
heating	   by	   the	   laser	   causes	   localised	   sublimation	   of	   the	   matrix	   crystals	   and	  
expansion	  of	  the	  matrix	  into	  the	  gas	  phase	  while	  encapsulating	  intact	  analyte	  in	  
the	   expanding	  matrix	   plume	   [192].	   The	   ionisation	   of	   the	   analyte	   in	  MALDI	   is	  
also	   incompletely	   understood	   [193].	   The	   widely	   accepted	   view	   is	   that	   the	  
analyte	  molecules	   are	   ionised	  by	   acid-­‐base	  proton	   transfer	   reactions	  with	   the	  
protonated	  matrix	   ions	   in	   a	   dense	   phase	   just	   above	   the	   surface	   of	   the	  matrix	  
[192]	  (Figure	  1.6).	  The	   ions	   in	  the	  gas	  phase	  are	  then	  accelerated	  towards	  the	  







Figure. 1.6 Desorption and ionisation in MALDI. The 'solid solution' containing the analyte 
molecules is bombarded with a high-energy laser, which causes sublimation of the matrix 
crystals and while encapsulating intact analyte in the expanding matrix plume. It is thought 
that the analyte molecules are subsequently ionised by acid-base proton transfer reactions 
with the protonated matrix ions in a dense phase just above the surface of the matrix.	  
	  
	  
	   Early	  mass	   spectrometers	  used	   lasers	   that	  were	  applied	  directly	   to	   the	  
sample.	   This	   direct	   mode	   of	   application	   of	   laser	   (termed	   laser/desorption	  
ionisation,	  LDI)	  often	  resulted	  in	  excessive	  fragmentation	  of	  the	  sample.	  Hence,	  
LDI	  restricted	  MS	  analysis	  to	  only	  small	  organic	  molecules	  with	  molecular	  mass	  
less	   than	   1000	   Da.	   In	   MALDI,	   the	   use	   of	   a	   matrix	   with	   the	   sample	   has	  
revolutionised	   the	   analysis	   of	   large,	   non-­‐volatile	   and	   thermally	   labile	  
compounds	   such	   as	   proteins,	   oligonucleotides,	   polymers	   and	   large	   inorganic	  
molecules.	   Indeed,	   in	   the	   field	   of	   protein	   chemistry,	   it	   is	   arguably	   the	   most	  
efficient	  method	  of	  ionising	  peptides	  [184].	  Other	  advantages	  of	  MALDI	  include	  
the	   tolerance	   for	   contaminants	   and	   buffers,	   high	   sensitivity,	   uncomplicated	  
mass	  spectra	  (since	  most	  ions	  are	  singly	  charged)	  and	  rapid	  analysis	  [194].	  	  
	  
	   The	  use	  of	  a	  matrix,	  which	  provides	  for	  both	  desorption	  and	  ionisation,	  is	  
crucial	   to	   the	   success	   of	   this	   ionisation	   method	   [195].	   The	   most	   important	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function	  of	  the	  matrix	  is	  to	  rapidly	  and	  efficiently	  absorb	  energy	  from	  the	  laser	  
and	  transform	  this	  into	  excitation	  energy	  for	  the	  sample,	  which	  brings	  about	  the	  
ionisation	  of	  the	  sample	  (and	  matrix).	  More	  importantly,	  this	  spares	  the	  sample	  
from	   excessive	   and	   direct	   energy	   that	   may	   otherwise	   result	   in	   thermal	  
decomposition.	  To	  allow	  for	  the	  matrix	  to	  achieve	  this	  function,	  it	  needs	  to	  have	  
strong	  optical	  absorption	  at	  the	  wavelength	  of	  the	  laser	  radiation	  [196].	  	  
	  
	   Other	  characteristics	   required	  of	  an	  effective	  matrix	   include:	  1)	  a	   fairly	  
low	  molecular	  weight	  to	  be	  sublimable	  yet	  large	  enough	  so	  as	  not	  to	  evaporate	  
during	  sample	  preparation;	  2)	  vacuum	  stability;	  3)	  ability	  to	  promote	  ionisation	  
of	   the	   analyte;	   4)	   solubility	   in	   solvents	   compatible	  with	   the	   analyte	   and	  bring	  
about	   homogenous	   co-­‐crystallisation;	   5)	   lack	   of	   chemical	   reactivity	   and	   6)	  
ability	   to	   separate	   the	   analyte	  molecules	   to	  prevent	   analyte	   aggregation	   [195,	  
197].	  
	  
	   Most	   present	   day	   MALDI	   mass	   spectrometers	   use	   ultraviolet	   lasers	  
because	  of	   their	   ease	  of	   operation	  and	   low	  cost.	  Among	   these,	  nitrogen	   lasers	  
with	   a	   wavelength	   of	   337	   nm	   are	   considered	   the	   standard,	   but	   others	   used	  
include	   frequency-­‐tripled	   and	   quadrupled	   Nd:YAG	   (neodymium:yttrium	  
aluminium	  garnet)	  lasers,	  with	  wavelengths	  355	  nm	  and	  266	  nm	  respectively.	  	  
	  
	   A	  range	  of	  compounds	  is	  suitable	  for	  use	  as	  matrices,	  but	  the	  three	  most	  
commonly	  used	  are	  3,5-­‐dimethoxy-­‐4-­‐hydroxycinnamic	  acid	  (sinapinic	  acid),	  α-­‐
cyano-­‐4-­‐hydroxycinnamic	  acid	  (ACHC)	  and	  2,5-­‐dihydroxybenzoic	  acid	  (DHB).	  A	  
solution	   of	   the	   matrix	   in	   purified	   water	   generally	   also	   includes	   an	   organic	  
solvent	   (such	   as	   acetonitrile	   to	   solubilise	   hydrophobic	   molecules)	   and	  
trifluoroacetic	   acid	   (to	   act	   as	   a	   proton	   source	   to	   encourage	   ionisation	   of	   the	  
analyte).	  	  
	  
	   MALDI	  is	  most	  commonly	  coupled	  to	  time-­‐of-­‐flight	  (TOF)	  mass	  analysers	  
[198].	   There	   are	   two	   main	   reasons	   for	   this.	   First,	   TOF	   has	   the	   capability	   of	  
analysing	  ions	  over	  a	  wide	  mass	  range;	  thus	  it	  is	  able	  to	  analyse	  the	  high-­‐mass	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ions	   generated	   by	   MALDI.	   Second,	   both	   MALDI	   and	   TOF	   mass	   analysis	   are	  
pulsed	   rather	   than	   continuous	   events	   [184,	   195].	   MALDI-­‐TOF	   instruments	  
typically	  have	  an	   ‘ion	  mirror’	   that	  doubles	   the	   ion	   flight	  path	  and	   increase	   the	  
resolution	  of	  the	  m/z	  measurements.	  
	  
	   In	  protein	  chemistry,	  MALDI-­‐TOF	   is	  particularly	  useful	   in	  peptide	  mass	  
fingerprinting	   (PMF),	   where	   digested	   peptides	   are	   mass-­‐analysed	   and	  
compared	   against	   protein	   databases	   to	   identify	   the	   parent	   protein	   [199-­‐203].	  
Protein	  identification	  by	  PMF	  is	  further	  described	  in	  Chapter	  1.6.4.	  
	  
	   The	   MALDI	   mass	   spectra	   of	   proteins	   and	   peptides	   typically	   include	  
mainly	   the	   singly	  protonated	  molecular	   species	  and	   their	  oligomeric	   ions	   (e.g.	  
[M+H]+,	  [2M+H]+).	  Additionally,	  Na+	  and	  K+	  adducts	  are	  also	  common	  features	  of	  
these	  MALDI	  spectra.	  	  
	  
	  
1.6.2.2	   Electrospray	  ionisation	  
	  
	   The	  widespread	  use	  of	  ESI	  was	  started	  by	  the	  work	  of	  Fenn	  et	  al	  when	  
they	   obtained	   multiply	   charged	   ions	   from	   proteins	   and	   determined	   their	  
molecular	  weights	  using	  mass	  spectrometers	  of	  modest	  m/z	  range	   [180,	  204].	  
ESI	  is	  a	  type	  of	  atmospheric	  pressure	  ionisation	  (API),	  which	  allows	  the	  analysis	  
of	  non-­‐volatile	  samples	  without	  first	  converting	  them	  to	  the	  gaseous	  phase.	  The	  
most	  important	  advantage	  of	  API	  sources	  is	  the	  simplicity	  for	  the	  direct	  on-­‐line	  
coupling	  of	  separation	  techniques	  such	  as	  high-­‐pressure	  liquid	  chromatography	  
(HPLC)	  to	  the	  mass	  spectrometer	  [195].	  
	  
	   During	  standard	  ESI,	  the	  sample	  is	  dissolved	  in	  an	  organic	  solvent	  that	  is	  
continuously	  pumped	  through	  a	  narrow	  stainless	  steel	  capillary	  tube	  at	  a	   flow	  
rate	  of	  1	  -­‐	  1000	  µL/min).	  A	  potential	  difference	  of	  3	  –	  4	  kV	  between	  the	  tip	  of	  
the	   capillary	   and	   the	   walls	   of	   the	   surrounding	   atmospheric	   pressure	   region	  
produces	   an	   electrostatic	   field	   of	   sufficient	   strength	   to	   disperse	   the	   emerging	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sample	   in	  a	   fine	  mist	  of	  charged	  droplets.	  This	  process	   is	  aided	  by	  a	  co-­‐axially	  
introduced	  nebulising	  gas	  (usually	  nitrogen)	  flowing	  around	  the	  outside	  of	  the	  
capillary	   tube,	  which	  helps	   to	  direct	   the	  spray	  emerging	   from	  the	  capillary	   tip	  
towards	  the	  mass	  analyser.	  The	  charged	  droplets	  are	  gradually	  stripped	  of	  the	  
solvent	   molecules	   as	   they	   flows	   through	   a	   region	   containing	   a	   drying	   gas	  
(usually	  warm	  nitrogen)	  before	  the	  charged	  sample	  ions	  (free	  from	  solvent)	  are	  
directed	  through	  a	  sample	  cone	  or	  orifice	  into	  an	  low-­‐pressure	  transport	  region	  





Figure 1.7 Standard ESI process. Dissolved sample is continuously pumped through narrow 
stainless steel capillary tube. The electrostatic field brought about by the potential difference 
between the tip of the capillary and the walls of the surrounding atmospheric pressure region 
disperses the emerging sample in a fine mist of charged droplets. This process is aided by a 
co-axially introduced nebulising gas, which also helps to direct the emerging spray towards 
the mass analyser. The charged droplets are gradually desolvated as they flows through a 
drying gas before the charged sample ions are directed through a sample cone or orifice into 
a low-pressure transport region before entering the mass analyser held under high vacuum. 
	  
	  
	   Thus,	   there	   are	   three	   main	   stages	   in	   ESI:	   droplet	   formation,	   droplet	  
shrinkage,	  and	  gaseous	   ion	   formation.	  Microscopic	  examination	  of	   the	  nascent	  
drop	  forming	  at	  the	  tip	  of	  the	  capillary	  shows	  that	  when	  the	  applied	  voltage	  is	  
low,	   the	  drop	   is	   almost	   spherical.	  With	   increasing	  voltage,	   the	  drop	  elongates,	  
eventually	   adopting	   the	   form	   of	   a	   Taylor	   cone	   [205,	   206]	   just	   before	   small	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droplets	   are	   released,	   creating	   the	   spray	   [207,	   208].	   As	   the	  droplets	   travelled	  
through	   the	   drying	   gas,	   they	   become	   desolvated	   and	   reduced	   in	   size	   until	  
surface-­‐coulombic	   forces	   overcome	   surface-­‐tension	   forces	   and	   the	   droplets	  
break	   up	   further	   into	   even	   smaller	   droplets	   [209,	   210].	   This	   continues	   until	  
either	  an	   ion	  desorbs	   from	  a	  droplet	   (Ion-­‐Desorption	  Model)	  or	   the	   solvent	   is	  
completely	   removed	   (Charge	   Residue	   Model)	   [211,	   212].	   There	   is	   still	  
considerable	  debate	   as	   to	   the	   exact	  mechanism	  of	   ion	   formation,	   and	   is	   likely	  
that	  different	  mechanisms	  occur	  under	  different	  scenarios	  [213-­‐215].	  
	  
	   Nanoelectrospray	  ionisation	  (nESI)	  is	  a	  modification	  of	  the	  standard	  ESI	  
developed	   by	   Wilm	   and	   Mann	   [186,	   216].	   It	   has	   proven	   to	   be	   enormously	  
important	   in	   the	   analysis	   of	   biochemical	   and	   pharmaceutical	   samples	   since	  
much	  smaller	  quantities	  of	  analytes	  are	  required	  [217].	  With	  nESI,	  the	  capillary	  
tip	  used	  is	  much	  smaller,	  and	  the	  flow	  rate	  reduced	  to	  30	  –	  1000	  nL/min.	  Thus,	  
not	   only	   is	   far	   less	   sample	   consumed,	   a	   small	   volume	  of	   sample	   also	   lasts	   for	  
several	  minutes,	  allowing	  multiple	  analyses	  to	  be	  performed.	  This	  is	  particularly	  
advantageous	   in	   tandem	  mass	  spectrometric	   (MS/MS)	  amino	  acid	   sequencing.	  
In	   this	   study,	   samples	   are	   first	   passed	   through	   a	   liquid	   chromatography	   (LC)	  
column	  before	  nESI	  and	  MS/MS,	  in	  a	  set	  up	  known	  as	  nano	  LC-­‐MS/MS.	  	  
	  
	  
1.6.3	   Mass	  analysers	  
	  
1.6.3.1	   Time-­of-­flight	  mass	  analysers	  
	  
	   The	   TOF	   mass	   spectrometer	   is	   one	   of	   the	   simplest	   mass	   analysing	  
devices.	  It	  separates	  ions	  according	  to	  their	  velocities	  when	  they	  drift	  in	  a	  free-­‐
field	   region	   that	   is	   called	   a	   flight	   tube.	   The	   charged	   ions	   generated	   at	   the	   ion	  
source	   (e.g.	   MALDI)	   are	   accelerated	   towards	   the	   flight	   tube	   by	   a	   potential	  
difference	  between	  an	  electrode	  and	  the	  extraction	  grid	  [195].	  Since	  all	  the	  ions	  
acquire	  the	  same	  kinetic	  energy	  (equal	   to	  zVs,	  where	  z	   is	   the	  charge	  of	   the	   ion	  
and	  Vs	  the	  accelerating	  potential),	  ions	  travel	  at	  velocities	  v	  that	  are	  an	  inverse	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function	   of	   the	   square	   root	   of	   their	  m/z	   values	   (Equation	   1.1).	   That	   is,	   the	  
velocity	  of	  lighter	  ions	  will	  be	  higher	  and	  hence	  will	  arrive	  at	  the	  detector	  at	  the	  
end	  of	  the	  flight	  tube	  faster	  than	  heavier	  ions.	  	  
	  
Equation	  1.1:	   	   	   	  	  
	  
The	  time	  t	  needed	  to	  cover	  the	   length	  of	  the	  flight	  tube	  L	   is	  given	  by	  Equation	  
1.2.	  
Equation	  1.2:	  	   	   	   	  
	  
Therefore,	  replacing	  v	  by	  its	  value	  in	  Equation	  1.2	  gives	  Equation	  1.3.	  
	  
Equation	  1.3:	   	   	   	  
	  
	  
	   Thus,	   the	  m/z	  of	  an	   ion	  entering	  that	   flight	  tube	  can	  be	  calculated	  from	  
its	  time	  of	  arrival	  at	  the	  detector.	  The	  conversion	  of	  the	  flight	  times	  measured	  to	  
mass	   values	   involves	   a	   simple	   mass	   calibration	   using	   the	   flight	   times	   of	   two	  
different	  known	  mass	  ions	  [195].	  Apart	  from	  this	  ease	  of	  mass	  calibration,	  other	  
advantages	  of	   the	  TOF	  analyser	   include	   its	   (theoretical)	  unlimited	  upper	  mass	  
range,	  high	  sensitivity	  and	  rapid	  speed	  of	  analysis	  [218-­‐221].	  
	  
	   The	   recent	   renewed	   interest	   in	   TOF	   is	   largely	   attributed	   to	   its	   natural	  
coupling	  to	  the	  MALDI	  ion	  source.	  In	  the	  past,	  TOF	  analysers	  suffered	  from	  poor	  
mass	   resolution.	   One	   main	   factor	   that	   restricted	   resolution	   in	   early	   TOF	  
analysers	  was	   the	  variation	  of	   the	  kinetic	  energy	  distribution	  of	   the	   ion	  beam,	  
resulting	  in	  ions	  with	  higher	  initial	  energy	  arriving	  at	  the	  detector	  sooner	  those	  
with	  the	  same	  mass	  but	  with	  lower	  initial	  energy.	  There	  are	  two	  main	  ways	  to	  


























equilibrate	   and	  dissipate	  before	   they	   are	   accelerated	   into	   the	   flight	   tube.	  This	  
mode	   of	   operation	   is	   known	   as	   ‘delayed	   pulsed	   extraction’,	   which	   helps	   to	  
overcome	  the	  kinetic	  energy	  spread	  among	  ions	  with	  the	  same	  m/z	  leaving	  the	  
source	   [222].	   Another	   way	   of	   improving	   mass	   resolution	   is	   the	   use	   of	   a	  
reflectron.	  This	  is	  an	  electrostatic	  mirror	  consisting	  of	  a	  series	  of	  electric	  lenses	  
with	   increasing	   repelling	   potential	   that	   reflects	   the	   ion	   beam	   back	   to	   the	  
detector.	  In	  principle,	  ions	  with	  more	  kinetic	  energy	  (therefore	  higher	  velocity)	  
will	  travel	  deeper	  into	  the	  reflectron	  compared	  to	  less	  energetic	  ions.	  Since	  the	  
faster	   ions	   spend	   more	   time	   in	   the	   reflectron,	   they	   will	   arrive	   back	   at	   the	  
detector	  at	  the	  same	  time	  as	  slower	  ions	  with	  the	  same	  m/z	  [223].	  
	  
	  
1.6.3.2	   Three-­dimensional	  (3D)	  ion	  trap	  mass	  analysers	  
	  
	   The	  quadrupole	  ion	  trap	  was	  first	  described	  in	  1960	  [224],	  although	  only	  
modified	  to	  a	  useful	  mass	  spectrometer	  in	  the	  1980s	  by	  Stafford	  et	  al	  [225].	  The	  
3D	   ion	   trap	   is	   a	   device	   that	   traps	   ions	   in	   a	   radio	   frequency	   (RF)	   quadrupolar	  
field,	   in	  a	  space	  defined	  by	  a	  ring	  electrode	  between	  two	  endcap	  electrodes.	  A	  
high	  voltage	  RF	  potential	   is	   applied	   to	   the	   ring,	  while	   the	  endcaps	  are	  held	  at	  
ground.	   The	   oscillating	   potential	   difference	   between	   the	   ring	   and	   endcap	  
electrodes	  forms	  a	  substantially	  quadrupolar	  field.	  Depending	  on	  the	  RF	  voltage	  
level,	   the	   field	  can	  trap	   ions	  of	  a	  particular	  mass	  range.	  An	  auxiliary	  voltage	   is	  
also	  fed	  to	  the	  exit	  endcap,	  which	  is	  used	  for	  various	  purposes	  during	  precursor	  







Figure 1.8 The 3D ion trap geometry. A high voltage RF potential is applied to the ring 
electrode, while the endcap electrodes are held at ground. The oscillating potential difference 





	   In	   order	   to	   reduce	   ion	   losses	   in	   the	   trap,	   a	   collision	   gas	   (helium)	   is	  
present	  in	  the	  trap	  to	  extract	  energy	  from	  the	  ion	  beam	  and	  cause	  retention	  of	  at	  
least	  a	  certain	  portion	  of	  the	  ions	  entering	  the	  trap.	  Other	  parameters	  that	  affect	  
trapping	   efficiency	   include	   the	   ion	   injection	   directions,	   initial	   phase	   of	   the	  RF	  
voltage,	  energy	  of	  the	  incoming	  ion	  beam,	  and	  the	  m/z	  value	  and	  mass	  of	  the	  ion	  
[226].	  
	  
	   There	  are	  various	  ways	  of	  analysing	  the	  ions	  according	  to	  their	  mass,	  but	  
the	  most	  commonly	  used	  is	  the	  mass	  instability	  mode.	  Here,	  there	  is	  a	  stability	  
limit	   (determined	   by	   the	   RF	   potential)	   within	   which	   the	   orbit	   of	   ions	   with	   a	  
certain	  mass	  is	  stable	  while	  those	  with	  lower	  masses	  are	  unstable	  and	  ejected.	  
As	   the	   RF	   potential	   is	   ramped,	   ions	   of	   higher	   masses	   become	   sequentially	  
unstable	  and	  are	  ejected.	  	  
31	  
	  
	   Although	  having	  a	  mainly	  quadrupolar	  field,	  the	  high	  capacity	  trap	  (HCT)	  
as	  used	  in	  this	  work	  is	  really	  a	   'multipole-­‐superimposed'	  ion	  trap	  in	  which	  the	  
quadrupolar	  field	  has	  contributions	  from	  hexapolar,	  octopolar	  and	  even	  higher-­‐
order	  fields.	  This	  induces	  non-­‐linear	  resonances	  that	  cause	  energy	  to	  be	  rapidly	  
taken	  up	  in	  the	  ion	  motion.	  The	  ions,	  by	  taking	  up	  energy	  very	  quickly,	  can	  then	  
leave	  the	  ion	  trap	  without	  becoming	  unstable	  in	  the	  field.	  This	  ultimately	  allows	  
for	  fast	  data	  acquisition	  without	  compromising	  mass	  resolution.	  The	  sequential	  
mass	  ejection	  of	  the	  ions	  is	  then	  detected	  by	  the	  ion	  detector	  to	  produce	  a	  mass	  
spectrum	  [227].	  	  
	  
	  
1.6.4	   Protein	  identification	  by	  peptide	  mass	  fingerprinting	  
	  
	   In	  PMF,	  a	  protein	  is	  first	  digested	  into	  peptides	  using	  a	  sequence-­‐specific	  
protease.	   	   The	  masses	   of	   this	   group	  of	   peptides	   are	   then	  matched	   against	   the	  
theoretical	  masses	  of	  peptides	  from	   in	  silico	  digested	  proteins	  (using	  the	  same	  
protease)	   in	   a	   database	   [201,	   203].	   It	   is	   called	   peptide	   mass	   fingerprinting	  
because	   a	   protein	   digested	   by	   a	   sequence-­‐specific	   protease	   generates	  
predictable	   masses	   that	   are	   generally	   unique	   to	   the	   protein	   (hence	   a	   ‘mass	  
fingerprint’).	  Trypsin	  is	  the	  most	  commonly	  used	  protease,	  cleaving	  proteins	  at	  
the	  C-­‐termini	   of	   arginine	   (R)	   and	   lysine	   (K)	   residues.	  Although	   it	   is	   known	  as	  
peptide	  mass	   fingerprinting,	  MS	  analysis	  of	  peptides	  actually	  provides	  a	   list	  of	  
m/z	  ratios.	  This	  experimentally	  obtained	  m/z	  ratios	  of	  peptides	  is	  then	  matched	  
using	  an	  algorithm	  to	  compare	  with	  theoretically	  predicted	  peptide	  m/z	  ratios	  
of	   proteins	   in	   a	   database.	   Scores	   are	   assigned	   according	   to	   the	   number	   of	  
matches	   obtained,	   as	   well	   as	   the	   quality	   of	   the	   matches.	   PMF	   is	   generally	  






1.6.5	   Protein	  identification	  using	  tandem	  mass	  spectrometry	  
	  
	   MS/MS	   involves	   at	   least	   two	   stages	   of	   mass	   analysis.	   In	   the	   most	  
common	  MS/MS	  experiment,	  a	   first	  analyser	   isolates	  a	  precursor	   ion,	  which	   is	  
focused	   into	   a	   collision	   region	   where	   it	   undergoes	   fragmentation	  
(spontaneously	  or	  by	  some	  activation)	  to	  yield	  product	  ions.	  These	  product	  ions	  
are	  then	  analysed	  by	  a	  second	  analyser	  [195].	  	  
	  
	   MS/MS	  for	  the	  structural	  characterisation	  of	  organic	  molecules	  was	  first	  
utilised	  by	  Beynon	  and	  colleagues	  [228].	   It	   is	  particularly	   in	  protein	  chemistry	  
that	  MS/MS	  has	  become	  most	  widely	  utilised	  [185,	  186,	  229-­‐232].	  In	  fact,	  it	  has	  
largely	   replaced	   PMF	   as	   the	   main	   protein	   identification	   approach.	   There	   are	  
various	   ways	   by	   which	   peptide	   ions	   can	   be	   fragmented,	   which	   is	   largely	  
dependent	   on	   the	   type	   of	   mass	   spectrometer	   used.	   This	   in	   turn	   determines	  
where	  in	  the	  peptide	  backbone	  the	  peptides	  are	  fragmented	  [233].	  An	  inert	  gas	  
is	  generally	  introduced	  into	  the	  collision	  region	  to	  enable	  collision	  between	  the	  
precursor	   ion	   and	   inert	   gas	   atoms	   or	   molecules.	   The	   result	   of	   this	   is	   a	  
population	  of	  excited	  peptide	  ions	  that	  decompose	  to	  product	  ions	  in	  a	  process	  
known	   as	   'collision-­‐induced	   dissociation'	   (CID)	   which	   is	   the	   decomposition	  
process	   used	   in	   triple	   quadrupole,	   ion	   trap	   and	   quadrupole-­‐time	   of	   flight	  
(QTOF)	  hybrids	  mass	   spectrometers	   [234].	   The	  process	   of	   CID	  on	   each	  of	   the	  
peptide	   ions	   can	   be	   automated	  with	   various	   protocols	   developed	   to	   allow	   for	  
specific	  precursor	   ions	   to	  be	   selected	   for	  CID.	  For	   instance,	   in	  data-­‐dependent	  
acquisition	  MS/MS,	  the	  most	  abundant	  ion	  is	  selected	  first	  for	  CID	  with	  the	  next	  
most	  abundant	  ion	  analysed	  next,	  and	  so	  forth	  [235].	  
	  
	   Low-­‐energy	  CID	   generally	   results	   in	   the	   cleavage	   of	   the	   amide	  bond	  of	  
peptides.	  Hence	  the	  majority	  of	  the	  product	  ions	  formed	  are	  b	  and	  y	  ions	  (Figure	  
1.9).	   A	   b	   ion	   is	   formed	   when	   the	   positive	   charge	   associated	   with	   the	   parent	  
peptide	   ion	   is	  retained	  by	  the	  N-­‐terminal	   fragment	  side,	  while	  a	  y	   ion	   is	  when	  






Figure 1.9 Roepstorff-Fohlmann-Biemann nomenclature of fragment ions that can be 
generated following gas phase fragmentation [230]. Peptide fragmentation through collision 




	   From	  the	  peptide	  fragmentation	  spectra	  obtained	  from	  MS/MS,	  proteins	  
can	   be	   identified	   using	   two	   methods.	   The	   first	   method	   is	   known	   as	   de	   novo	  
sequencing	   which	   is	   based	   on	   the	   principle	   that	   each	   peptide	   fragment	   in	   a	  
series	  differs	  from	  its	  neighbour	  by	  one	  amino	  acid.	  Therefore,	  in	  principle,	  it	  is	  
possible	   to	   determine	   the	   amino	   acid	   sequence	   by	   mass	   difference	   between	  
neighbouring	  peaks	  in	  a	  series	  [237].	  The	  main	  advantage	  of	  de	  novo	  sequencing	  
is	  that	  peptide	  sequencing	  is	  not	  restricted	  to	  peptides	  contained	  in	  a	  database.	  
However,	   there	   are	   significant	   difficulties	   with	   this	   method,	   which	   primarily	  
stems	   from	   the	   fact	   that	   information	   in	   MS/MS	   is	   often	   incomplete	   and	  
intervening	  peaks,	  which	  may	  or	  may	  not	  belong	  to	  a	  peptide	  series,	  can	  make	  
analysis	   very	   difficult	   [238].	   Although	   attempts	   have	   been	  made	   to	   automate	  
this	  process,	  it	  is	  still	  a	  time-­‐consuming	  and	  difficult	  task	  [239].	  
	  
	   The	  second	  method	  of	  protein	  identification	  is	  to	  compare	  the	  m/z	  peaks	  
in	   the	   CID	   spectra	  with	   theoretical	   in	   silico	   generated	  MS/MS	   CID	   spectra.	   In	  
contrast	   to	   de	   novo	   sequencing,	   this	   is	   easily	   automated	   and	   is	   the	   more	  
commonly	  used	  method.	  The	  reason	  database	  searching	   is	  easier	  than	  de	  novo	  
34	  
sequencing	   is	   that	   only	   a	   minute	   fraction	   of	   the	   possible	   peptide	   amino	   acid	  
sequences	   actually	   occur	   naturally.	   Thus,	   even	   if	   a	   peptide	   fragmentation	  
spectrum	  is	  inadequate	  for	  complete	  amino	  acid	  sequencing,	  it	  may	  still	  contain	  
sufficient	  information	  for	  it	  to	  be	  uniquely	  matched	  to	  a	  peptide	  sequence	  in	  a	  




1.7	   Objectives	  of	  this	  study	  
	  
	   There	  were	   two	  main	   focuses	   in	   the	  study	  described	   in	   this	   thesis.	  The	  
first	  was	  a	  functional	  study	  whose	  primary	  objective	  was	  to	  determine	  whether	  
FLG	  mutations	   correlated	  with	   altered	   skin	   barrier	   function	   in	   AD	   subjects.	   A	  
correlation	  between	  FLG	  mutations	  and	  AD	  has	  been	  well	   established	   [23,	  26,	  
33,	  35],	  and	  it	  has	  also	  been	  shown	  that	  skin	  barrier	  dysfunction	  is	  a	  feature	  of	  
AD	  skin	  [15,	  242].	  However,	  there	  is	  at	  present	  limited	  evidence	  for	  a	  defective	  
skin	   barrier	   function	   in	   filaggrin-­‐related	   AD,	   with	   the	   few	   studies	   that	   had	  
attempted	   to	   analyse	   this	   reporting	   inconsistent	   results	   [243,	   244].	   For	   this	  
functional	   study	   (as	   detailed	   in	   Chapter	   5),	   a	   cohort	   of	   AD	   subjects	   was	  
recruited	   and	   genotyped	   for	   the	  FLG	   gene.	   The	   skin	   barrier	   function	   of	   these	  
individuals	   was	   assessed	   by	   three	   different	   measures,	   and	   analysed	   to	   see	   if	  
they	  correlated	  with	  the	  presence	  of	  FLG	  mutations.	  There	  was	  also	  a	  secondary	  
aim	  in	  this	  functional	  study,	  which	  was	  to	  test	  the	  hypothesis	  that	  corneocytes	  
were	   less	   adherent	   to	   one	   another	   in	   filaggrin-­‐related	   AD	   compared	   to	   wild-­‐
type	   AD	   skin.	   This	   hypothesis	   was	   developed	   from	   an	   unexpected	   finding	  
reported	   by	   Nemoto-­‐Hasebe	   et	   al	   [244],	   who	   showed	   that	   SC	   thickness	   was	  
greater	  in	  the	  skin	  of	  filaggrin-­‐related	  AD.	  	  
	  
	   The	   second	   focus	   of	   this	   study	   aimed	   to	   interrogate	   the	   structure-­‐
function	  relationship	  of	  filaggrin,	  by	  comparing	  filaggrin	  protein	  extracted	  from	  
AD	  and	  non-­‐AD	  skin.	  Although	  FLG	  mutations	  are	  strongly	  associated	  with	  AD,	  
only	  up	  to	  about	  half	  of	  AD	  individuals	  possess	  these	  mutations	  while	  the	  rest	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have	  the	  wild-­‐type	  genotype	  [38].	  Genetics,	  of	  course,	  cannot	  completely	  inform	  
about	   cell	   physiology.	   For	   instance,	   there	   may	   be	   post-­‐translational	  
modifications,	  or	  dynamic	  processes	  of	  protein	  maturation	  and	  degradation	  can	  
alter	  the	  structure	  and	  function	  of	  the	  final	  active	  protein	  [245].	  Therefore,	  the	  
aim	  of	   this	   structural	   study	  was	   to	   analyse	   filaggrin	  protein	  directly	  using	  MS	  
techniques,	   specifically	   MALDI	   MS	   and	   nano	   LC-­‐MS/MS.	   Any	   structural	  
differences	   noted	   in	   filaggrin	   between	   AD	   and	   non-­‐AD	   skin	   would	   hopefully	  
provide	   further	   insight	   into	   its	   role	   in	  AD.	   This	   structural	   study	   is	   detailed	   in	  
Chapter	  6.	  	  	  
	  
	   In	  order	  to	  analyse	  filaggrin	  using	  MS	  techniques,	  a	  sufficient	  amount	  of	  
the	  protein	  had	  to	  be	  extracted	  and	  purified.	  Traditionally,	  discarded	  skin	  from	  
procedures	  such	  as	  breast	  reduction	  surgery	  and	  abdominoplasty	  is	  used	  in	  skin	  
research	  that	  requires	  a	  large	  amount	  of	  skin	  cells.	  Indeed,	  breast	  reduction	  skin	  
was	   collected	   from	   several	   healthy	   non-­‐AD	   individuals	   for	   use	   in	   the	  
development	  of	  the	  filaggrin	  extraction	  and	  purification,	  but	  it	  would	  have	  been	  
impractical	  to	  recruit	  only	  subjects	  who	  underwent	  breast	  reduction	  surgeries	  
or	   abdominoplasties.	   As	   such,	   tape	   stripping	  was	   used	   for	   the	   first	   time	   as	   a	  
minimally-­‐invasive	  method	  of	  extracting	  filaggrin	  from	  subjects'	  skin.	  Chapter	  3	  
describes	  the	  development	  of	  tape	  strip	  extraction	  and	  purification	  of	  filaggrin.	  	  
	  
	   Soon	   after	   commencing	   this	   study,	   it	   became	   clear	   that	   there	   were	  
practical	   benefits	   to	   having	   a	   relatively	   quick	   screening	   test	   to	   detect	   and	  
quantify	   filaggrin	   in	   the	   skin.	  This	  was	  primarily	  because	  FLG	   genotyping	  was	  
time-­‐consuming	   and	   expensive,	   and	   also	   because	   the	   detection	   of	   filaggrin	   in	  
significant	   quantity	   in	   skin	   samples	   should	   make	   genotyping	   these	   samples	  
unnecessary,	   as	   reasoned	   in	   Chapter	   4.	   In	   the	   absence	   of	   any	   commercially-­‐
available	  filaggrin-­‐specific	  ELISA	  at	  that	  time,	  attempts	  were	  made	  to	  develop	  a	  















Chapter	  2	   Materials	  and	  Methods	  
37	  
2.0	   MATERIALS	  AND	  METHODS	  
	  
2.1	   Recruitment	  of	  subjects	  
	  
	   Subjects	  with	  AD,	  as	  well	  as	  non-­‐AD	  control	  subjects,	  were	  recruited	  from	  
the	  general	  dermatology	  outpatient	  and	  patch	  test	  clinics	  at	  the	  Royal	  Infirmary	  
of	  Edinburgh.	  Additionally,	  in	  order	  to	  recruit	  AD	  subjects	  with	  a	  wide	  range	  of	  
AD	  severity	  (since	  AD	  individuals	  who	  attend	  dermatology	  clinics	  tend	  to	  have	  
more	   severe	   disease),	   advertisements	   about	   the	   study	   were	   also	   placed	   on	  
student	  notice	  boards	  throughout	  the	  University	  of	  Edinburgh.	  
	  
	   Informed	  written	  consent	  was	  obtained	  from	  all	  subjects.	  The	  study	  had	  
received	  prior	  approval	  by	  the	  Lothian	  Research	  Ethics	  Committee.	  
	  
	  
2.1.1	   Entry	  criteria	  of	  atopic	  dermatitis	  
	  
	   All	   subjects	  were	  of	  Western	  European	  descent	  since	  different	   filaggrin	  
mutations	  are	  prevalent	  in	  different	  populations.	  Most	  of	  the	  AD	  subjects	  were	  
already	   diagnosed	   with	   the	   condition	   by	   their	   dermatologists	   or	   general	  
practitioners.	  Nonetheless,	  every	  subject	  was	  interviewed	  and	  examined	  at	  the	  
start	  of	   recruitment	   to	  ensure	   fulfilment	  of	   the	  UK	  Working	  Party’s	  diagnostic	  
criteria	   of	   AD	   [246].	   These	   criteria	   are	   shown	   in	   Table	   2.1.	   Similarly,	   these	  












Diagnosis of AD requires the presence of an itchy skin condition plus 3 or more of the 
following: 
  1. Visible flexural dermatitis 
  2. Personal history of flexural dermatitis 
  3. Personal history of dry skin in the last 12 months 
  4. Personal history of asthma or hay fever 
  5. Childhood eczema 
 
 
Table 2.1 UK Working Partyʼs diagnostic criteria for the diagnosis of AD [246]. All subjects in 
the AD group had to fulfil these criteria at the point of recruitment. 
	  
	  
2.1.2	   Exclusion	  criteria	  
	  
	   Subjects	   who	   had	   active	   inflammation	   or	   infection	   on	   the	   flexural	  
surfaces	   of	   the	   forearms	   (where	   skin	   barrier	   function	   tests	   were	   performed)	  
were	   excluded,	   as	   were	   those	   who	   did	   not	   discontinue	   topical	   treatment	   for	  
their	  AD	  on	  the	  test	  areas	  at	  least	  1	  week	  prior	  to	  skin	  barrier	  assessment.	  	  
	  
	  
2.2	   Clinical	  assessment	  of	  atopic	  dermatitis	  severity	  
	  
	   The	   Six	   Area	   Six	   Sign	   Atopic	   Dermatitis	   (SASSAD)	   severity	   score	   was	  
chosen	   as	   the	  measure	   of	   AD	   severity	   in	   this	   study	   because	   it	   is	   a	   validated,	  
simple	   and	  effective	   system	   to	   record	  and	  monitor	  disease	   activity	   [247].	  The	  
score	   is	   obtained	   by	   grading	   six	   signs	   (erythema,	   exudation,	   excoriation,	  
dryness,	   cracking	  and	   lichenification)	  on	  a	   scale	  of	  0	   (absent)	   to	  3	   (severe)	  at	  
each	  of	  six	  anatomical	  sites	  (Table	  2.2).	  
	  
	   During	  the	  initial	  interview,	  subjects	  were	  also	  asked	  about	  the	  past	  and	  
present	   treatment	   for	   their	  AD,	   including	  any	  previous	   inpatient	   treatment,	   in	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order	  to	   fully	  characterise	  their	  disease	  severity.	  Additional	   information	  noted	  




	   Six clinical signs   Six anatomical sites 
 
 1. Erythema   1. Head and neck 
 2. Exudation   2. Trunk 
 3. Excoriation   3. Hands 
 4. Dryness   4. Feet 
 5. Cracking   5. Arms 
 6. Lichenification   6. Legs 
 
 
Table 2.2 The Six Area Six Sign Atopic Dermatitis Severity (SASSAD) score. The six signs 
are graded on a scale of 0 (absent), 1 (mild), 2 (moderate), or 3 (severe) at six anatomical 
sites. The maximum score is 108.  
	  
	  
2.3	   Genotyping	  
	  
	   All	   AD	   subjects	  were	   screened	   for	  FLG	  mutations,	  with	   the	   genotyping	  
performed	   at	   the	   Molecular	   Medicine	   Unit	   at	   the	   University	   of	   Dundee.	  
Specifically,	   the	   four	   FLG	   mutations	   that	   were	   most	   prevalent	   in	   Western	  
European	  populations	  (2282del4,	  R501X,	  R2247X	  and	  S3247X)	  were	  screened	  
for.	  Together,	  these	  mutations	  had	  been	  shown	  to	  account	  for	  up	  to	  95%	  of	  the	  
known	   FLG	   mutations	   in	   European	   populations	   [248].	   Genotyping	   was	  
performed	   using	   a	   TAQMAN-­‐based	   allelic	   discrimination	   assay	   (Applied	  
Biosystems)	   on	   an	   Applied	   Biosystems	   7900HT	   sequence	   detection	   system.	  
Details	   of	   the	   assay,	   including	   the	   probes	   and	   primers	   used,	   were	   previously	  





2.4	   Serum	  IgE	  level	  
	  
	   All	   subjects	   had	   their	   total	   serum	   IgE	   levels	   (IU/ml)	   measured	   at	   the	  
start	   of	   the	   study.	   Blood	   samples	   were	   analysed	   by	   the	   Blood	   Transfusion	  
Service	  at	  the	  Royal	  Infirmary	  of	  Edinburgh.	  
	  
	  
2.5	   Skin	  barrier	  function	  tests	  
	  
	   To	   objectively	   assess	   the	   function	   of	   the	   skin	   barrier,	   three	   different	  
measures	  were	  performed:	   1)	  TEWL,	   2)	   skin	   capacitance	   (as	   a	  measure	   of	   SC	  




2.5.1	   TEWL	  and	  skin	  capacitance	  
	  
	   TEWL	  and	  skin	  capacitance	  were	  measured	  on	  all	  subjects	  according	  to	  
the	  European	  Society	  of	  Contact	  Dermatitis	  guidelines	  [137].	  	  
	  
	   TEWL	  was	  measured	  with	  a	  Tewlameter	  TM300	  (Courage	  and	  Khazaka)	  
using	  an	  open	  chamber	  probe	  that	  contained	  a	  hygrometer.	  This	  measures	  the	  
humidity	  of	   the	   incoming	  and	  outgoing	  air	  passing	   through	   the	   test	  area,	  with	  
the	   TEWL	   being	   the	   difference	   between	   the	   two	   values.	   Since	   TEWL	   is	   a	  
measure	   of	   the	   amount	   of	   water	   loss	   from	   the	   skin	   surface,	   it	   is	   therefore	  
essentially	   a	  measure	  of	   how	  effective	   the	   skin	  barrier	   is	   at	   keeping	  moisture	  
within.	  
	  	  
	   Skin	   capacitance	   was	   measured	   with	   a	   Corneometer	   CM825	   (Courage	  
and	   Khazaka).	   Skin	   capacitance	   is	   determined	   by	   the	   dielectric	   nature	   of	   the	  
epidermis,	   which	   varies	   depending	   on	   the	   amount	   of	   moisture	   in	   the	   skin.	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Therefore,	  skin	  with	  different	  amount	  of	  hydration	  will	  have	  different	  dielectric	  
constants,	  thus	  giving	  different	  capacitance	  values.	  	  
	  
	   One	   week	   prior	   to	   the	   TEWL	   and	   skin	   capacitance	   measurements,	   all	  
subjects	  were	   asked	   to	  discontinue	   the	  use	   of	   emollients,	   topical	   steroids	   and	  
any	  other	  treatment	  for	  their	  AD.	  	  Subjects	  were	  rested	  for	  at	  least	  15	  min	  prior	  
to	  measurements	   being	   taken	   from	   the	   flexural	   surface	   of	   the	   forearm	   (4	   cm	  
below	   the	   antecubital	   fossa)	   that	   was	   free	   from	   any	   eczematous	   rash	   or	  
infection.	   The	   room	   temperature	   was	   kept	   between	   20-­‐22	   oC	   and	   humidity	  
between	  40–60	  %.	  Additionally,	  both	  tests	  were	  performed	  in	  an	  open-­‐topped	  
box	   to	   limit	   convection	   currents	   and	   condensation.	   	   These	   standardised	  
conditions	   were	   taken	   to	   minimise	   variability	   in	   the	   measurements.	   Three	  
measurements	  were	  obtained	  for	  each	  test	  from	  each	  subject,	  with	  the	  average	  
of	  the	  three	  measurements	  used	  for	  subsequent	  analysis.	  
	  
	  
2.5.2	   Tape	  stripping	  
	  
	   In	  addition	  to	  being	  used	  as	  a	  method	  of	  protein	  extraction	  (as	  described	  
in	  Chapter	  3),	  tape	  stripping	  was	  also	  used	  as	  a	  measure	  of	  skin	  barrier	  function.	  
Specifically,	   the	   number	   of	   tape	   strips	   required	   to	   abrogate	   the	   permeability	  
barrier	  (defined	  as	  TEWL	  >	  20	  g/m2/h)	  had	  been	  shown	  to	  be	  a	  good	  indicator	  
of	   skin	  barrier	   [145-­‐147].	  D-­‐Squame	   tape	  discs	   (14	  mm	  and	  22	  mm	  diameter	  
tape	   discs,	   CuDerm	  Corporation),	  which	  were	   specifically	   designed	   for	   SC	   cell	  
sampling,	   were	   used.	   Each	   tape	  was	   placed	   on	   a	  marked	   site	   on	   the	   forearm	  
before	   a	   spring-­‐loaded	   device	   delivering	   a	   fixed	   pressure	   of	   225	   g/cm2	   was	  
applied	  over	   it	   for	  10	   s.	  The	   tape	  was	   then	  peeled	  off	  unidirectionally	  using	  a	  
forceps.	   Consistency	   in	   the	   applied	   pressure	   and	   tape	   stripping	   procedures	  
were	  maintained	  to	  optimise	  the	  removal	  of	  a	  consistent	  amount	  of	  SC	  cells	   in	  




2.6	   Bicinchoninic	  acid	  (BCA)	  protein	  assay	  
	  
	   The	   Pierce	   BCA	   protein	   assay	   kit	   (Thermo	   Scientific)	   was	   used	   for	   all	  
protein	  quantification.	  A	  working	  reagent	  was	  first	  prepared	  by	  mixing	  50	  parts	  
of	   BCA	   Reagent	   A	   to	   1	   part	   of	   BCA	   Reagent	   B.	   Bovine	   serum	   albumin	   (BSA)	  
standards	   ranging	   from	  25-­‐2000	  µg/ml	  were	  prepared	   in	  water.	   To	  200	  ul	   of	  
working	   reagent	   was	   pipetted	   10	   ul	   of	   unknown	   sample	   or	   standard.	   The	  
resultant	  solution	  was	  then	  incubated	  at	  37	  oC	  for	  30	  min	  before	  its	  absorbance	  
was	  determined	  at	  562	  nm	  with	  a	  BioPhotometer	  (Fisher	  Scientific).	  A	  standard	  




2.7	   SDS-­polyacrylamide	   gel	   electrophoresis	   (SDS-­PAGE)	   and	  
	   immunoblotting	  
	  
2.7.1	  	   SDS-­PAGE	  
	  
2	  x	  SDS	  Sample	  Buffer	  
20	  mM	  NaH2PO4	  
0.2	  M	  DTT	  
2	  %	  (v/v)	  glycerol	  
2	  %	  (w/v)	  SDS	  
0.001	  %	  bromophenol	  blue	  
	  
SDS	  Running	  Buffer	  
30	  mM	  MOPS	  
60	  mM	  Tris-­‐base	  
6	  mM	  NaHSO3	  
0.1	  %	  (w/v)	  SDS	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   10	   ul	   of	   SDS	   Sample	   Buffer	   was	  mixed	   with	   10	   ul	   of	   protein	   samples.	  
These	  were	  heated	  at	  100	  oC	  for	  2	  min	  before	  they	  were	  loaded	  onto	  a	  4-­‐20	  %	  
RunBlue	  precast	  gel	  (Expedeon).	  The	  samples	  were	  resolved	  by	  electrophoresis	  
in	  the	  SDS	  Running	  Buffer	  on	  a	  BioRad	  gel	  apparatus	  at	  150	  V	  for	  40-­‐45	  min.	  	  
	  
2.7.2	   Detection	  of	  separated	  protein	  	  
	  
2.7.2.1	   Staining	  with	  InstantBlue	  
	  
	   Staining	  of	   the	  protein	  bands	  was	  performed	  using	   InstantBlue	  protein	  
gel	  stain	  (Expedeon),	  which	  is	  a	  Coomassie-­‐based	  stain.	  The	  SDS-­‐PAGE	  gel	  was	  
immersed	  in	  approximately	  20	  ml	  of	  InstantBlue	  and	  stained	  for	  at	  least	  1	  h.	  
	  
	  
2.7.2.2	   Immunoblotting	  
	  
Semi-­dry	  transfer	  buffer	  (SDTB)	  
48	  mM	  Tris	  
39	  mM	  glycine	  
20	  %	  (v/v)	  ethanol	  
	  
Ponceau	  S	  stain	  
0.1	  %	  (w/v)	  Ponceau	  S	  in	  5	  %	  acetic	  acid	  
	  
Tris	  Buffered	  Saline	  (TBS)	  
20	  mM	  Tris	  
150	  mM	  NaCl	  
(pH	  adjusted	  to	  7.5	  using	  HCl)	  
	  
TBS-­tween	  (TBST)	  




5	  %	  (w/v)	  ovalbumin	  (Sigma-­‐Aldrich)	  in	  TBST	  
	  
Dilution	  Buffer	  
1	  %	  (w/v)	  ovalbumin	  (Sigma-­‐Aldrich)	  in	  TBST	  
	  
SuperSignal	  West	  Femto	  Maximum	  Sensitivity	  Substrate	  	  
Working	  Solution	  (Thermo	  Scientific)	  
Substrate	  components	  1	  and	  2	  in	  equal	  amount	  
	  
	   Immediately	  following	  electrophoresis,	  the	  SDS-­‐PAGE	  gel	  was	  washed	  in	  
SDTB	   for	   15	  min.	   Resolved	   protein	   bands	  were	   transferred	   onto	   a	   Hybond-­‐P	  
PVDF	  membrane	   (Amersham)	   in	  SDTB	  at	  20	  V	   for	  50	  min,	   in	  a	  Trans-­‐Blot	   SD	  
Transfer	  Cell	   (Bio-­‐Rad).	  Following	   transfer,	   the	  membrane	  was	  stained	  briefly	  
with	  Ponceau	  S	  stain	  to	  allow	  visualisation	  of	  successful	  transfer	  of	  the	  protein	  
bands.	   After	  washing	   the	   stain	   off	   with	  water,	   the	  membrane	  was	   blocked	   in	  
Blocking	   Buffer	   for	   1	   h	   before	   being	   incubated	  with	   a	   primary	   antibody	   (see	  
Table	  2.3)	   in	  Dilution	  Buffer	  for	  1	  h	  at	  room	  temperature	  or	  overnight	  at	  4	  oC.	  	  
The	  blot	  was	  then	  washed	  three	  times	  (5	  min	  each	  time)	  in	  TBST	  before	  being	  
incubated	   in	   a	   horseradish	   peroxidise	   (HRP)-­‐coupled	   secondary	   antibody	   in	  
Dilution	  Buffer	   for	  1	  h	   at	   room	   temperature.	  After	   the	  blot	  was	  washed	   twice	  
with	  TBST	  (5	  min	  each	  time)	  and	  once	  with	  TBS	  (5	  min),	  it	  was	  incubated	  for	  5	  
min	   in	   500	   µl	   of	   SuperSignal	   West	   Femto	   Maximum	   Sensitivity	   Substrate.	  












Primary antibodies Species/Description  Dilutions Company 
 
ab24584  Rabbit polyclonal  1:1000  Abcam 
AKH1   Mouse monoclonal  1:200  Santa Cruz 
G-20   Goat polyclonal   1:200  Santa Cruz 
ab17808  Mouse monoclonal  1:200  Abcam 
 
HRP-coupled  Species/Description  Dilutions Company 
secondary antibodies  
 
P0448   Polyclonal goat anti-rabbit 1:10,000 Dako 
P0447   Polyclonal goat anti-mouse 1:10,000 Dako 
P0449   Polyclonal rabbit anti-goat 1:10,000 Dako 
 
 
Table 2.3 Primary anti-filaggrin antibodies and HRP-coupled secondary antibodies used in 
immunoblotting, with their corresponding dilutions used.  
	  
	  
2.8	   One-­way	   filaggrin-­specific	   enzyme-­linked	   immunosorbant	   assay	  
	   (ELISA)	  	  
	  
Carbonate-­bicarbonate	  Buffer	  
One	   carbonate-­‐bicarbonate	   buffer	   capsule	   (Sigma-­‐Aldrich)	   in	   100	  ml	   distilled	  
water	  
	  
Tris	  Buffered	  Saline	  (TBS)	  
20	  mM	  Tris	  
150	  mM	  NaCl	  
(pH	  adjusted	  to	  7.5	  using	  HCl)	  
	  
TBS-­tween	  (TBST)	  





1	  %	  (w/v)	  ovalbumin	  (Sigma-­‐Aldrich)	  in	  TBST	  
	  
Dilution	  Buffer	  
0.1	  %	  (w/v)	  ovalbumin	  (Sigma-­‐Aldrich)	  in	  TBST	  
	  
	  
	   In	  this	  novel	  ELISA	  system	  (further	  discussed	  in	  Chapter	  4),	  filaggrin	  was	  
quantified	   using	   two	   antibodies:	   a	   mouse	   monoclonal	   IgG1	   anti-­‐filaggrin	  
antibody	   (ab17808,	   Abcam),	   and	   a	   biotinylated	   rat	   anti-­‐mouse-­‐IgG1	   antibody	  
(550331,	  BD	  Pharmingen).	  	  
	  
	   Filaggrin-­‐containing	   samples	   were	   bound	   to	   high-­‐binding	   enzyme	  
immunoassay	   (EIA)	   plates	   (Corning-­‐Costar)	  with	   a	   1:1	   dilution	   in	   Carbonate-­‐
bicarbonate	   Buffer	   (Sigma-­‐Aldrich).	   These	   were	   measured	   against	   an	   8-­‐point	  
standard	   curve	   generated	   by	   sequential	   dilutions	   of	   pooled	   purified	   filaggrin	  
(200,	   100,	   50,	   25,	   12.5,	   6.25,	   3.125,	   0	   ng/ml).	   Samples	   and	   standards	   were	  
analysed	  in	  duplicates,	   loaded	  in	  50	  µl	  volumes	  per	  well.	  The	  plates	  were	  then	  
incubated	  at	  37	   oC	   for	  2	  h.	  Unless	  stated	  otherwise,	  all	   subsequent	  steps	  were	  
separated	   by	   five	  wash	   steps	   (full-­‐well	   volumes)	   using	   TBST,	  where	   the	   final	  
wash	  was	  forcefully	  blotted	  onto	  absorbent	  paper	  towels	  on	  a	  flat	  surface.	  	  
	  
	   After	   washing,	   the	   plates	   were	   then	   blocked	   with	   the	   Blocking	   Buffer	  
(200	   µl	   per	   well)	   for	   2	   h	   at	   room	   temperature.	   Following	   another	   wash,	  
ab17808	   was	   added	   (50	   µl	   per	   well)	   at	   1:250	   dilution	   before	   an	   overnight	  
incubation	  at	  4	  oC.	  The	  plates	  were	  washed	  again	  before	  50	  µl	  of	  the	  biotinylated	  
rat	   anti-­‐mouse-­‐IgG1	   antibody	  was	   added	   to	   each	  well	   at	   1:2000	   dilution.	   The	  
plates	   were	   then	   incubated	   at	   37	   oC	   for	   2	   h.	   After	   washing,	   the	   biotinylated	  
signal	  was	  developed	  and	  visualised	  using	  a	  streptavidin/substrate	  system.	  This	  
involved	  adding	  50	  µl	  of	  streptavidin	  (R&D)	  at	  1:200	  dilution	  into	  each	  well	  and	  
incubating	   at	   room	   temperature	   for	   30	   min.	   After	   washing,	   50	   µl	   of	   3,3,5	  
tetramethylbenzidine	   (TMB,	   Sigma-­‐Aldrich)	  was	   added	   to	   each	  well	   for	   about	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30	  min	   at	   room	   temperature.	   Colour	   development	  was	   stopped	   (without	   any	  
washing	  step)	  with	  the	  addition	  of	  25	  µl	  of	  2	  N	  H2SO4	  (Sigma-­‐Aldrich).	  
	  
	   All	   ELISA	   data	   were	   collected	   on	   a	   Synergy	   HT	   Multi-­‐Detection	  
Microplate	   Reader	   using	   Gen	   5	   Microplate	   Data	   Collection	   and	   Analysis	  
Software	   (both	   BioTek	   Instruments)	   at	   a	   wavelength	   of	   450	   nm,	   with	   a	  
subtracted	  reference	  at	  650	  nm.	  
	  
	  
2.9	   Mass	  spectrometry	  
	  
2.9.1	   	   In-­gel	  digestion	  of	  protein	  
	  
Destaining	  Solution	  
50	  %	  (v/v)	  acetonitrile	  
	  
Reducing	  Solution	  
10	  mM	  DTT	  
0.2	  %	  (w/v)	  EDTA	  
100	  mM	  NH4HCO3	  
	  
Alkylating	  Solution	  
50	  mM	  iodoacetamide	  
100	  mM	  NH4HCO3	  
	  
Trypsin	  Solution	  
0.1	  µg/µl	  sequencing	  grade	  modified	  trypsin	  (Promega)	  in	  50	  mM	  NH4HCO3	  
	  
Peptide	  Extraction	  Solution	  
5	  %	  (v/v)	  trifluoroacetic	  acid	  
50	  %	  (v/v)	  acetonitrile	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   Protein	  bands	  on	  SDS-­‐PAGE	  gels	  were	  excised	  using	  a	  disposable	  scalpel	  
before	  being	   further	   cut	   into	   smaller	   cubes	   (approximately	  1	  x	  1	  mm	   in	   size).	  
These	   were	   transferred	   into	   a	   microcentrifuge	   tube	   containing	   200	   ul	   of	  
Destaining	   Solution	   and	   incubated	   at	   room	   temperature	   for	   5	   min.	   The	  
destaining	  step	  was	  then	  repeated	  before	  excess	  liquid	  was	  removed	  and	  the	  gel	  
pieces	  dried	  in	  a	  Gyrovap	  for	  15	  min.	  Next,	  the	  gel	  pieces	  were	  incubated	  at	  56	  
oC	  for	  30	  min	  in	  15	  ul	  Reduction	  Solution	  and	  cooled	  to	  room	  temperature.	  Any	  
excess	   Reduction	   Solution	   was	   then	   removed	   before	   the	   gel	   pieces	   was	  
incubated	   at	   room	   temperature,	   in	   the	   dark	   for	   30	   min,	   with	   10-­‐50	   µl	   of	  
Alkylating	   Solution.	   The	   Alkylating	   Solution	   was	   removed	   and	   the	   gel	   pieces	  
washed	  with	  200	  ul	  of	  100	  mM	  NH4HCO3	  for	  10	  min.	  The	  solution	  was	  removed	  
before	  dehydrating	  the	  gel	  pieces	  with	  200	  ul	  neat	  acetonitrile	  for	  10	  min.	  The	  
washing	  and	  dehydration	  process	  was	  repeated	  prior	  to	  drying	  the	  gel	  pieces	  in	  
a	  Gyrovap	  for	  15	  min.	  Next,	  5	  ul	  of	  Trypsin	  Solution	  was	  added	  to	  the	  gel	  pieces,	  
which	  were	  then	  incubated	  at	  37	  oC	  for	  15	  min.	  To	  the	  gel	  pieces	  was	  added	  10-­‐
15	  ul	  of	  50	  mM	  NH4HCO3	  before	   they	  were	   incubated	  at	  37	   oC	  overnight.	  The	  
digestion	   liquid	  was	   removed	   and	   transferred	   to	   a	   new	  microcentrifuge	   tube.	  
Enough	  Peptide	  Extraction	  Solution	  was	  then	  added	  to	  immerse	  the	  gel	  pieces,	  
which	  were	   shaken	   at	   room	   temperature	   for	   30	  min.	   The	   extraction	   solution	  
was	  then	  pooled	  with	  the	  digestion	  liquid	  from	  the	  previous	  step	  and	  dried	  in	  a	  
Gyrovap.	   The	   dried	   peptides	  were	   resuspended	   in	   10	   ul	   of	   0.1	  %	   formic	   acid	  
prior	  to	  analysis	  by	  mass	  spectrometry.	  
	  
	  
2.9.2	   	   In-­solution	  digestion	  of	  protein	  
	  
Resuspension	  Solution	  
50	  mM	  NH4HCO3	  
	  
Reducing	  Stock	  Solution	  
200	  mM	  DTT	  
100	  mM	  NH4HCO3	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Alkylating	  Stock	  Solution	  
1	  M	  iodoacetamide	  
100	  mM	  NH4HCO3	  
	  
Trypsin	  Solution	  
0.1 µg/ul	  sequencing	  grade	  modified	  trypsin	  (Promega)	  in	  200	  µL	  acetic	  acid	  
	  
	  
	   Purified	  protein	  was	  dried	  in	  a	  Gyrovap	  before	  being	  resuspended	  in	  100	  
µl	  of	  50	  mM	  NH4HCO3.	  The	  sample	  was	  then	  reduced	  by	  adding	  5	  µl	  of	  Reducing	  
Stock	  Solution	  and	  heating	  at	  56	  oC	  for	  30	  min.	  Next,	  4	  µl	  of	  the	  Alkylating	  Stock	  
Solution	  was	   added	   to	   the	   sample	   and	   incubated	   at	   room	   temperature	   in	   the	  
dark	  for	  1	  h.	  The	  alkylation	  was	  stopped	  by	  adding	  20	  µl	  of	  the	  Reducing	  Stock	  
Solution	  and	  incubating	  the	  sample	  at	  room	  temperature	  for	  1	  h.	  Next,	  enough	  
Trypsin	  Solution	  was	  added	  to	  give	  a	  ratio	  of	  trypsin	  to	  sample	  of	  1	  µg	  trypsin	  to	  
20	   µg	   protein.	   The	   sample	  was	   incubated	   overnight	   at	   37	   oC	   before	   digestion	  
was	  terminated	  by	  the	  addition	  of	  1	  %	  formic	  acid.	  
	  
	  
2.9.3	   	   Zip	  tipping	  
	  
Wash	  Buffer	  
0.1 %	  (v/v)	  formic	  acid	  
	  
Elution	  Buffer	  
0.1	  %	  (v/v)	  formic	  acid	  
50	  %	  (v/v)	  acetonitrile	  
	  
	  
	   ZipTip18	   and	   ZipTip4	   (Millipore)	   were	   used	   to	   desalt	   and	   concentrate	  
samples	  prior	  to	  MALDI-­‐TOF	  analysis.	  The	  former	  was	  used	  for	  tryptic-­‐digests	  
while	   the	   latter	   was	   used	   for	   intact	   protein	   samples.	   Protein	   samples	   (both	  
50	  
intact	  and	  tryptic-­‐digests)	  were	  dried	  in	  a	  Gyrovap	  before	  being	  resuspended	  in	  
20	  µl	  of	  Wash	  Buffer.	  A	  new	  ZipTip	  was	  first	  equilibrated	  by	  aspirating	  10	  ul	  of	  
Elution	  Buffer	  onto	  the	  tip	  before	  dispensing	  the	  buffer.	  This	  was	  repeated	  twice	  
before	   the	   tip	  was	  washed	   three	   times	  with	   the	  Wash	  Buffer.	  The	  sample	  was	  
then	   loaded	  onto	   the	   tip	  by	  aspirating	  and	  dispensing	   the	  sample	  10-­‐15	   times	  
for	  maximal	  binding.	  The	  tip	  was	  then	  washed	  three	  times	  with	  the	  Wash	  Buffer.	  
Finally,	   10	   ul	   of	   the	   Elution	   Buffer	  was	   aspirated	   and	   dispensed	   3-­‐5	   times	   to	  
elute	  the	  sample.	  	  
	  
	  
2.9.4	   	   MALDI-­TOF	  MS	  
	  
Matrix	  for	  peptide	  digest	  analysis	  
10	  mg/ml	  α-­‐cyano-­‐4-­‐hydroxycinnamic	  acid	  
50	  %	  (v/v)	  acetonitrile	  
0.05	  %	  (v/v)	  formic	  acid	  
	  
Matrix	  for	  intact	  protein	  analysis	  
10	  mg/ml	  sinnapinic	  acid	  
50	  %	  (v/v)	  acetonitrile	  
0.05%	  (v/v)	  formic	  acid	  
	  
	  
	   0.5	  µl	  of	  sample	  (tryptic-­‐digest	  or	  intact	  protein)	  was	  spotted	  onto	  a	  96-­‐
well	  MALDI	  plate	  before	  an	  equal	  volume	  of	  the	  appropriate	  matrix	  was	  added	  
to	   it.	   These	   were	   then	   air-­‐dried	   before	   analysis	   with	   a	   MALDI	   De-­‐STR	   (ABI)	  
mass	  spectrometer.	  Data	  were	  collected	  in	  positive	  reflectron	  mode	  using	  a	  337	  
nm	  nitrogen	  laser.	  Each	  spectrum	  obtained	  was	  an	  average	  of	  200	  spectra	  (200	  
laser	  shots	  per	  spot).	  For	  intact	  protein	  analysis,	  a	  summation	  of	  at	  least	  three	  
average	   spectra	   was	   performed.	   All	   spectra	   were	   batch	   processed	   in	   Data	  
Explorer	  with	  default	   settings	   of	   advanced	  background	   correction,	   noise	   filter	  
and	  de-­‐isotoping.	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2.9.5	   	   Online	  nano	  LC-­MS/MS	  
	  
Solvent	  A	  
0.1	  %	  (v/v)	  formic	  acid	  
2	  %	  (v/v)	  acetonitrile	  
98	  %	  	  (v/v)	  distilled	  water	  
	  
Solvent	  B	  
0.1	  %	  (v/v)	  formic	  acid	  
20	  %	  	  (v/v)	  acetonitrile	  
80	  %	  distilled	  water	  
	  
	  
	   Tryptic-­‐digests	   (in-­‐gel	   or	   in-­‐solution)	   were	   separated	   online	   by	  
reversed-­‐phase	   nano	   LC.	   This	   was	   performed	   on	   an	   UltiMate	   3000	   (Dionex)	  
equipped	  with	  a	  C18	  PepMap100	  trap	  (C18,	  300	  µm	  i.d.	  x	  5	  mm;	  5	  µm,	  100	  Å,	  
Dionex)	  and	  C18	  PepMap100	  analytical	  column	  (C18,	  75	  µm	  i.d.	  x	  15	  cm;	  3	  µm,	  
100	   Å,	   Dionex).	   The	   protein	   concentration	   in	   the	   samples	   was	   adjusted	   to	  
approximately	  25	  µg/ml.	  Each	  analysis	  was	  then	  performed	  by	  injecting	  5	  µl	  of	  
this	   diluted	   solution,	   and	   subsequently	   repeated	  with	   10	   µl.	   The	   trap	   column	  
was	  loaded	  and	  washed	  with	  0.1	  %	  trifluoroacetic	  acid	  (TFA)	  at	  a	  flow	  rate	  of	  30	  
µl/min.	   Analytical	   flow	   rate	   was	   0.35	   µl/min	   with	   the	   column	   temperature	  
maintained	   at	   40	   oC.	  An	   increasing	   gradient	   of	   4-­‐90	  %	  of	   Solvent	  B	   across	  35	  
min	  was	  applied	   to	  elute	   the	  peptides.	  This	  was	   followed	  by	  a	  5-­‐min	  washout	  
phase	  using	  100	  %	  Solvent	  B,	  before	  the	  column	  was	  re-­‐equilibrated	  for	  5	  min	  
with	  95	  %	  Solvent	  A/4	  %	  Solvent	  B.	  
	  
	   The	  eluent	  was	  electrosprayed	  directly	  into	  the	  High	  Capacity	  Trap	  mass	  
spectrometer	  (HCT	  Ultra,	  Bruker)	  through	  a	  non-­‐coated	  picotip	  (360	  µm	  o.d.,	  20	  




	   The	   HCT	   ion	   trap	  was	   operated	   in	   positive	   ion	  mode,	   and	   ions	  with	   a	  
mass	  range	  of	  300–1500	  m/z	  were	  accumulated	  in	  the	  ion	  trap	  for	  a	  maximum	  
of	   200	  ms.	   The	   Auto	  MS/MS	   function	  was	   used	   for	   alternating	   precursor	   ion	  
scanning	   and	   the	  MS/MS	   of	   three	   precursor	   ions	   fragmented	   by	   CID.	   Any	   ion	  
from	  which	  a	  spectrum	  was	  collected	  was	  added	  to	  an	  exclusion	  list	  for	  2	  min.	  	  
	  
	   Raw	  data	  from	  the	  HCT	  was	  processed	  using	  DataAnalysis	  and	  Biotools	  
(both	  from	  Bruker).	  Peak	  lists	  in	  Mascot	  Generic	  Format	  (MGF)	  were	  submitted	  
to	  Mascot	  using	  an	  in-­‐house	  MASCOT	  service	  (Matrix	  Science)	  
	  
	  
2.10	   Statistical	  analysis	  
	  
	   Statistical	  analysis	  was	  performed	  using	  PASW	  Statistics	  18.0.	  Depending	  
on	  whether	   the	  data	  were	  normally	  distributed,	  either	   the	   t-­‐test	  or	   the	  Mann-­‐
Whitney	   U-­‐test	   was	   used	   to	   compare	   the	   variables	   between	   the	   two	   AD	  
subgroups.	  For	  the	  comparison	  of	  categorical	  data	  between	  the	  AD	  subgroups,	  
either	  the	  chi-­‐square	  test	  or	  the	  Fisher's	  exact	  test	  was	  used.	  P-­‐values	  of	  <	  0.05	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3.0	   DEVELOPMENT	   AND	   OPTIMISATION	   OF	   FILAGGRIN	   EXTRACTION	  
	   AND	  PURIFICATION	  
	  
	   To	   allow	   for	   accurate	   structural	   studies	   of	   filaggrin	   using	   mass	  
spectrometry,	  an	  adequate	  amount	  of	  filaggrin	  had	  to	  be	  extracted	  and	  purified	  
from	  individuals.	  To	  date,	  only	  three	  laboratories	  had	  described	  the	  extraction	  
and	   purification	   of	   filaggrin:	   Dale/Steinert/Walsh’s	   group	   at	   the	  University	   of	  
Washington,	  von	  Essen’s	  group	  at	  the	  University	  of	  Helsinki	  and	  Serre’s	  group	  at	  
the	  University	  of	  Toulouse.	  The	  methods	  described	  by	  the	  first	  two	  groups	  [92,	  
251]	   involved	  using	  a	  denaturing	  extraction	  buffer	  while	  Serre’s	  group	  used	  a	  
Tris/EDTA	   buffer	   [252].	   Interestingly,	   the	   final	   purified	   filaggrin	   from	   each	  
group	   had	   different	   molecular	   weights	   as	   seen	   on	   SDS-­‐PAGE.	   Also,	   while	   the	  
purified	   filaggrin	   from	  the	  University	  of	  Washington	  group	  was	  strongly	  basic,	  
that	  from	  Serre's	  group	  produced	  an	  acidic/neutral	  isoform	  of	  the	  protein	  (pI	  of	  
5.8-­‐7.4).	  The	  Helsinki’s	  group	  provided	  no	  pI	  information	  for	  their	  protein.	  
	  
	   In	  all	  these	  papers,	  filaggrin	  was	  extracted	  from	  either	  human	  foreskins	  
or	  breast	  reduction	  tissues.	  To	  date,	  no	  one	  has	  attempted	  to	  extract	  filaggrin	  by	  
tape	  stripping.	  	  
	  
	   All	   the	   extraction	   and	   purification	   methods	   described	   had	   common	  
features.	   First,	   the	   epidermal	   layer	   was	   removed	   by	   either	   heating	   the	   skin	  
tissue	   alone,	   or	   immediately	   plunging	   the	   skin	   into	   ice	   water	   after	   the	  
application	   of	   heat.	   The	   aim	   was	   to	   separate	   the	   epidermal	   layer	   from	   the	  
underlying	   skin.	   Next,	   some	   form	   of	   homogenisation	   was	   performed	   to	  
solubilise	   the	   protein	   extracted.	   The	   subsequent	   purification	   of	   filaggrin	  
involved	   the	   use	   of	   LC,	   primarily	   to	   separate	   out	   keratin	   which	   is	   the	   most	  
abundant	  protein	  found	  in	  the	  epidermis.	  
	  
	   There	   were	   considerable	   difficulties	   encountered	   while	   attempting	   to	  
replicate	  the	  filaggrin	  extraction	  and	  purification	  procedures	  published	  to	  date.	  
One	   reason	   was	   the	   absence	   of	   sufficient	   details;	   another	   was	   the	   use	   of	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reagents	   (e.g.	   1,1,2-­‐trichloro-­‐trifluoro-­‐ethane)	   that	   were	   no	   longer	  
commercially	   available.	   Additionally,	   the	   use	   of	   tape	   stripping	   to	   extract	  
filaggrin	  from	  skin	  also	  meant	  that	  further	  modifications	  were	  required	  in	  order	  
to	   optimise	   the	   purification	   process.	   The	   procedures	   described	   were,	  
nonetheless,	  mostly	  based	  on	  that	  described	  by	  Thulin	  and	  Walsh	  [253].	  	  
	  
	  
3.1 Extraction	  of	  filaggrin	  
	  
3.1.1	   Extraction	  from	  human	  breast	  tissues	  
	  
	   In	   the	   initial	   stages	   of	   developing	   and	   refining	   the	   extraction	   and	  
purification	  of	  filaggrin,	  skin	  from	  human	  breast	  tissues	  was	  used.	  Filaggrin	  thus	  
extracted	  was	  also	  used	  in	  the	  development	  of	  the	  filaggrin-­‐specific	  ELISA.	  	  
	  
	   Discarded	  breast	  tissues	  from	  patients	  who	  underwent	  breast	  reduction	  
procedures	  performed	  by	  a	   local	  plastic	  surgeon	  were	  collected.	   Informed	  and	  
written	  consent	  were	  obtained	  prior	   to	  surgery.	  None	  of	   these	  volunteers	  had	  
AD	   and	  were	   therefore	   presumed	   to	   have	  wild-­‐type	  FLG,	   although	  none	  were	  
genotyped.	  
	  
	   The	   breast	   tissues	   were	   heated	   at	   55	   oC	   in	   a	   15	   mM	   EDTA,	   85%	   PBS	  
solution	   for	  5	  min.	  This	  allowed	  the	  epidermis	  to	  be	  peeled	  off.	  About	  1	  g	  wet	  
weight	   of	   epidermis	  was	   generally	   obtained	   from	   a	   bilateral	   breast	   reduction	  
procedure	   and	   was	   used	   for	   each	   purification	   procedure.	   The	   epidermis	  
obtained	  was	  then	  roughly	  divided	  and	  placed	   into	  10	  Precellys	  CK14	  ceramic	  
beads	  tubes	  (Bertin	  Technologies).	  	  
	  
	   800	   µl	   of	   a	   buffer	   containing	   9	   M	   urea	   and	   50	   mM	   Tris	   (pH	   8),	   and	  
several	  crystals	  of	  phenylmethylsulfonyl	   fluoride	  (PMSF)	  were	  also	  added	  into	  
each	  tube.	  	  The	  tubes	  were	  then	  placed	  into	  a	  Precellys	  24	  homogeniser	  (Bertin	  
Technologies)	   and	   subjected	   to	   two	   sessions	   of	   homogenisation.	   Each	   session	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consisted	   of	   three	   cycles	   of	   20-­‐s	   homogenisation	   at	   5,500	   rpm,	   with	   a	   30-­‐s	  
pause	  between	  each	  cycle.	  The	  tubes	  were	  then	  initially	  centrifuged	  at	  12,000	  g	  
for	  10	  min	  at	  4	  oC.	  The	  supernatant	  from	  each	  tube	  was	  combined	  before	  further	  
centrifugation	   at	   50,000	   g	   for	   1	   h.	   The	   combined	   supernatant	   was	   then	  
sequentially	  filtered	  through	  a	  5	  µm	  and	  0.22	  µm	  syringe	  filters	  to	  remove	  any	  
particulates	  prior	  to	  purification.	  
	  
	  
3.1.2	   Extraction	  using	  tape	  stripping	  
	  
	   The	  use	  of	  tape	  stripping	  to	  extract	  filaggrin	  from	  skin	  is	  a	  method	  first	  
described	  in	  this	  study.	  Tape	  stripping	  has	  the	  advantages	  of	  being	  minimally-­‐
invasive,	   relatively	   pain-­‐free	   and	   quick.	   As	   described	   earlier,	   D-­‐Squame	   tapes	  
(CuDerm)	   were	   used,	   with	   100	   tapes	   collected	   from	   four	   to	   six	   sites	   on	   the	  
medial	  aspect	  of	  each	  subject's	  forearm	  for	  each	  preparation.	  These	  were	  placed	  
in	   a	   conical	   flask	   containing	  30	  ml	   of	   extraction	  buffer	   (9	  M	  urea	   and	  50	  mM	  
Tris,	  pH	  8)	  and	  shaken	  at	  250	  rpm	  in	  a	  shaking	  incubator	  at	  20	  oC	  for	  two	  days.	  
The	  tapes	  were	  then	  manually	  rubbed	  to	  optimise	  the	  removal	  of	   the	  material	  
adherent	  to	  them.	  The	  extract	  was	  then	  sequentially	  filtered	  through	  a	  5	  µm	  and	  
a	  0.45	  µm	  filter	  prior	  to	  purification.	  
	  
	  
3.2	   Comparison	  of	  various	  homogenisation	  methods	  
	  
	   In	   order	   to	   extract	   and	   purify	   filaggrin	   from	   skin	   tissues,	   the	   protein	  
needs	   to	   be	   solubilised	   in	   an	   extraction	   buffer.	   Full	   thickness	   skin	   poses	   a	  
challenge	   for	   homogenisation	  mainly	   because	   of	   the	   elastic	   nature	   of	   the	   skin	  
tissue.	   The	   best	   homogenisation	   method	   is	   one	   that	   produces	   uniform	  
homogenisation	   with	   minimal	   loss	   of	   skin	   sample.	   Several	   homogenisation	  
methods	  are	  generally	  used	  in	  the	  extraction	  of	  protein	  from	  skin	  tissues.	  These	  
include	   the	   Dounce	   homogeniser,	   grinding	   with	   sand,	   using	   a	   rotator/stator	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3.2.1	   Dounce	  homogeniser	  
	  
	   This	   is	   essentially	   a	   round	   glass	   pestle	   that	   is	   manually	   and	   repeated	  
driven	   into	   a	   glass	   tube	   containing	   the	   skin	   tissues	   and	  extraction	  buffer.	  The	  
number	   of	   strokes	   and	   the	   force	   administered	   are	   obviously	   important	   in	  
determining	  its	  effectiveness	  in	  homogenising	  the	  sample.	  For	  the	  breast	  tissue	  
samples,	   50	   strokes	   were	   administered.	   There	   were	   always	   residual	   bits	   of	  
unhomogenised	   epidermis,	   even	   when	   up	   to	   200	   strokes	   were	   administered.	  
Also,	   there	  was	   significant	   loss	   of	   sample	   during	   the	   homogenisation	   process	  
due	   to	   the	   transfer	   of	   sample	   into	   and	   out	   of	   the	   glass	   tube,	   as	  well	   as	   those	  
adhering	   to	  and	  precipitating	  on	   the	  glass	   tube	  walls.	  None	  of	   the	  purification	  




3.2.2	   Rotor/stator	  type	  homogeniser	  
	  
	   The	   tissue	   tearor	   (Biospec	   Products)	   is	   a	   rotor/stator	   type	   tissue	  
homogeniser	   that	   is	   supposed	   to	  have	   the	   capability	   of	   rapidly	  homogenising,	  
dispersing	  and	  emulsifying	  samples.	   It	  has	  a	  rotor	   that	   turns	  at	  5-­‐30,000	  rpm.	  
However,	   significant	   problems	   were	   encountered	   while	   using	   this	   method	   of	  
homogenisation.	  First,	  the	  epidermis	  had	  to	  be	  cut	  up	  into	  bits	  small	  enough	  to	  
get	   through	   the	   protective	   outer	   casing	   around	   the	   rotor	   blade.	   Second,	   even	  
when	   the	   epidermal	   tissues	  were	   small	   enough	   to	   get	   through	   the	   protective	  
outer	  casing,	  they	  were	  still	  frequently	  stuck	  between	  this	  casing	  and	  the	  rotor.	  
Finally,	   even	   after	   30	   minutes	   of	   vigorous	   homogenisation,	   there	   were	   still	  
visible	  unhomogenised	  epidermal	  tissues.	  Once	  again,	  purification	  of	  epidermal	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3.2.3	   Precellys	  24	  tissue	  homogeniser	  (Bertin	  Technologies)	  
	  
	   Epidermal	   tissues	   were	   placed	   into	   single-­‐use	   Precellys	   CK14	   tubes	  
containing	   ceramic	  beads	   (Bertin	  Technologies).	  High-­‐speed	  whirl	  mixing	   in	   a	  
‘figure	   of	   eight’	   motion	   resulted	   in	   the	   rapid,	   uniform	   homogenisation	   of	   the	  
samples.	   The	   final	   extract	   is	   homogenous	   and	   milky-­‐white,	   with	   no	   residual	  
tissue	   fragments	   visible.	   The	   effective	   homogenisation	   of	   epidermal	   tissues	  
required	   two	   sessions	   of	   homogenisation	   with	   a	   3-­‐min	   break	   between	   each.	  
Each	   session	   consisted	   of	   three	   cycles	   of	   20-­‐s	   homogenisation	   at	   5,500	   rpm,	  
with	  a	  30-­‐s	  pause	  between	  each	  cycle.	  Twenty-­‐four	  samples	  can	  be	  processed	  at	  
any	   one	   time.	   The	   obvious	   advantages	   of	   the	  Precellys	   homogeniser	  were	   the	  
speed	   of	   homogenisation,	   minimal	   loss	   of	   the	   skin	   tissues,	   and	   most	  
importantly,	   effective	   homogenisation	   since	   it	  was	   the	   only	  method	   tried	   that	  




3.3	   Purification	  of	  filaggrin	  
	  
3.3.1	   Weak	  anionic	  exchange	  liquid	  chromatography	  	  
	  
Buffer	  A	  (pH	  8.0)	  
9	  M	  urea	  






Buffer	  B	  (pH	  8.0)	  
9	  M	  urea	  
50	  mM	  Tris-­‐base	  
1	  M	  NaCl	  
	  
	   A	   previous	   study	   on	   mouse	   epidermis	   showed	   that	   extraction	   with	   a	  
denaturing	  buffer	  dissolved	  about	  95	  %	  of	   the	   tissue	  proteins,	  of	  which	  about	  
60%	  consisted	  of	  keratin	  subunits	  with	  much	  of	   the	  remainder	  being	   filaggrin	  
[254].	  So	  the	  main	  aim	  during	  purification	  was	  the	  removal	  of	  keratin	  from	  the	  
initial	  protein	  extract.	  	  
	  
	   Filaggrin	   has	   a	   strongly	   cationic	   charge	   [92],	   and	   so	   can	   be	   separated	  
easily	   from	   the	   anionic	   keratin	   subunits	   using	   ion	   exchange	   chromatography.	  
Most	   LC	   protein	   purification	   generally	   starts	   with	   an	   anion	   exchange	  
chromatography.	   In	   this	   study,	   a	  DEAE	   Sepharose	   FF	   (GE	  Healthcare)	   column	  
(Vt	  5	  ml,	  1.6	  x	  2.5	  cm)	  attached	  onto	  an	  AKTAexplorer	  system	  (GE	  Healthcare)	  
was	   used.	   	   After	   an	   initial	   wash	   of	   2	   column	   volume	   (CV)	   with	   Buffer	   A,	   the	  
filtered	   extract	   was	   pumped	   into	   the	   weak	   anionic	   exchange	   column	   at	   5	  
ml/min	  and	  the	  flow-­‐through	  collected	  in	  1	  ml	  fractions.	  The	  bound	  keratin	  was	  




































Figure 3.1 Typical chromatogram from the DEAE sepharose purification step. The blue and 
red curves are the UV traces at 280 nm and 214 nm, respectively. UV at 280 nm wavelength 
detects aromatic groups of protein side chains, while UV at 214 nm wavelength is about 10 
times more sensitive as it detects peptide bonds. However, the latter is also less specific 
because it also picks up nucleotides, certain metabolites and buffer salts. The green curve 
indicates the ionic strength of the elution buffer. Fractions were collected during the run, and 
the flow-through fractions corresponding to that under the broad peak (indicated by the 
horizontal black line) were pooled for further purification. 
	  
	  
3.3.2	   Acetone	  precipitation	  
	  
Resuspension	  buffer	  
47	  mM	  Tris	  (pH	  8.0)	  
5	  mM	  EDTA	  (pH	  7)	  
1	  mM	  PMSF	  
	  
	   The	   flow-­‐through	   fractions	   containing	   filaggrin	   were	   pooled	   and	  
precipitated	  by	  adding	  3	  volume	  of	  ice-­‐cold	  acetone	  and	  kept	  in	  ice	  for	  10	  min.	  
This	  allowed	  the	  protein	  to	  be	  concentrated,	  as	  well	  as	  the	  removal	  of	  salt	  and	  
lipid-­‐soluble	  contaminants.	  The	  main	  disadvantage	  was	  that	  invariably,	  some	  of	  
the	  precipitated	  protein	  would	   fail	   to	  resuspend,	  resulting	   in	  a	   loss	  of	  protein.	  
After	  centrifugation	  for	  20	  min	  at	  12,000	  g,	  the	  supernatant	  was	  discarded	  and	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the	   precipitate	   resuspended	   in	   10	  ml	   of	  Resuspension	  Buffer.	   The	   suspension	  
was	  centrifuged	  at	  12,000	  g	  for	  another	  20	  min	  and	  the	  supernatant	  collected.	  
	  
	   In	   the	   case	   of	   filaggrin	   extraction	   using	   tape	   stripping,	   this	   acetone	  
precipitation	  step	  was	  replaced	  by	  a	  desalting	  step	  using	  a	  gel	  filtration	  column	  
instead.	  This	  was	  because	  the	  amount	  of	  protein	  extracted	  by	  tape	  stripping	  was	  
much	  less	  compared	  to	  using	  homogenised	  epidermis	  and	  therefore	  only	  a	  very	  
small	   amount	   of	   precipitate	  was	   formed	   following	   acetone	   precipitation,	  with	  
significant	   loss	   of	   protein	   upon	   resuspension	   of	   the	   precipitate.	   Additionally,	  
since	   tape	  stripping	  was	  a	   ‘cleaner’	   extraction	  method	  without	   the	   substantial	  
lipidaceous	  contaminants	  present	  in	  full	  epidermis,	  there	  was	  even	  less	  reason	  
for	  this	  precipitation	  process.	  Nonetheless,	  prior	  to	  the	  subsequent	  purification	  




3.3.3	   Buffer	  exchange	  with	  gel	  filtration	  chromatography	  
	  
	   For	   the	   purification	   of	   filaggrin	   extract	   from	   tape	   stripping,	   a	   HiPrep	  
26/10	  (GE	  Healthcare)	  gel	  filtration	  column	  (Vt	  ~53	  ml,	  2.6	  x	  10	  cm)	  was	  used	  
to	   replace	   the	   initial	   urea	   buffer	   to	   the	   Resuspension	   Buffer.	   Pooled	   fractions	  
containing	   filaggrin	   from	   the	   DEAE-­‐Sepharose	   column	   flow-­‐through	   were	  
applied	  to	  the	  column	  pre-­‐equilibrated	  in	  Resuspension	  Buffer,	  at	  a	  flow	  rate	  of	  
8	   ml/min.	   Fractions	   under	   the	   protein	   peak	   from	   the	   chromatogram	   was	  









3.3.4	   Strong	  cation	  exchange	  liquid	  chromatography	  
	  
Buffer	  A	  
100	  mM	  NaH2PO4	  (pH	  3.5)	  
Buffer	  B	  
100	  mM	  NaH2PO4	  (pH	  3.5)	  
1.5	  M	  NaCl	  
	  
	   To	   further	   purify	   the	   protein	   extract,	   a	   strong	   cation	   exchange	   column	  
was	   used.	   The	   aim	   of	   this	   was	   to	   bind	   the	   strongly	   cationic	   filaggrin	   to	   the	  
column	   matrix,	   which	   would	   then	   be	   eluted	   and	   collected	   subsequently.	   The	  
final	   supernatant	   from	   the	   acetone	   precipitation	   step	   (for	   breast	   tissue	  
extracts),	  or	  the	  pooled	  fractions	  from	  the	  desalting	  step	  (for	  tape	  strip	  extracts)	  
was	   applied	   to	   a	   POROS	   S/10	   (Applied	   Biosystems)	   strong	   cation	   exchange	  
column	  (Vt	  	  1.7	  ml,	  4.6	  x	  100	  mm).	  A	  chromatogram	  was	  developed	  at	  a	  flow	  rate	  
of	  10	  ml/min	  as	  follows:	  After	  an	  initial	  wash	  of	  2	  CV	  in	  100	  mM	  NaH2PO4	  buffer	  
(pH	  3.5),	  and	  a	  further	  2	  CV	  wash	  with	  66	  %	  Buffer	  A/33	  %	  Buffer	  B,	  a	  gradient	  
to	  33	  %	  Buffer	  A/66	  %	  Buffer	  B	  was	  developed	  over	  10	  CV.	  After	  this,	  there	  was	  
a	   step	   up	   to	   100	   %	   Buffer	   B.	   Fractions	   of	   1	   ml	   volume	   were	   collected	   and	  













































Figure 3.2 (a) Typical chromatogram from the POROS S/10 strong cation exchange column 
purification step. The blue and red curves are the UV traces at 280 nm and 214 nm, 
respectively. The green curve indicates the ionic strength of the elution buffer. Fractions 
were collected during the run, and those corresponding to that under the main peak 
(indicated by the horizontal black line) were pooled. (b) Immunoblotting of these fractions 
using a monoclonal mouse filaggrin antibody confirmed filaggrin bands at around 45 kDa. 
	  
	  
3.3.5	   Desalting	  step	  using	  reversed-­phase	  chromatography	  
	  
	   Finally,	   in	   order	   to	   desalt	   the	   buffer	   prior	   to	   MS	   analysis,	   the	   pooled	  
fractions	   from	   the	   previous	   purification	   step	   were	   applied	   to	   a	   POROS	   R1	  
(Applied	  Biosystems)	   reversed-­‐phase	  column	  (Vt	   0.1	  ml,	  2.1	  x	  30	  mm).	  A	   step	  
gradient	   is	   developed	   from	   0	   to	   80	   %	   acetonitrile	   in	   0.05	   %	   TFA.	   Fractions	  
under	  the	  sharp	  protein	  peak	  were	  collected	  for	  MS	  analysis	  (Figure	  3.3).	  
	  
	  






























Figure 3.3 (a) Typical chromatogram from the POROS R1 reversed-phase column desalting 
step. The blue and red curves are the UV traces at 280 nm and 214 nm, respectively. The 
green curve indicates the concentration of the organic solvent. Fractions under the sharp 
peak (indicated by the horizontal black line) were pooled. (b) Immunoblotting of these 




3.4	   Modifications	  made	  to	  extraction	  and	  purification	  process	  
	  
	   Various	  modifications	  to	  the	  extraction	  and	  purification	  of	  filaggrin	  were	  
attempted	   during	   this	   study	   in	   the	   hope	   of	   increasing	   the	   yield	   of	   the	   final	  
purified	  filaggrin.	  These	  included	  increasing	  the	  size	  of	  the	  tape	  strips	  used	  (by	  
replacing	   the	   14	   mm-­‐diameter	   tapes	   with	   larger	   22	   mm-­‐diameter	   ones),	  
extending	   the	   extraction	   time	   (from	   one	   day	   to	   two	   days)	   and	   replacing	   the	  
acetone	  protein	  precipitation	  step	  with	  an	  LC	  desalting	  step	   to	  reduce	  protein	  



















Chapter	  4	   Development	  of	  a	  	  
Filaggrin-­specific	  ELISA	  
	   67	  
4.0	   DEVELOPMENT	  OF	  A	  FILAGGRIN-­SPECIFIC	  ELISA	  	  
	  
	   Genotyping	   of	   the	   FLG	   gene	   is	   technically	   difficult	   due	   to	   its	   size	   and	  
repetitive	   nature	   of	   the	   filaggrin	   subunits	   within	   the	   gene.	   Hence	   this	   is	  
currently	   only	   routinely	   performed	   by	   a	   few	   genetics	   departments	   in	   the	  
country,	   and	   is	   consequently	   time-­‐consuming	   and	   expensive.	   There	   are,	  
therefore,	   obvious	   practical	   benefits	   to	   having	   a	   quick	   screening	   test	   (e.g.	   an	  
ELISA	  system)	  to	  detect	  and	  quantify	  filaggrin	  in	  the	  skin.	  Previous	  biochemical	  
and	  immunohistochemical	  studies	  have	  shown	  that	  any	  null	  mutation	  in	  the	  FLG	  
allele	  result	  in	  an	  absence	  of	  filaggrin	  expression,	  which	  means	  that	  individuals	  
who	  are	  homozygous	  or	  compound	  heterozygous	   for	   the	  FLG	  mutation	  do	  not	  
express	   filaggrin	   in	   their	   skin,	   and	   that	   individuals	  who	  are	  FLG	   heterozygous	  
express	   less	   filaggrin	   [23,	   73,	   255].	   Therefore,	   if	   a	   relatively	   large	   amount	   of	  
filaggrin	   protein	   is	   detected	   in	   an	   individual's	   skin,	   it	   is	   likely	   that	   that	  
individual	   will	   have	   a	   wild-­‐type	   FLG	   genotype	   and	   hence	   will	   not	   require	  
genotyping.	  Conversely,	  if	  filaggrin	  is	  found	  to	  be	  relatively	  reduced	  or	  absent	  in	  
the	  skin,	  then	  it	  may	  infer	  the	  presence	  of	  a	  FLG	  mutation.	  Confining	  genotyping	  
to	  this	  latter	  group	  would	  therefore	  save	  resources.	  	  
	  
	   The	  aim	  of	  the	  work	  described	  in	  this	  chapter	  was	  to	  develop	  a	  filaggrin-­‐
specific	   ELISA	   system.	   There	   are	   two	   common	  ELISA	   formats	   -­‐	   'one	  way'	   and	  
'sandwich'	   ELISAs.	   The	   'one	  way'	   ELISA	   involves	   coating	   a	   96-­‐well	   plate	  with	  
filaggrin-­‐containing	  samples	  before	  the	  addition	  of	  filaggrin-­‐specific	  antibodies	  
to	   detect	   and	   quantify	   the	   amount	   of	   the	   filaggrin.	   The	   'sandwich'	   ELISA	  
involves	  pre-­‐coating	  the	  wells	  with	  one	  anti-­‐filaggrin	  antibody	  prior	  to	  sample	  
addition,	  before	  a	  different	  detecting	  filaggrin	  antibody	  was	  added.	  As	  the	  latter	  
has	   the	   advantage	   of	   better	   sensitivity	   and	   specificity,	   developing	   a	   filaggrin-­‐
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4.1	   Development	  of	  a	  filaggrin-­specific	  'sandwich'	  ELISA	  
	  
	   The	  ‘sandwich’	  ELISA	  involved	  pre-­‐coating	  a	  high-­‐binding	  EIA	  plate	  with	  
an	   anti-­‐filaggrin	   antibody	   as	   a	   'capture'	   layer,	   followed	   by	   a	   protein-­‐rich	  
blocking	   step	   to	   reduce	   subsequent	   non-­‐specific	   binding.	   The	   filaggrin-­‐
containing	   sample	   was	   then	   added	   before	   another	   anti-­‐filaggrin	   antibody	  
(different	   from	   that	   used	   as	   the	   capture	   antibody)	   was	   used	   as	   the	   ‘primary	  
detection	   antibody’.	   Next,	   the	   relevant	   biotinylated	   antibody	   (‘secondary	  
detection	   antibody’)	   against	   the	   primary	   detection	   antibody	   was	   added	   for	  
subsequent	   streptavidin/substrate	   detection,	   which	   was	   a	   colourimetric	  
development	  system	  used	  by	  many	  commercial	  ELISA	  systems.	  
	  
	   At	  the	  start	  of	  developing	  this	  ELISA,	  there	  were	  only	  a	  limited	  number	  of	  
filaggrin	   antibodies	   commercially	   available.	   Three	   were	   initially	   obtained:	   a	  
rabbit	  (RaF)	  polyclonal	  (ab24584,	  Abcam),	  a	  mouse	  (MaF)	  monoclonal	  (AKH1,	  
Santa	   Cruz	   Biotechnology),	   and	   a	   goat	   (GaF)	   polyclonal	   (G-­‐20,	   Santa	   Cruz	  




Antibodies	   Species/Description	   Immunogen	   	   	   	   Company	  
	  
ab24584	   Rabbit	  polyclonal	   DSQVHSGVQVEGRRGH	   	   	   Abcam	  
	   	   	   	   	   (corresponding	  to	  amino	  acids	  
	   	   	   	   	   	  24-­‐39	  of	  filaggrin)	  
	  
AKH1	   	   Mouse	  monoclonal	   Purified	  filaggrin	  of	  foreskin	   	   Santa	  Cruz	  
	   	   	   	   	   of	  human	  origin	  
	  
G-­‐20	   	   Goat	  polyclonal	   	   Peptide	  mapping	  within	  an	  internal	   Santa	  Cruz	  
	   	   	   	   	   region	  of	  filaggrin	  of	  human	  origin	  
	  
 
Table 4.1 Details of the three anti-filaggrin antibodies assessed for suitability for 'sandwich' 
ELISA development. All three antibodies detected filaggrin as shown in Figure 4.1. 
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   Immunoblot	  analysis	  confirmed	  that	  all	   three	  detected	   filaggrin	  (Figure	  
4.1).	   Initial	   experiments	   utilised	   the	   antibodies	   (all	   at	   0.1	   µg/well)	   in	   three	  
different	  orientations:	  1)	  RaF	  as	  capture/MaF	  as	  primary	  detection,	  2)	  MaF	  as	  
capture/GaF	   as	   primary	   detection,	   and	   3)	   GaF	   as	   capture/RaF	   as	   primary	  
detection.	   Skin	   extracts	   from	   two	   healthy	   control	   subjects	   (A	   and	   B)	   were	  
analysed.	  The	  concentrations	  of	  the	  biotinylated	  secondary	  detection	  antibodies	  
were	   those	   suggested	   by	   the	   manufacturers.	   Results	   (shown	   in	   Figure	   4.2)	  
indicated	   that	   the	   last	   orientation	   (GaF/RaF)	   was	   the	   most	   promising,	   with	  
fairly	   linear	   optical	   density	   (OD)	   readings,	   although	   detection	   was	   saturated	  










Figure 4.1 Immunoblot confirming that the three anti-filaggrin antibodies (RaF, MaF and 
GaF) used in the development of the 'sandwich' ELISA detected filaggrin. Also shown is 
filaggrin detected using the mouse monoclonal anti-filaggrin antibody (ab17808) used in the 








GaF	   ab17808	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Figure 4.2 Results of ELISA experiments using three anti-filaggrin antibodies in three 
different orientations. Skin extracts from two healthy normal subjects (A and B) were 
analysed, with the samples sequentially diluted as shown. The concentration of the three 
anti-filaggrin antibodies was 0.1 µg/ml, while those of the biotinylated secondary detection 
antibodies were as per manufacturers' recommendations. The last orientation (GaF/RaF) 
appeared the most promising with fairly linear OD readings. However, OD readings from the 
control wells were high. This high background was investigated further (see Section 4.1). 
	  
	  
	   In	  an	  attempt	  to	  reduce	  the	  detection	  saturation,	  the	  concentration	  of	  the	  
RaF	   capture	   antibody	   was	   variably	   reduced	   (0.1,	   0.03,	   0.01	   µg/well)	   in	   a	  
subsequent	  experiment.	  This	  showed	  that	  0.01	  µg/well	  of	  RaF	  was	  sufficient	  to	  
detect	   filaggrin,	   although	   the	   detection	   was	   still	   too	   saturated	   with	   the	   OD	  
signals	   from	   the	   control	   wells	   giving	   unacceptably	   high	   readings.	   Hence,	   the	  
concentration	   of	   the	   GaF	   primary	   detection	   antibody	   was	   reduced	   while	   the	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that	  GaF	  at	  a	  concentration	  of	  0.01	  µg/well	  was	  sufficient	  to	  give	  good	  detection,	  
although	  the	  high	  OD	  signals	  in	  the	  control	  wells	  persisted.	  
	  
	   In	  subsequent	  experiments,	  one	  or	  more	  of	  the	  antibodies	  were	  omitted	  
in	   the	   negative	   control	  wells	   in	   order	   to	   study	   the	   nature	   of	   any	   non-­‐specific	  
binding	   that	  was	   the	   likely	   cause	   of	   the	   high	   OD	   signals	   in	   the	   control	   wells.	  





	   Experiments	   Antibodies	  within	  the	  control	  wells	   	   Results	  
	  
	   	  	  	  	  	  	  	  	  	  1	   	   RaF,	  GaF	  and	  secondary	  detection	  antibody	  	   High	  OD	  signals	  
	   	  	  	  	  	  	  	  	  	  2	   	   RaF	  and	  secondary	  detection	  antibody	   	   Low	  OD	  signals	  
	   	  	  	  	  	  	  	  	  	  3	  	   	   Secondary	  detection	  antibody	  only	   	   Low	  OD	  signals	  
	  
	  
Table 4.2. Experiments to study the nature of possible non-specific binding. One or more of 
the antibodies were omitted in the control wells. The secondary detection antibody used was 
a polyclonal rabbit anti-goat biotinylated antibody (E0466, DakoCytomation). Results suggest 
non-specific binding between RaF and GaF. 
	  
	  
	   The	  results	  of	  these	  experiments	  suggested	  the	  presence	  of	  non-­‐specific	  
binding	  between	  RaF	  and	  GaF.	  Subsequent	  experiments	  included	  the	  use	  of	  GaF	  
that	   was	   pre-­‐incubated	   overnight	   at	   4	   0C	   with	   rabbit	   serum,	   as	   well	   as	   the	  
addition	   of	   rabbit	   serum	   in	   the	   blocking	   and	   dilution	   buffers.	   	   Unfortunately,	  
these	   alterations	   did	   not	   affect	   non-­‐specific	   signals.	   Finally,	   to	   exclude	   the	  
possibility	   that	   the	   blocking	   step	   was	   inefficient,	   BSA	   was	   replaced	   with	  
ovalbumin	   as	   the	   blocking	   agent.	   This	   brought	   about	   a	   dramatic	   general	  
reduction	  in	  the	  OD	  signals,	  not	  just	  in	  the	  control	  wells	  but	  also	  in	  the	  sample	  
wells.	  Various	  alterations	  to	  the	  protocol	  were	  subsequently	  implemented	  in	  an	  
attempt	   to	   increase	   the	   sample	   OD	   signals	   while	   keeping	   ‘blank’	   signals	   low.	  
These	   included	   testing	  other	  orientations	  of	   the	  antibodies	  with	  ovalbumin	  as	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the	   blocking	   agent,	   as	   well	   as	   increasing	   the	   concentration	   of	   the	   various	  
antibodies.	  However,	  none	  of	  these	  were	  successful	   in	  eradicating	  non-­‐specific	  
signal.	  
	  
	   It	  was	  eventually	  decided	  that	  the	  ‘sandwich’	  ELISA	  was	  not	  sufficiently	  
specific	   with	   these	   three	   anti-­‐filaggrin	   antibodies	   in	   any	   orientation.	   Hence,	  
efforts	  were	  subsequently	  focussed	  on	  just	  developing	  a	  'one	  way'	  ELISA.	  
	  
	  
4.2	   Development	  of	  a	  filaggrin-­specific	  'one	  way'	  ELISA	  
	  
	   The	   'one	   way'	   ELISA	   involved	   coating	   a	   high-­‐binding	   EIA	   plate	   with	   a	  
filaggrin-­‐containing	  sample.	  This	  was	  followed	  by	  a	  protein-­‐rich	  blocking	  step	  to	  
minimise	  subsequent	  non-­‐specific	  binding	  before	  an	  anti-­‐filaggrin	  antibody	  was	  
added	  as	  a	  ‘primary	  detection’	  antibody.	  A	  biotinylated	  antibody	  raised	  against	  
the	   relevant	   species	   of	   the	   primary	   antibody	   was	   then	   added	   to	   detect	   the	  
bound	  anti-­‐filaggrin	  antibody	  (‘secondary	  detection	  step’).	  Biotinylated	  binding	  
was	  then	  quantified	  with	  the	  addition	  of	  Streptavidin-­‐HRP/substrate.	  	  
	  
	   At	   the	   time	  when	   the	  decision	  was	  made	   to	   focus	  on	  developing	  a	   'one	  
way'	   ELISA,	   several	   more	   anti-­‐filaggrin	   antibodies	   became	   available	  
commercially	   while	   others	   that	   were	   previously	   available	   (such	   as	   RaF,	  
ab24584)	  were	  no	   longer	   sold.	   A	   new	  mouse	  monoclonal	   antibody	   (ab17808,	  
Abcam)	  raised	  against	  a	  recombinant	  full-­‐length	  filaggrin	  was	  purchased	  for	  the	  
purpose	  of	  developing	  this	  assay.	  Again,	  immunoblot	  analysis	  confirmed	  that	  it	  
detected	   filaggrin	   (Figure	   4.1).	   Initial	   experiments	   aimed	   to	   determine	   the	  
detection	  sensitivity	  of	   ab17808,	  with	   the	  EIA	  plate	   coated	  with	   serial	  10-­‐fold	  
dilutions	  of	  filaggrin	  standards	  ranging	  from	  1000	  ng/ml	  to	  1	  pg/ml.	  The	  wells	  
were	   then	   blocked	   with	   ovalbumin,	   before	   ab17808	   (at	   1:250	   dilution)	   was	  
added	  as	  the	  primary	  detection	  antibody.	  Following	  this,	  a	  biotinylated	  rat	  anti-­‐
mouse-­‐IgG1	   antibody	   (550331,	   BD	   Pharmingen)	   was	   added	   as	   the	   secondary	  
detection	   antibody	   (1:2000	   dilution)	   before	   streptavidin/substrate	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visualisation.	   Antibodies	   concentrations	   were	   selected	   either	   on	   the	   basis	   of	  
previous	  chequerboard	  titres,	  or	  as	  per	  manufacturers'	  recommendations.	  This	  
experiment	  demonstrated	  that,	  at	  these	  antibodies	  concentrations,	  filaggrin	  was	  
detected	  from	  1000	  to	  10	  ng/ml.	   In	  order	  to	   increase	  detectable	  colourimetric	  
signal,	  the	  substrate	  development	  duration	  was	  extended	  from	  10	  minutes	  to	  30	  
minutes,	  which	  resulted	  in	  good	  standard	  curves	  with	  a	  linear	  profile	  between	  






Figure 4.3 A typical standard curve obtained with the 'one way' filaggrin ELISA, showing 
good linearity between concentrations 200 to 25 ng/ml. The full protocol for the ELISA is 
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   In	   summary,	   this	   chapter	   describes	   the	   development	   of	   a	   novel	   ELISA	  
that	   can	   quantify	   filaggrin	   with	   a	   detection	   sensitivity	   of	   approximately	   30	  
ng/ml.	   Given	   more	   time	   and	   resources,	   newer	   anti-­‐filaggrin	   antibodies	   could	  
have	  been	  purchased	  and	  tested	  to	  refine	  the	  'sandwich'	  ELISA	  that	  was	  limited	  
by	   non-­‐specific	   binding.	   Recently,	   a	   filaggrin-­‐specific	   'sandwich'	   ELISA	   has,	   in	  
fact,	   been	   marketed	   by	   UCSN	   Life	   Science	   (Wuhan,	   China).	   According	   to	   the	  
assay's	   documentation,	   it	   is	   capable	   of	   detecting	   human	   filaggrin	   from	   tissue	  
homogenates	  and	  biological	  fluids,	  with	  a	  detection	  lower	  limit	  of	  312	  pg/ml.	  If	  
validated,	  this	  would	  be	  much	  more	  sensitive	  than	  the	  one-­‐way	  filaggrin	  ELISA	  
described	  in	  this	  chapter.	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5.0	   CORRELATION	   OF	   FLG	   VARIANTS	   WITH	   AD	   AND	   SKIN	   BARRIER	  
	   DYSFUNCTION	  
	  
	  
	   FLG	   loss-­‐of-­‐function	   mutations	   are	   associated	   with	   early	   onset,	   and	  
persistent	  AD	  [31].	  In	  the	  presence	  of	  AD,	  they	  also	  predispose	  towards	  asthma	  
and	  hay	  fever	  [42].	  It	  has	  previously	  been	  shown	  that	  skin	  barrier	  dysfunction	  is	  
a	  feature	  of	  AD	  skin,	  as	  demonstrated	  by	  raised	  TEWL	  and	  reduced	  SC	  hydration	  
[15,	   242].	   However,	   the	   few	   studies	   that	   have	   looked	   at	   these	   measures	   in	  
relation	  to	  FLG	  status	  have	  reported	  inconsistent	  results	  [243,	  244].	  
	  
	   Although	  there	  is	  an	  unequivocal	  correlation	  between	  FLG	  mutations	  and	  
atopic	   disease,	   there	   is	   less	   evidence	   for	   a	   defective	   skin	   barrier	   function	   in	  
filaggrin-­‐related	  AD.	  The	  primary	  aim	  of	  this	  functional	  study,	  therefore,	  was	  to	  
determine	  whether	  FLG	  mutations	  correlated	  with	  altered	  skin	  barrier	  function	  
in	   AD	   subjects.	   Skin	   barrier	   function	   was	   assessed	   using	   three	   functional	  
measures,	  specifically	  TEWL,	  skin	  capacitance	  (which	  measures	  SC	  hydration),	  
and	   the	   number	   of	   tape	   strips	   required	   to	   achieve	   TEWL	   >20	   g/m2/h.	   In	  
addition,	  the	  amount	  of	  protein	  extracted	  with	  tape	  strips	  was	  also	  quantified	  in	  
eight	  of	  these	  subjects	  (four	  from	  the	  filaggrin-­‐related	  AD	  group	  and	  four	  from	  
the	   wild-­‐type	   AD	   group).	   This	   was	   to	   test	   a	   hypothesis	   developed	   from	   an	  
unexpected	  finding	  reported	  by	  Nemoto-­‐Hasebe	  et	  al	  [244],	  who	  showed	  that	  SC	  
thickness	  was	  greater	  in	  filaggrin-­‐related	  AD	  compared	  to	  wild-­‐type	  AD	  skin.	  To	  
possibly	  explain	  this	  finding,	  it	  was	  hypothesised	  in	  this	  study	  that	  corneocytes	  
in	  filaggrin-­‐related	  AD	  skin	  were	  less	  adherent	  to	  one	  another	  and	  therefore	  less	  
densely	   packed,	   which	   should	   translate	   to	   more	   corneocytes	   (and	   therefore	  
more	   protein)	   being	   removed	   by	   each	   tape	   strip.	   Testing	   this	   hypothesis	  was	  
the	  secondary	  aim	  of	  this	  study.	  
	  
	   The	  cohort	  in	  this	  functional	  study	  consisted	  of	  only	  mild	  and	  moderate	  
AD	  subjects,	  which	  were	  representative	  of	  the	  majority	  of	  AD	  sufferers.	  As	  the	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main	  objective	  was	  to	  study	  the	  effects	  of	  FLG	  mutations	  on	  the	  AD	  phenotype,	  
non-­‐AD	  subjects	  were	  not	  included.	  
	  
	  
5.1	   Correlation	  between	  FLG	  variants	  and	  the	  presence	  and	  severity	  of	  
	   AD	  
	  
	   A	  total	  of	  55	  mild	  to	  moderate	  AD	  subjects	  of	  Western	  European	  ancestry	  
were	   recruited.	   All	   were	   screened	   for	   the	   four	   FLG	   null	   mutations	   most	  
commonly	   found	   in	   European	   populations	   (2282del4,	   R501X,	   R2247X	   and	  
S3247X).	  	  
	  
	   Forty-­‐two	  of	   the	  subjects	  were	   labelled	   'wild-­‐type	  AD'	  (that	   is,	   they	  did	  
not	  possess	  any	  of	  the	  four	  FLG	  mutations	  screened	  for).	  The	  remaining	  13	  were	  
labelled	   'filaggrin-­‐related	   AD'.	   Among	   this	   latter	   group,	   12	   were	   FLG	  
heterozygotes	   (of	  which	   10	   had	   the	   2282del4	  mutation,	   three	   had	   the	  R501X	  
mutation,	  one	  had	  the	  S3247X	  mutation,	  and	  one	  was	  a	  compound	  heterozygote	  
[2282del4/R501X]).	  Only	  one	  subject	  was	  found	  to	  be	  homozygous	  for	  the	  FLG	  
mutation	  (R501X).	  
	  
	   The	  demographic	  and	  clinical	  data	  of	  these	  subjects	  are	  shown	  in	  Table	  
5.1.	  Notably	  age,	  sex,	  a	  history	  of	  asthma,	  a	  family	  history	  of	  atopy	  and	  mean	  IgE	  
level	  were	   similar	   between	   the	   filaggrin-­‐related	  AD	   and	  wild-­‐type	  AD	   groups.	  
On	   the	   other	   hand,	   the	   prevalence	   of	   hay	   fever	  was	   found	   to	   be	   significantly	  
higher	   in	   the	   filaggrin-­‐related	   AD	   group	   (85%	   versus	   53%,	   p	   <	   0.05).	   The	  
severity	   of	   AD	   in	   the	   two	   groups	   was	   also	   similar,	   as	   demonstrated	   by	   the	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   Filaggrin-­related	  AD	   	   Wild-­type	  AD	  
	  
Number	  of	  subjects	  	   	   	   13	  (24%)	   	   	   42	  (76%)	  
Mean	  age	  ±	  SEM	  	   	   	   36.0	  ±	  3.5	   	   	   36.2	  ±	  2.1	  
Male	   	   	   	   	   5	  (39%)	  	   	   	   14	  (33%)	  
Asthma	   	   	   	   	   5	  (39%)	  	   	   	   17	  (40%)	  
Hay	  fever*	   	   	   	   11	  (85%)	   	   	   22	  (52%)	  
Family	  history	  of	  atopy	   	   	   11	  (85%)	   	   	   32	  (75%)	  
Mean	  total	  IgE	  (IU)	  ±	  SEM	   	   420.1	  ±	  238.0	   	   	   731.3	  ±	  220.3	  
Mean	  SASSAD	  score	  ±	  SEM	   	   11.4	  ±	  2.1	   	   	   12.4	  ±	  1.4	  
	  
 
Table 5.1 Demographic and clinical data of the filaggrin-related AD and wild-type AD groups. 
Age, sex, a history of asthma, a family history of atopy and mean IgE level were similar 
between the two groups. However there was a significantly higher prevalence of hay fever in 
the filaggrin-related AD group compared to the wild-type AD group (85% vs 53%, p <0.05). 
The SASSAD score (which measured AD severity) was found to be similar between the two 




5.2	   Correlation	  between	  FLG	  variants	  and	  skin	  barrier	  dysfunction	  
	  
	   Table	  5.2	  compares	  the	  three	  measures	  of	  skin	  barrier	  function	  between	  
the	   filaggrin-­‐related	  AD	  and	  wild-­‐type	  AD	  groups.	  Using	   the	  Mann-­‐Whitney	  U-­‐
test,	  TEWL	  was	  found	  to	  be	  higher	  in	  the	  filaggrin-­‐related	  AD	  group	  compared	  
to	   the	  wild-­‐type	  AD	   group	   (mean	  8.4	   ±	   2.0	   g/m2/h	   vs	   8.1	   ±	   5.9	   g/m2/h).	   The	  
distribution	  in	  the	  two	  groups	  differed	  significantly	  (Mann-­‐Whitney	  U	  =	  163.0,	  p	  
=	  0.029	  two-­‐tailed).	  The	  number	  of	  tape	  strips	  required	  to	  achieve	  TEWL	  >	  20	  
g/m2/h	  was	  lower	  in	  the	  filaggrin-­‐related	  AD	  group	  compared	  to	  the	  wild-­‐type	  
AD	  group	  (mean	  11.3	  ±	  1.9	  vs	  14.1	  ±	  5.5),	  which	  was	  also	  statistically	  significant	  
(p	   =	   0.007).	   There	   was,	   however,	   no	   significant	   difference	   in	   capacitance	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   Four	  randomly	  selected	  subjects	  in	  each	  group	  also	  had	  the	  total	  amount	  
of	  protein	  extracted	  from	  their	  tape	  strips	  quantified.	  The	  mean	  protein	  amount	  
extracted	   from	   the	   tape	   strips	   was	   found	   to	   be	   almost	   twice	   as	   much	   in	   the	  
filaggrin-­‐related	  AD	  subjects	  (33.4	  ±	  8.1	  µg/cm2)	  as	  in	  the	  wild-­‐type	  AD	  subjects	  




	   	   	   	   	   Filaggrin-­related	  AD	   	   Wild-­type	  AD	  
	  
Median	  TEWL	  (g/m2/h)*	  	   	  	  	  	   	  	  	  	  	  	  	  7.9	  (IQR	  7.1-­‐9.7)	   	   6.8	  (IQR	  5.5-­‐8.7)	  
Mean	  capacitance	  (i.u.)	  ±	  SEM	   	   	  	  	  	  	  	  	  58.3	  ±	  4.9	   	   	   58.2	  ±	  2.8	  
Mean	  number	  of	  tape	  strips	  
required	  to	  achieve	   	   	  
TEWL	  >	  20	  g/m2/h	  ±	  SEM*	   	   	  	  	  	  	  	  	  11.3	  ±	  0.5	   	   	   14.1	  ±	  0.8	  
Mean	  protein	  amount	  (µg/cm2)	  in	  	   	   	  
tape	  strips	  (n=4	  in	  each	  group)	  ±	  SEM	  *	   	  	  	  	  	  	  	  33.4	  ±	  2.2	   	   	   18.6	  ±	  1.0	  
 
 
Table 5.2 Comparison of skin barrier function and mean amount of protein extracted 
between the filaggrin-related AD and wild-type AD groups. TEWL was significantly higher in 
the filaggrin-related AD group (8.4 ± 2.0 g/m2/h) compared to the wild-type AD group (8.1 ± 
5.9 g/m2/h) while the number of tape strips required to achieve TEWL > 20 g/m2/h was found 
to be significantly lower in the filaggrin-related AD group (11.3 ± 0.5) compared to the wild-
type AD group (14.1 ± 0.8). No significant difference was found in skin capacitance between 
the two groups. The mean amount of protein extracted from the tape strips was also 
determined and was found to be significantly higher in the filaggrin-related AD compared to 
the wild-type AD group (33.4 ± 2.2 vs 18.6 ± 1.0). * indicates significant statistical difference, 
i.u. = instrument unit. 
	  
	  
5.3	   Discussion	  
	  
	   Previous	  studies	  have	  demonstrated	  a	  defective	  skin	  barrier	  function	  in	  
AD	  subjects	  compared	  to	  healthy	  controls,	  using	  measures	  such	  as	  TEWL	  and	  SC	  
hydration	   [15,	   242,	   256].	   In	   these	   earlier	   studies,	   the	   AD	   subjects	   recruited	  
would	  have	  consisted	  of	  individuals	  with	  and	  without	  FLG	  mutations,	  since	  they	  
were	  not	  specifically	  genotyped.	  The	  primary	  aim	  of	  this	  functional	  study	  was	  to	  
determine	   if	   FLG	   loss-­‐of-­‐function	   alleles	   had	   any	   functional	   relevance	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(determined	  by	  measures	  of	  skin	  barrier	  function).	  If	  this	  were	  the	  case,	  it	  might	  
be	  possible	  to	  stratify	  AD	  phenotype	  by	  FLG	  genotype.	  
	  
	   In	   this	   study,	   a	   total	   of	   55	   subjects	   with	   mild	   and	   moderate	   AD	   were	  
recruited,	  as	   these	  categories	  of	  AD	  were	  representative	  of	   the	  majority	  of	  AD	  
sufferers.	   These	   subjects	  were	  divided	   into	   filaggrin-­‐related	  AD	  and	  wild-­‐type	  
AD	   groups	   based	   on	   their	   FLG	   genotype.	   The	   two	   groups	   were	   found	   to	   be	  
comparable,	   with	   similar	   age,	   sex,	   history	   of	   asthma,	   family	   history	   of	   atopy,	  
mean	   IgE	   level	   and	   AD	   severity	   (similar	   SASSAD	   scores).	   The	   only	   significant	  
difference	  found	  when	  comparing	  their	  clinical	  data	  was	  a	  higher	  prevalence	  of	  
hay	  fever	  in	  the	  filaggrin-­‐related	  AD	  group.	  Hence,	  in	  general,	  the	  comparison	  of	  
skin	  barrier	  function	  between	  the	  two	  groups	  was	  deemed	  to	  be	  valid.	  
	  
	   In	  2007,	  Hubiche	  et	  al	  [243]	  studied	  a	  French	  cohort	  of	  AD	  patients	  and	  
confirmed	  the	  association	  of	  AD	  with	  FLG	  variants.	  Although	  they	  found	  a	  trend	  
for	   higher	   TEWL	   values	   in	   AD	   subjects	   with	   FLG	   mutations,	   the	   association	  
between	  FLG	  variants	  and	  TEWL	  was	  not	  statistically	  significant.	  They	  also	  did	  
not	  find	  any	  association	  between	  FLG	  variants	  and	  AD	  severity.	  These	  findings	  
were	   generally	   consistent	   with	   the	   results	   of	   this	   functional	   study	   reported	  
here,	   although	   the	   higher	   TEWL	   in	   the	   filaggrin-­‐related	   AD	   group	   reached	  
statistical	  significance	  in	  this	  study.	  An	  explanation	  for	  this	  could	  be	  that	  while	  
Hubiche	   et	   al	   only	   screened	   for	   two	   common	   FLG	   mutations	   (R501X	   and	  
2282del4),	   this	   study	   screened	   for	   the	   four	   FLG	   mutations	   that	   were	   most	  
prevalent	  in	  European	  populations.	  
	  
	   A	  second	  study	  on	  a	  small	   Japanese	  AD	  cohort	  by	  Nemoto-­‐Hasebe	  et	  al	  
[244]	  reported	  marginally	  lower	  SC	  hydration	  in	  filaggrin-­‐related	  AD	  compared	  
to	   wild-­‐type	   AD,	   although	   this	   was	   not	   statistically	   significant.	   Similarly,	   this	  
functional	  study	  reported	  in	  this	  thesis	  failed	  to	  show	  any	  significant	  difference	  
in	  capacitance	  (which	  equates	  to	  SC	  hydration)	  between	  the	  filaggrin-­‐related	  AD	  
and	   wild-­‐type	   AD	   groups.	   Paradoxically,	   Nemoto-­‐Hasebe	   et	   al	   additionally	  
reported	  that	  TEWL	  was	  significantly	  lower	  in	  filaggrin-­‐related	  AD	  compared	  to	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wild-­‐type	   AD.	   They	   also	  measured	   SC	   thickness,	   and	   found	   that	   SC	   thickness	  
was	  significantly	  greater	  in	  filaggrin-­‐related	  AD.	  It	  is	  important	  to	  note	  that	  the	  
FLG	   mutations	   found	   in	   the	   Japanese	   populations	   (Ser2554X,	   3321del,	  
Ser2889X	   and	   Ser3296X)	   were	   different	   from	   those	   prevalent	   in	   European	  
populations,	  although	  the	  Japanese	  FLG	  variants	  were	  all	  similarly	  significantly	  
associated	   with	   AD.	   The	   authors	   conjectured	   that	   this	   difference	   in	   FLG	  
mutations	  might	  explain	  for	  their	  unexpected	  findings.	  
	  
	   In	   addition	   to	   TEWL	   and	   skin	   capacitance,	   another	   measure	   of	   skin	  
barrier	   function	   is	   the	   number	   of	   tape	   strips	   required	   to	   achieve	   TEWL	   >	   20	  
g/m2/h.	  This	   level	  of	  TEWL	   is	   generally	   accepted	  as	   the	   level	  where	   the	   SC	   is	  
abrogated	   [146,	   147].	   Since	   filaggrin	   is	   generally	   considered	   an	   essential	  
component	   of	   the	   cytoskeletal	   scaffolding	   that	   ultimately	   forms	   functional	  
corneocytes,	   one	   would	   expect	   the	   number	   of	   tape	   strips	   required	   to	   reach	  
TEWL	  >	  20	  g/m2/h	  to	  be	  less	  in	  filaggrin-­‐related	  AD	  compared	  to	  wild-­‐type	  AD	  
skin.	  This	  was	  supported	  by	  the	  findings	  in	  this	  study.	  In	  an	  attempt	  to	  reconcile	  
this	   with	   the	   greater	   SC	   thickness	   in	   filaggrin-­‐related	   AD	   skin	   reported	   by	  
Nemoto-­‐Hasebe	  et	  al	  [244],	  it	  was	  hypothesized	  that	  the	  corneocytes	  were	  less	  
adherent	  to	  one	  another,	  and	  therefore	  less	  densely	  packed	  in	  filaggrin-­‐related	  
AD	   skin.	   This	   should	   mean	   that	   although	   the	   SC	   in	   filaggrin-­‐related	   AD	   skin	  
might	   be	   thicker,	   their	   less-­‐adherent	   corneocytes	   should	   be	   more	   easily	  
removed,	  with	  a	  greater	  amount	  of	  corneocytes	  extracted	  by	  each	  tape.	  Testing	  
this	  hypothesis	  was	  the	  secondary	  aim	  of	  this	  study	  and	  involved	  measuring	  the	  
total	  protein	  (which	  should	  correlate	  with	  the	  amount	  of	  corneocytes)	  extracted	  
from	   the	   tape	   strips	   from	   eight	   randomly	   selected	   subjects	   (four	   from	   the	  
filaggrin-­‐related	   AD	   group	   and	   four	   from	   the	  wild-­‐type	   AD	   group).	   The	  mean	  
amount	   of	   protein	   extracted	   from	   filaggrin-­‐related	   AD	   skin	   was	   found	   to	   be	  
significantly	  higher	  than	  that	  from	  the	  wild-­‐type	  AD	  group	  (33.4	  ±	  8.1	  vs	  18.6	  ±	  
6.4	  µg/cm2,	  p	  =	  0.028),	   lending	  support	  to	  the	  hypothesis.	  However,	   in	  view	  of	  
the	   small	   sample	   size	   (n	   =	   8),	   this	   finding	   should	   be	   further	   validated	   by	  
extending	  the	  protein	  quantification	  to	  a	  larger	  cohort.	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   In	  this	  study,	  FLG	  variants	  were	  not	  found	  to	  be	  significantly	  associated	  
with	  AD	  severity,	  as	  evidenced	  by	  the	  similar	  SASSAD	  scores	  between	  filaggrin-­‐
related	  AD	  and	  wild-­‐type	  AD	  groups	   (11.4	  ±	  7.5	   vs	  12.4	  ±	  9.1).	  However,	   this	  
finding	  should	  be	  interpreted	  in	  the	  knowledge	  that	  only	  individuals	  with	  mild	  
and	  moderate	  AD	  were	   recruited	   for	   this	   study.	  Nonetheless,	   this	   finding	  was	  
consistent	   with	   that	   of	   Hubiche	   et	   al	   [243],	   although	   there	   have	   been	  
suggestions	  from	  other	  studies	  that	  filaggrin-­‐related	  AD	  may	  be	  associated	  with	  
increased	  severity	  in	  childhood	  [22,	  120],	  as	  well	  as	  AD	  with	  an	  early	  onset	  that	  
persists	  into	  adulthood	  [31].	  	  
	  
	   In	  summary,	  the	  results	  from	  this	  study	  suggest	  that	  it	  might	  be	  possible	  
to	   stratify	   AD	   phenotype	   by	   FLG	   genotype,	   with	   filaggrin-­‐related	   AD	   likely	   to	  
exhibit	   poorer	   skin	   barrier	   and	   possibly	   run	   a	   more	   severe	   disease	   course.	  
There	   is	   therefore	  potentially	   prognostic	   value	   in	  determine	  FLG	   status	   in	  AD	  
patients.	  This	  study	  of	  AD	  phenotype	  was	  the	  most	  detailed	  yet	  on	  a	  European	  
AD	   cohort,	   including	   as	   yet	   unreported	   studies	   on	   the	   ease	  of	   perturbation	   in	  
filaggrin-­‐related	   AD	   skin	   to	   a	   chemical	   irritant	   (sodium	   lauryl	   sulfate),	   the	  
association	  between	  FLG	   variants	  with	   irritant	  and	  allergic	   contact	  dermatitis,	  
and	   the	   effects	   of	   FLG	  mutations	   on	   epidermal	   dendritic	   cell	   populations.	   In	  
addition,	   as	   there	  have	  been	   suggestions	   that	  measuring	  baseline	   skin	  barrier	  
function	  may	  provide	  an	  incomplete	  assessment	  [257],	  future	  work	  will	  analyse	  
acute	   perturbations	   of	   the	   SC	   with	   subsequent	   assessment	   of	   the	   kinetics	   of	  
barrier	  recovery.	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6.0	   MASS	  SPECTROMETRIC	  ANALYSIS	  OF	  FILAGGRIN	  
	  
	   To	   date,	   perhaps	   the	   most	   detailed	   mass	   spectrometric	   analyses	   of	  
filaggrin	   was	   carried	   out	   by	   Walsh's	   group	   at	   the	   University	   of	   Washington	  
almost	  20	  years	  ago.	  Using	  techniques	  such	  as	  MALDI-­‐TOF	  MS	  and	  LC/MS,	  they	  
studied	   rat	   and	   human	   filaggrin	   to	   characterise	   the	   protease	   processing	   sites	  
during	  profilaggrin	  to	  filaggrin	  conversion	  [84],	  identify	  the	  amino	  terminus	  of	  
filaggrin	   [253],	   analyse	   the	   phosphorylation	   sites	   of	   profilaggrin	   [258],	   and	  
study	  the	  microheterogeneity	  of	  the	  protein	  [251].	  	  
	  
	   In	   contrast	   to	   rat	   and	   mouse	   filaggrin,	   cDNA	   sequences	   for	   human	  
filaggrin	  display	  marked	  variability	  (40%	  of	  the	  amino	  acid	  residues)	  [59,	  61].	  It	  
has	  been	  shown	  that	  even	  within	  a	  single	  individual,	  filaggrin	  is	  a	  population	  of	  
homologous	   but	   heterogeneous	   proteins	   [251].	   Because	   of	   this	   extensive	  
heterogeneity,	  structural	  studies	  of	  filaggrin	  have	  proven	  to	  be	  challenging.	  
	  
	   The	   main	   aim	   of	   this	   structural	   study	   is	   to	   interrogate	   the	   structure-­‐
function	   relationship	   of	   filaggrin,	   specifically	   by	   comparing	   filaggrin	   extracted	  
from	   AD	   and	   non-­‐AD	   skin.	   With	   the	   use	   of	   long-­‐range	   PCR,	   the	   entire	   DNA	  
sequence	   of	   profilaggrin	   has	   finally	   been	   sequenced	   by	   the	   McLean	   group	   in	  
Dundee	  [23].	  However,	  genetics	  cannot	  completely	  inform	  about	  cell	  physiology	  
for	   several	   reasons.	   For	   instance,	   it	   is	   known	   that	   a	   single	   gene	   (due	   to	  
alternative	   splicing	   of	   primary	   transcripts)	   can	   generate	   several	   different	  
proteins.	  Also,	  there	  are	  many	  post-­‐translational	  modifications	  that	  can	  alter	  the	  
structure	  and	  function	  of	  the	  final	  protein.	  Additionally,	  there	  are	  also	  dynamic	  
processes	  of	  protein	  maturation	  and	  degradation	  that	  can	  alter	  the	  final	  active	  
protein	  [245].	  Therefore,	  although	  studying	   filaggrin	  at	   the	  protein	   level	   could	  
pose	  significant	  challenges	  due	  to	  its	  extensive	  heterogeneity,	  this	  was	  believed	  
to	  be	  essential	   in	  order	   to	  gain	   further	   insight	   into	   its	  role	   in	  diseases	  such	  as	  
AD.	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   MS	  has	  been	  used	   for	   the	   analysis	  of	  proteins	   and	  peptides	   since	  1989	  
with	  the	  development	  of	  'soft'	  ionisation	  techniques	  for	  large,	  polar	  and	  highly-­‐
charged	   molecules	   [180,	   189].	   It	   is	   now	   the	   primary	   technique	   used	   for	  
structural	  characterisation	  of	  proteins,	  including	  the	  determination	  of	  the	  amino	  
acid	  sequence,	  studying	  the	  nature	  of	  post-­‐translational	  modifications,	  and	  the	  
verification	  of	  protein	  structure.	  Hence,	  to	  better	  understand	  the	  structure	  and	  
function	   of	   filaggrin	   in	   AD	   and	   non-­‐AD	   skin,	   MS	   techniques	   were	   employed,	  
specifically	   MALDI-­‐TOF	   MS	   and	   nano	   LC-­‐MS/MS	   (see	   Chapter	   1.6	   for	  
description	  of	  techniques).	  
	  
	   The	   AD	   subjects	   recruited	   for	   this	   study	   was	   from	   the	   genotyped	  
participants	  of	   the	   functional	   study	  (described	   in	  Chapter	  5).	  Non-­‐AD	  controls	  
were	   healthy	   volunteers	   (without	   any	   history	   or	   clinical	   evidence	   of	   AD)	  
recruited	  from	  the	  University	  of	  Edinburgh	  School	  of	  Chemistry,	  Department	  of	  
Dermatology,	  as	  well	  as	  patients	  who	  underwent	  breast	  reduction	  surgery.	  
	  
	  
6.1	   MALDI-­TOF	  MS	  analysis	  of	  human	  filaggrin	  
	  
	   The	   extraction	   and	   purification	   of	   filaggrin	   are	   detailed	   in	   Chapter	   3.	  
Filaggrin	  extracted	  from	  both	  breast	  tissues	  and	  tape	  strips	  were	  analysed,	  with	  
the	  protein	  studied	  in	  both	  its	  intact	  and	  tryptic-­‐digest	  states.	  Details	  of	  sample	  
preparation	  and	  MS	  methodology	  are	  described	  in	  Chapter	  2.9.	  
	  
	  
6.1.1	   MALDI-­TOF	  MS	  analysis	  of	  intact	  filaggrin	  protein	  
	  
	   Intact	  purified	  filaggrin	  extracted	  from	  eight	  subjects	  (four	  AD	  and	  four	  
non-­‐AD)	  were	  analysed	  using	  MALDI-­‐TOF	  MS.	  Filaggrin	  from	  two	  of	  the	  non-­‐AD	  
controls	  were	  extracted	  from	  breast	  reduction	  tissues,	  while	  the	  other	  two	  were	  
from	  tape	  strips.	  All	  the	  filaggrin	  from	  the	  AD	  subjects	  were	  extracted	  using	  tape	  
strips	  only.	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   MALDI-­‐TOF	   MS	   of	   all	   non-­‐AD	   samples,	   whether	   those	   extracted	   from	  
breast	  reduction	  tissues	  or	  tape	  strips,	  produced	  similar	  mass	  spectra.	  The	  main	  
peak	  was	   broad,	   centred	   at	   around	  m/z	  35,000	   ±	   1400	   at	   half-­‐height	   (Figure	  
6.1).	   There	   was	   also	   a	   smaller	   peak	   at	   around	  m/z	   17,000	   that	   was	   likely	   a	  
doubly-­‐charged	  molecular	  ion	  of	  the	  m/z	  35,000	  species,	  and	  one	  at	  around	  m/z	  
70,000	  which	  was	  thought	  to	  be	  a	  dimer	  of	  the	  dominant	  species.	  	  
	  
	   MALDI-­‐TOF	   MS	   analysis	   of	   intact	   filaggrin	   purified	   from	   all	   four	   AD	  
subjects	   failed	   to	   yield	   any	   significant	   mass	   peaks,	   suggesting	   an	   inadequate	  






Figure 6.1. MALDI-TOF mass spectrum of intact filaggrin extracted from a non-AD subject.  
Mass spectra of all four non-AD samples were similar, showing a main broad peak [M+H]+ 
centred at around m/z 35,000 ± 1400 at half-height. The broadness of the peak is consistent 
with the heterogeneity of filaggrin. The smaller peak at around m/z 17,000 was likely a 
doubly-charged molecular ion of the dominant m/z 34,000 species, while the small peak at 
around m/z 70,000 was possibly a dimer of the m/z 35,000 species. The small peaks at the 
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6.1.2	   MALDI-­TOF	  analysis	  of	  filaggrin	  tryptic-­digests	  
	  
	   Filaggrin	  protein	  that	  was	  extracted	  and	  purified	  from	  10	  subjects	  were	  
subjected	  to	  digestion	  with	  trypsin	  before	  being	  analysed	  using	  MALDI-­‐TOF	  MS.	  
The	   first	   eight	   of	   these	   subjects	  were	   the	   same	   as	   those	  described	   in	  Chapter	  
6.1.1.	   The	   additional	   two	   subjects	   were	   non-­‐AD	   controls,	   with	   their	   filaggrin	  
extracted	  from	  breast	  reduction	  tissues.	  In	  total,	  tryptic-­‐digests	  from	  six	  non-­‐AD	  
and	  four	  AD	  subjects	  were	  analysed.	  
	  
	   The	   MALDI-­‐TOF	   mass	   spectra	   of	   two	   of	   the	   non-­‐AD	   filaggrin	   tryptic-­‐
digests	  (one	  extracted	  from	  breast	  reduction	  tissues	  and	  one	  from	  tape	  strips)	  
are	   shown	   in	   Figure	  6.2.	  As	  was	   the	   case	  with	   the	  MALDI-­‐TOF	  MS	  analysis	   of	  
intact	   filaggrin,	  all	  six	  mass	  spectra	  of	   the	  non-­‐AD	  tryptic-­‐digest	  samples	  were	  






























Figure 6.2. MALDI-TOF MS mass spectra of filaggrin tryptic-digests from (a) breast tissues 
and (b) tape strips, showing similarity in the mass spectra. In fact, the mass spectra from all 
the non-AD samples were very similar. Indicated are the m/z peaks observed in the mass 
spectra of all six non-AD samples (excluding those peaks from trypsin auto-digestion). The 





	   Using	  PMF	  (detailed	  in	  Chapter	  1.6.4),	  the	  peptide	  masses	  obtained	  from	  
each	   MALDI-­‐TOF	   spectrum	   were	   matched	   against	   the	   theoretical	   peptide	  
masses	   from	   in	   silico-­‐digested	   proteins	   in	   the	   comprehensive	   NCBInr	   protein	  
database.	   An	   online	   database	   search	   programme,	   MS-­‐FIT,	  
(http://prospector.ucsf.edu/prospector/cgi-­‐bin/msform.cgi?form=msfitstandard)	  was	  
used	   to	   facilitate	   this	   matching	   process.	   All	   the	   six	   non-­‐AD	   samples	   were	  
matched	   very	   well	   to	   filaggrin,	   with	   high	   MOWSE	   scores,	   despite	   the	   scores	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being	   generally	   higher	   for	   the	   breast	   samples.	   Figure	   6.3	   shows	   the	  














Figure 6.3. Database search results using the online database search programme MS-FIT. 
(a) Search results using the peptide masses obtained from the mass spectrum in Figure 
6.2a. (b) Search results corresponding to the mass spectrum in Figure 6.2b. All the tryptic-
digest samples obtained from the six non-AD subjects matched well to filaggrin, with high 
MOWSE scores. 
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   Several	  m/z	  peaks	  were	  observed	  in	  all	  the	  mass	  spectra	  of	  the	  six	  non-­‐
AD	  samples,	  disregarding	   those	   that	  were	  due	   to	   trypsin	  auto-­‐digestion.	  Table	  
6.1	   lists	   these	   m/z	   peaks	   and	   their	   corresponding	   peptide	   sequences	   as	  
suggested	  by	  MS-­‐FIT.	  
	  
	  
m/z	   	   Corresponding	  peptides	  
	  
864.4	   	   GQSGESSGRGQSGESSGR	  
1122.6	   	   KENLPISGHKKENLPISGHK	  
1284.6	   	   NHLGSAWEQSRNHLGSAWEQSR	  
1328.6	   	   HSASQEGQDTIRHSASQEGQDTIR	  
1353.6	   	   HGSGHQQSADSSRHGSGHQQSADSSR	  
1363.7	   	   HSGIGHGQASSAVRHSGIGHGQASSAVR	  
2235.9	   	   NQGSSVSQDSDSQGHSEDSERNQGSSVSQDSDSQGHSEDSER	  
2932.4	   	   VTNELYTVMKTYHMYHAESISAESKVTNELYTVMKTYHMYHAESISAESK	  	  
	  
Table 6.1 List of m/z peaks observed in all the mass spectra of the non-AD filaggrin tryptic-
digests, along with the corresponding peptides as suggested by MS-FIT. 
	  
	  
	   As	   was	   the	   case	   with	   the	   intact	   filaggrin	   samples,	   MALDI-­‐TOF	   MS	  
analysis	  of	  the	  AD	  tryptic-­‐digests	  yielded	  similarly	  poor	  mass	  spectra.	  The	  lack	  
of	  any	  significant	  peptide	  m/z	  peaks	  once	  again	  suggests	  an	  inadequate	  amount	  
or	  absence	  of	  filaggrin	  in	  the	  analysed	  samples.	  
	  
	  
6.2	   Online	  nano	  LC-­MS/MS	  of	  filaggrin	  tryptic-­digests	  
	  
	   In	   addition	   to	  MALDI-­‐TOF	  MS,	   purified	   filaggrin	   samples	   from	   AD	   and	  
non-­‐AD	   subjects	   were	   also	   analysed	   using	   nano	   LC-­‐MS/MS,	   which	   has	   the	  
advantage	  of	  providing	  accurate	  sequence	  information.	  	  
	  
	   Purified	   filaggrin	   samples	   from	   a	   total	   of	   21	   non-­‐AD	   and	   AD	   subjects	  
were	   digested	   with	   trypsin	   before	   being	   analysed	   by	   nano	   LC-­‐MS/MS.	   These	  
subjects	  included	  all	  those	  whose	  intact	  samples	  were	  analysed	  by	  MALDI-­‐TOF	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MS.	  As	  shown	  in	  Table	  6.2,	  all	   the	  AD	  subjects	  were	  genotyped	  as	  being	  either	  
FLG	  wild-­‐type	  or	  heterozygous	   for	   the	  2282del4	  or	  R501X	  mutations.	  None	  of	  




Phenotype	   Genotype	   	   	   Number	  of	  subjects	  
	  
	  
Non-­AD	  	   FLG	  wild-­‐type	   	   	   6	  (2	  were	  extracted	  from	  breast	  tissues)	  
	  
AD	   	   FLG	  wild-­‐type	   	   	   9	  
	   	   2282del4	  heterozygote	   	   5	  
	   	   R501X	  heterozygote	   	   1	  
	  
	   	   	   	   	   Total	   21	  
	  
 
Table 6.2 Phenotype and genotype of the subjects from which filaggrin were extracted and 
purified for nano LC-MS/MS analysis. Included among these were the 8 subjects whose 
purified filaggrin were analysed with MALDI-TOF MS. In two of the non-AD control subjects, 
filaggrin was extracted from breast reduction tissues. Filaggrin from the remaining four non-
AD subjects, as well as from all the AD subjects, was extracted using tape strips. 
	  
	  
	   As	  detailed	  in	  Chapter	  2.9.5,	  the	  peptide	  fragmentation	  data	  obtained	  for	  
each	   sample	  were	  matched	   against	   the	   NCBInr	   protein	   database	   using	   an	   in-­‐
house	   MASCOT	   search	   engine	   (Matrix	   Science).	   The	   tryptic-­‐digests	   of	   all	   six	  
non-­‐AD	   protein	   samples	   were	   matched	   to	   filaggrin.	   Again,	   there	   was	   a	  
difference	  in	  the	  matching	  scores	  between	  those	  samples	  extracted	  from	  breast	  
reduction	  tissues	  and	  those	  from	  tape	  strips.	  The	  two	  breast	  tryptic-­‐digests	  had	  
higher	  MASCOT	  scores	  (ranged	  from	  963	  to	  1736)	  compared	  to	  those	  from	  tape	  
strips	   (ranged	   from	   49	   to	   555).	   The	   full	   MASCOT	   search	   results	   for	   three	  
tryptic-­‐digests	  (one	  from	  breast	  reduction	  tissues,	  and	  two	  from	  tape	  strips)	  can	  
be	  viewed	  from	  the	  attached	  data	  disc	  for	  comparison.	  	  
	  
	   Analysis	  of	  the	  filaggrin	  tryptic-­‐digests	  from	  the	  15	  AD	  subjects	  produced	  
disappointing	   results.	   The	   initial	   base	   peak	   chromatograms	   of	   these	   samples	  
suggested	   insufficient	  or	  absent	  protein	  and	  so	   instead	  of	   the	  usual	  10	   -­‐	  15	  µl	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sample	  loading	  volume,	  higher	  loading	  volumes	  (up	  to	  250	  µl)	  were	  used	  in	  an	  
attempt	   to	   boost	   peptide	   detection.	   However,	   despite	   this,	   only	   two	   of	   these	  
subjects	  (FW	  and	  MOK,	  both	  FLG	  wild-­‐types)	  were	  matched	  weakly	  to	  filaggrin.	  
Sample	  FW	  required	  a	  sample	  loading	  volume	  of	  50	  µl	  before	  a	  weak	  match	  to	  
filaggrin	   with	   a	   MASCOT	   score	   of	   53	   was	   obtained.	   Increasing	   the	   sample	  
volume	  to	  250	  µl	  did	  not	  improve	  the	  MASCOT	  score.	  Sample	  MOK	  produced	  a	  
weak	  match	  to	  filaggrin	  with	  a	  loading	  volume	  of	  50	  µl	  (MASCOT	  score	  69),	  but	  
the	   match	   was	   slightly	   strengthened	   (MASCOT	   score	   152)	   when	   the	   sample	  
loading	  volume	  was	  increased	  to	  250	  µl.	  The	  attached	  data	  disc	  contains	  the	  full	  
MASCOT	   search	   results	   for	   samples	   FW	  and	  MOK.	  This	   lack	   of	   any	  detectable	  
filaggrin	  in	  the	  AD	  samples	  was	  confirmed	  by	  collecting	  fresh	  tape	  strips	  again	  
from	   five	   of	   the	   AD	   subjects	   (including	   subject	   FW)	   to	   repeat	   the	   entire	  
extraction	   and	   purification	   of	   their	   filaggrin.	   These	   replicated	   samples	   (again	  
using	  up	  to	  250	  µl	  sample	  loading	  volumes)	  produced	  results	  similar	  to	  those	  of	  
the	  initial	  samples.	  
	  
	   As	  mentioned	  earlier,	  the	  main	  advantage	  of	  using	  nano	  LC-­‐MS/MS	  is	  the	  
ability	  to	  determine	  sequence	  information.	  Figure	  6.4	  shows	  the	  CID	  spectrum	  
from	   one	   non-­‐AD	   sample	   and	   its	   assignment	   to	   the	   filaggrin	   peptide	  
HAETSSGGQAASSQEQAR	  (ion	  score	  of	  148).	  It	  illustrates	  an	  example	  of	  MS/MS	  
data	  and	  its	  interpretation.	  Indicated	  in	  the	  figure	  are	  the	  b	  and	  y	  ions.	  MASCOT	  
produces	  a	  peptide	  summary	  report	  that	  groups	  peptide	  matches	  like	  this	  into	  
protein	   hits,	   and	   derives	   a	   protein	   score	   (MASCOT	   score)	   from	   the	   combined	  
ions	  scores.	  In	  this	  case,	  the	  combined	  MASCOT	  score	  is	  1273.	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Figure 6.4 A CID spectrum for the filaggrin peptide HAETSSGGQAASSQEQAR, that is 
given an ion score of 148 by MASCOT. The b and y ions are indicated to illustrate how the 
data is interpreted. MASCOT groups peptide matches like this into protein hits and derives a 
protein score (MASCOT score) from the combined ion scores. In this case, the MASCOT 
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6.3	   Immunoblotting	  
	  
	   In	  order	  to	  further	  ascertain	  the	  presence	  (or	  absence)	  of	  filaggrin	  in	  the	  
non-­‐AD	   and	   AD	   samples,	   immunoblotting	   with	   a	   mouse	  monoclonal	   filaggrin	  
antibody	  (ab17808,	  Abcam)	  was	  performed	  on	  all	  the	  initial	  SC	  extracts	  as	  well	  
as	   the	   final	  purified	  protein	  samples.	   Immunoblots	  of	   the	   initial	  SC	  extracts	  of	  
the	   non-­‐AD	   subjects	   all	   produced	   a	   thick	   filaggrin	   bands	   (generally	   a	   thick	  
smear	   from	   about	   45	   kDa	   upwards),	  while	   the	   immunoblots	   of	   the	   AD	   initial	  
extracts	  were	  generally	   less	  prominent,	  regardless	  of	  whether	   the	  AD	  subjects	  
were	   of	   FLG	   wild-­‐type	   or	   heterozygous	   genotype.	   Figure	   6.5	   shows	   the	   band	  
from	   the	   initial	   SC	   extract	   of	   a	   non-­‐AD	   subject	   that	   was	   obtained	   by	   tape	  
stripping,	  as	  well	  as	  those	  from	  all	  the	  non-­‐AD	  subjects.	  As	  an	  equal	  volume	  of	  
sample	   was	   loaded	   into	   each	   well,	   this	   difference	   in	   band	   thickness	   suggests	  
that	  less	  filaggrin	  was	  present	  in	  the	  initial	  SC	  extract	  of	  the	  AD	  compared	  to	  the	  
non-­‐AD	   subjects.	   The	   final	   purified	   filaggrin	   samples	   were	   also	   analysed	   by	  
immunoblotting.	   Immunoblots	   of	   the	   non-­‐AD	   samples	   produced	   a	   prominent	  
band	   at	   around	   45	   kDa,	  which	  was	   absent	   in	   any	   of	   the	   AD	   subjects,	   even	   in	  
subjects	  FW	  and	  MOK	  (which	  were	  both	  weakly	  matched	  to	  filaggrin	  following	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Figure 6.5 Comparison of immunoblots of initial SC extracts. (a) Immunoblot of the initial SC 
extract from one non-AD subject, showing the typical thick prominent filaggrin bands seen in 
the non-AD samples. (b) Immunoblot of the initial SC extracts from all the AD subjects. 
Regardless of the genotype, the AD subjects' immunoblots all showed less prominent 
filaggrin bands. Since each of these samples was extracted from 100 tape strips, and an 
identical volume of sample was loaded into each well, this suggests that there was less 
filaggrin in the initial SC extracts of the AD subjects compared to non-AD subjects. Ideally, a 
loading control could have been used to ensure that protein loading was the same in each 
well. The immunoblots of the final purified filaggrin of the non-AD samples all showed a 
filaggrin band at 45 kDa, while no bands were seen in the purified AD samples (data not 
shown). 
	  
6.4	   Discussion	  
	  
	   The	  main	  aim	  of	   this	   structural	   study	  was	   to	   interrogate	   the	   structure-­‐
function	  of	  filaggrin	  by	  comparing	  filaggrin	  from	  AD	  skin	  to	  non-­‐AD	  skin	  using	  
mass	   spectrometric	   techniques.	   Any	   differences	   found	   in	   filaggrin	   structure	  
between	  the	  two	  groups	  could	  hopefully	  provide	  insight	  into	  the	  role	  of	  filaggrin	  
in	  AD.	  	  
	  
	   All	  the	  AD	  subjects	  recruited	  for	  this	  structural	  study	  were	  genotyped	  to	  
detect	  the	  presence	  of	  the	  four	  commonest	  European	  FLG	  mutations	  (2282del4,	  
R501X,	  R2247X	  and	  S3247X).	  It	  is	  certainly	  plausible	  that	  one	  or	  more	  of	  the	  AD	  
subjects	  could	  have	  possessed	  a	  rarer	  FLG	  mutation,	  which	  would	  result	   in	  an	  
underestimation	  of	  the	  number	  of	  heterozygotes	  or	  compound	  heterozygotes	  in	  
the	  AD	  cohort.	  However,	  the	  likelihood	  of	  possessing	  these	  rarer	  mutations	  was	  
relatively	  low	  since	  studies	  had	  shown	  that	  these	  four	  FLG	  mutations	  accounted	  
for	  up	  to	  95%	  of	  all	  known	  FLG	  mutations	  in	  European	  populations	  [248].	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   The	   non-­‐AD	   subjects	   in	   this	   structural	   study	   were	   not	   genotyped,	   but	  
since	   filaggrin	  was	   easily	   detected	   in	   all	   the	   non-­‐AD	   samples,	   it	  was	   assumed	  
that	   they	   all	   had	   the	   wild-­‐type	   genotype.	   Previous	   biochemical	   and	  
immunohistochemical	  studies	  had	  shown	  that	  a	  null	  mutation	  in	  the	  FLG	  allele	  
resulted	  in	  an	  absence	  of	  filaggrin	  expression	  [23,	  255],	  thereby	  supporting	  this	  
assumption.	   Of	   course,	   one	   or	   more	   of	   the	   non-­‐AD	   subjects	   could	   still	   be	  
heterozygous	  for	  the	  FLG	  mutation,	  which	  would	  mean	  that	  they	  still	  expressed	  
some	  filaggrin.	  However,	  this	  was	  unlikely	  to	  be	  the	  case	  for	  three	  reasons.	  First,	  
the	   MS	   analysis	   of	   these	   samples	   gave	   uniformly	   strong	   signals;	   second,	  
immunoblotting	  of	   these	   samples	   all	   showed	   thick	   filaggrin	  bands.	  Both	   these	  
suggested	  the	  presence	  of	  a	  large	  amount	  of	  filaggrin	  present	  in	  all	  the	  non-­‐AD	  
samples.	  Third,	  FLG	  mutations	  had	  also	  been	  shown	  to	  be	  much	  less	  prevalent	  in	  
non-­‐AD	   individuals	   compared	   to	   AD	   sufferers	   [22].	   Therefore	   for	   these	   three	  
reasons,	  all	   the	  non-­‐AD	  subjects	  were	  very	   likely	   to	  be	  FLG	  homozygous	  wild-­‐
types.	  	  
	  
	   Purified	   filaggrin	  extracted	   from	  both	  AD	  subjects	  and	  non-­‐AD	  controls	  
were	   analysed	   using	   MALDI-­‐TOF	   MS	   and	   nano	   LC-­‐MS/MS	   to	   elicit	   structural	  
information	  of	   filaggrin	   in	  both	   its	   intact	  and	  tryptic-­‐digest	  states.	  MALDI-­‐TOF	  
analysis	   of	   intact	   filaggrin	   from	   non-­‐AD	   subjects	   showed	   a	   dominant	   peak	  
centred	   at	   approximately	  m/z	   34,000	   that	   was	   broad	   (m/z	   ±	   1,400	   at	   half-­‐
height).	  The	  width	  of	   the	  peak	  was	  consistent	  with	   the	  heterogeneic	  nature	  of	  
filaggrin.	   There	   was	   also	   a	   smaller	   peak	   at	   around	   m/z	   17,000	   that	   likely	  
represented	   a	   doubly-­‐charged	  molecular	   ion	   of	   the	   dominant	   34,000	   species,	  
and	  one	  at	  around	  m/z	  70,000	  which	  was	  thought	  to	  be	  a	  dimer	  of	  the	  dominant	  
species.	  These	  data	  were	  similar	  to	  that	  reported	  by	  Thulin	  et	  al	  who	  reported	  a	  
broad	  main	  peak	  centred	  at	  m/z	  34,144	  ±	  1560	  at	  half-­‐height	  [251].	  A	  smaller	  
peak	  at	  m/z	  17,071	  was	  also	  seen	  in	  their	  intact	  filaggrin	  MALDI-­‐TOF	  spectrum.	  
They	  did	  not,	  however,	  comment	  on	  this	  peak,	  nor	  did	  they	  report	  the	  presence	  
of	  any	  possible	  dimeric	  species.	  The	  latter	  could	  be	  due	  to	  the	  authors	  setting	  an	  
upper	  m/z	  limit	  of	  50,000	  that	  was	  too	  low	  to	  detect	  this	  peak.	  These	  additional	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peaks	   at	   half	   and	   double	   the	   m/z	   value	   of	   the	   dominant	   species	   were	   not	  
unexpected	  as	  they	  are	  frequently	  observed	  in	  MALDI-­‐TOF	  analyses	  performed	  
in	  positive	  ionisation	  mode.	  
	  
	   Analysis	   of	   filaggrin	   tryptic-­‐digests	   from	   the	   non-­‐AD	   subjects	   using	  
either	  MALDI-­‐TOF	  MS	  or	  nano	  LC-­‐MS/MS	  yielded	   good	  data,	  with	   all	   samples	  
matching	   well	   to	   filaggrin.	   In	   the	   case	   of	   MALDI-­‐TOF	   MS,	   no	   significant	  
difference	  in	  the	  mass	  spectra	  was	  noted	  between	  the	  filaggrin	  extracted	  from	  
breast	   tissues	   and	   that	   from	   tape	   strips,	   although	   the	   MOWSE	   scores	   were	  
higher	  in	  the	  breast	  samples.	  This	  difference	  was	  more	  pronounced	  in	  the	  nano	  
LC-­‐MS/MS	   results	   with	   the	   matching	   scores	   from	   the	   breast	   tissue	   samples	  
being	  clearly	  better	  than	  those	  from	  tape	  strips,	  with	  more	  peptides	  matched.	  As	  
extraction	  from	  breast	  tissues	  generally	  yielded	  more	  protein	  compared	  to	  tape	  
stripping,	  this	  suggested	  that	  the	  amount	  of	  filaggrin	  extracted	  from	  tape	  strips	  
could	   be	   further	   increased	   to	   allow	   for	   optimal	   nano	   LC-­‐MS/MS	   analysis.	  
Possible	   solutions	  would	   be	   to	   collect	  more	   tape	   strips	   from	   each	   subject,	   or	  
increase	  the	  sample	  loading	  volume.	  
	  
	   None	  of	  the	  MS	  analysis	  of	  filaggrin	  (both	  intact	  and	  tryptic-­‐digests)	  from	  
AD	  subjects	  yielded	  any	   interpretable	  results.	  The	   lack	  of	  any	  significant	  mass	  
peaks	  in	  the	  MALDI-­‐TOF	  mass	  spectra	  suggested	  that	  filaggrin	  was	  either	  absent	  
or	   in	   too	  minute	  an	  amount	   for	  detection	  by	  MALDI-­‐TOF	  MS.	  Nano	  LC-­‐MS/MS	  
also	  did	  not	  match	  any	  of	  the	  15	  AD	  tryptic-­‐digest	  samples	  to	  filaggrin	  when	  the	  
usual	  15	  µl	  sample	  loading	  volume	  was	  injected.	  However,	  after	  increasing	  the	  
sample	  loading	  volume	  to	  a	  maximum	  of	  250	  µl,	  two	  AD	  samples	  (FW	  and	  MOK)	  
were	  matched	  weakly	  to	  filaggrin.	  Once	  again,	  this	  was	  further	  evidence	  that	  the	  
AD	   samples	   contained	   either	   no	   filaggrin,	   or	   in	   too	   small	   an	   amount	   for	   MS	  
analysis.	  	  
	  
	   Immunoblotting	  was	   used	   to	   ascertain	   the	   presence	   of	   filaggrin	   in	   the	  
initial	   SC	  extracts	  as	  well	   as	   the	   final	  purified	  protein	   samples.	  Comparison	  of	  
the	  immunoblots	  of	  the	  initial	  SC	  extracts	  showed	  that	  the	  filaggrin	  bands	  seen	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in	   the	   non-­‐AD	   samples	  were	   thicker	   and	  more	   intensely	   stained	   compared	   to	  
those	  of	  the	  AD	  samples,	  indicating	  a	  greater	  amount	  of	  filaggrin	  in	  the	  former	  
group.	  Also,	  while	  all	  the	  final	  purified	  protein	  samples	  of	  the	  non-­‐AD	  subjects	  
produced	   a	  distinct	   45	  kDa	   filaggrin	  band,	   this	   band	  was	   absent	   in	   all	   the	  AD	  
samples.	   The	   immunoblotting	   results	   suggested	   that	   there	   was	   less	   filaggrin	  
present	   in	   the	   AD	   initial	   tape	   strips,	   and	   with	   the	   subsequent	   protein	   loss	  
through	   the	   purification	   process,	   there	   was	   too	   little	   filaggrin	   in	   the	   final	  
purified	   samples	   for	   immunodetection.	   It	   is	   likely	   that	   if	   these	   samples	   were	  
concentrated	   prior	   to	   immunoblotting,	   or	   if	   more	   tape	   strips	   were	   obtained	  
from	  the	  AD	  subjects,	  filaggrin	  could	  have	  been	  detected.	  Certainly,	  at	   least	  for	  
samples	   FW	   and	  MOK	   that	  were	   both	   eventually	  matched	  weakly	   to	   filaggrin	  
after	   increasing	   their	   sample	   injection	   volumes,	   one	   would	   expect	   positive	  
filaggrin	  immunodetection	  following	  further	  concentration	  of	  these	  samples.	  
	  
	   It	   is	   interesting	   to	   note	   that	   all	   immunoblots	   in	   our	   study	   produced	  
filaggrin	  bands	  at	  around	  45	  kDa,	  agreeing	  with	  the	  calculated	  molecular	  mass	  
of	   human	   filaggrin	   (44.1	   kDa)	   [259],	   but	   higher	   than	   the	   37	   kDa	   reported	   in	  
recent	   studies	   [23].	   Other	   authors	   have	   also	   reported	   different	   molecular	  
weights	  for	  human	  filaggrin,	  such	  as	  42-­‐45	  kDa	  [260]	  to	  as	  high	  as	  51	  kDa	  [113].	  
These	   differences	   are	   likely	   due	   to	   variation	   in	   purification	   procedures,	  
resulting	  in	  different	  isoforms	  of	  the	  molecules.	  	  
	  
	   Various	  modifications	  to	  the	  extraction	  and	  purification	  of	  filaggrin	  were	  
attempted	  during	  this	  study	  in	  the	  hope	  of	  increasing	  the	  yield	  of	  filaggrin	  in	  the	  
initial	  SC	  extracts	  and	  the	  final	  purified	  protein	  samples.	  These	  included	  trying	  
various	   homogenisation	   methods,	   increasing	   the	   size	   of	   tape	   strips	   used	  
(replacing	  the	  initial	  14	  mm-­‐diameter	  tapes	  with	  larger	  22	  mm-­‐diameter	  ones),	  
extending	  the	  extraction	  time	  (from	  one	  day	  to	  two	  days),	  replacing	  an	  acetone	  
protein	   precipitation	   step	   with	   an	   LC	   desalting	   step	   to	   reduce	   protein	   loss,	  
trying	   different	   LC	   columns	   as	   well	   as	   deep	   cleaning	   and	   replacing	   the	   older	  
columns.	  A	  flow	  chart	  detailing	  the	  various	  modifications	  made	  to	  the	  extraction	  
and	  purification	  process	  is	  shown	  in	  Figure	  3.4.	  	  Eventually,	  it	  was	  decided	  that	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the	   process,	   as	   described	   in	   Chapter	   3,	   could	   not	   be	   further	   optimised	   to	  
increase	  protein	  yield.	  	  
	  
	   There	   are	   at	   least	   two	   possible	   reasons	   for	   the	   comparatively	   less	  
filaggrin	   found	   in	   the	   tape	   strips	   of	   AD	   subjects.	   Firstly,	   it	   could	   be	   that,	   for	  
reasons	   as	   yet	   unknown,	   tape	   stripping	   of	   AD	   skin	   does	   not	   extract	   as	  much	  
filaggrin	   compared	   to	   tape	   stripping	   non-­‐AD	   skin.	   A	   second	   more	   likely	  
explanation	   is	   that	   there	   is	   simply	   less	   filaggrin	   present	   in	   AD	   skin.	   This	   has	  
been	  previously	  observed	  in	  at	  least	  two	  studies.	  In	  1996,	  Seguchi	  et	  al	  obtained	  
skin	  biopsies	  from	  12	  AD	  and	  12	  non-­‐AD	  subjects	  and	  found	  that	  the	  amount	  of	  
filaggrin	   was	   significantly	   less	   in	   the	   AD	   skin	   samples	   [113].	   This	   study	   was	  
conducted	   prior	   to	   the	   establishment	   of	   the	   association	   between	   AD	   and	  
filaggrin,	   and	   also	   predated	   the	   ability	   to	   analyse	   for	  FLG	  mutations.	   As	   such,	  
with	   the	   absence	   of	   any	   genotype	   information	   on	   the	   AD	   subjects,	   it	   is	  
impossible	   to	   draw	   any	   firm	   conclusion	   from	   this	   study	   apart	   from	   the	  
suggestion	   that	   filaggrin	   protein	   expression	   is	   generally	   reduced	   in	   AD	  
individuals.	  More	  recently,	  Howell	  et	  al	  also	  studied	  filaggrin	  expression	  in	  AD	  
individuals	   [115].	   Importantly,	   all	   the	   subjects	   in	   this	   study	   were	   FLG	  
genotyped.	  They	  demonstrated	  that	  both	  filaggrin	  protein	  and	  gene	  expressions	  
were	   decreased	   in	   AD	   subjects	   compared	   to	   non-­‐AD	   subjects.	   They	  
subsequently	  showed,	  using	  primary	  keratinocytes	  in	  vitro,	  that	  this	  decrease	  in	  
filaggrin	  could	  be	  partly	  attributed	  to	  the	  over-­‐expression	  of	  TH2	  cytokines	  that	  
act	   to	   down-­‐regulate	   filaggrin	   expression.	   The	   authors	   did	   not	   specifically	  
comment	   on	   the	   difference	   in	   filaggrin	   protein	   expression	   between	   the	   AD	  
subgroups,	   but	   analysing	   their	   data	   revealed	   that	   filaggrin	   protein	   expression	  
was	   significantly	   reduced	   in	  AD	   FLG	  wild-­‐types	   compared	   to	  non-­‐AD	  subjects,	  
and	   also	   reduced	   in	   AD	   FLG	   heterozygotes	   compared	   to	   non-­‐AD	   subjects.	  
Interestingly,	   there	   was	   no	   significant	   difference	   noted	   in	   filaggrin	   protein	  
expression	   between	   AD	   subjects	   who	   were	   FLG	   wild-­‐type	   and	   FLG	  
heterozygous.	   To	   date,	   there	   is	   already	   convincing	   evidence	   that	   individuals	  
who	  are	  homozygous	  or	  compound	  heterozygous	   for	   the	  FLG	  mutation	  do	  not	  
express	   functional	   filaggrin	   in	   their	   skin,	   and	   that	   individuals	   who	   are	   FLG	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heterozygotes	  express	  less	  filaggrin	  [23,	  73].	  Results	  from	  this	  structural	  study	  
and	   those	   from	   Howell	   et	   al	   show	   that	   AD	   individuals,	   even	   if	   they	   do	   not	  
possess	  any	  FLG	  mutations,	  express	  less	  filaggrin	  protein	  in	  their	  skin.	  Although	  
this	   rather	   unexpected	   finding	   was	   interesting,	   the	   consequence	   was	   the	  
inability	   to	   extract	   sufficient	   filaggrin	   from	   the	   skin	   of	   AD	   subjects	   with	   tape	  
stripping.	  This	  prevented	  any	   subsequent	   comparison	  of	   the	   filaggrin	  primary	  
structure	   between	   AD	   and	   non-­‐AD	   skin.	   Nonetheless,	   this	   finding	   of	   reduced	  
filaggrin	  expression	  in	  AD	  skin	  could	  offer	  a	  possible	  explanation	  for	  why	  wild-­‐
type	  AD	   individuals	  develop	  AD	  while	  non-­‐AD	   individuals	  do	  not.	   It	   raises	   the	  
possibility	   that	  wild-­‐type	  AD	  could	  have	  a	  primary	   immunological	  dysfunction	  
that	   secondarily	   result	   in	   reduced	   filaggrin	   expression	   and	   impaired	   skin	  
barrier.	   As	   such,	   the	   clinical	   phenotype	   of	   AD	   may	   result	   from	   different	  
pathophysiological	  mechanisms	  -­‐	  one	  initiated	  by	  a	  FLG	  defective	  barrier	  failure	  
in	   which	   secondary	   immunological	   changes	   occur,	   and	   the	   other	   a	  
predominantly	   immunologically-­‐mediated	  disease	   in	  which	   cytokines	   released	  
into	  the	  skin	  reduce	  barrier	  function.	  	  
	  
	   The	  MS	  analysis	  of	  tryptic-­‐digests	  rely	  on	  matching	  experimental	  peptide	  
masses	  against	   theoretical	  peptide	  masses	   from	   in	  silico-­‐digested	   filaggrin	   in	  a	  
protein	  database.	  Within	  the	  NCBInr	  protein	  database	  that	  was	  used	  exclusively	  
in	  this	  study,	   there	   is	  an	  entry	  for	  the	  human	  profilaggrin	  consensus	  sequence	  
(RefSeq	  NP_002007,	  shown	  in	  Figure	  6.6)	  that	   is	   inaccurately	  called	   'filaggrin'.	  
This	   contains	   the	   sequences	   for	   the	   N-­‐	   and	   C-­‐termini,	   and	   10	   full	   filaggrin	  
repeats.	   The	   10	   filaggrin	   repeats	   are	   flanked	   by	   two	   partial	   filaggrin	   repeats	  
(marked	  by	  blue	  font	  in	  Figure	  6.6)	  that	  contain	  areas	  of	  high	  homology	  to	  the	  
full	   filaggrin	   repeats.	   The	   linker	   peptide	   sequence	   RSGRSGSFLY	   is	   arbitrarily	  




































































Figure 6.6 Consensus sequence of human profilaggrin, based on RefSeq NP_002007. This 
shows 10 full filaggrin repeats (marked by alternate use of bold type and and regular type), 
flanked by two partial filaggrin sequences (marked by blue font) that contain areas of high 
homology to the full repeats 1-10. The linker peptide sequence RSGRSGSFLY is arbitrarily 
assigned as the start of each repeat.  
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   Apart	   from	   the	   complete	   profilaggrin	   sequence	  RefSeq	  NP_002007,	   the	  
NCBInr	   protein	   database	   also	   contains	   16	   other	   entries	   for	   'profilaggrin'	   or	  
'filaggrin'.	  All	   these	   are	   truncated	   segments	  of	   the	  profilaggrin	   sequence,	  with	  
most	   containing	   the	   sequence	   of	   either	   one	   incomplete	   filaggrin	   repeat,	   or	  
several	   full	   filaggrin	   repeats.	   For	   instance,	   the	   entry	   'filaggrin,	   isoform	  CRA_a'	  
(NCBInr	   accession	   number	   EAW53383)	   contains	   the	   sequence	   for	   the	   N-­‐
terminus	  and	  almost	  the	  entire	  first	  and	  second	  filaggrin	  repeats.	  The	  presence	  
of	  these	  various	  entries	  of	  'profilaggrin'	  and	  'filaggrin'	  in	  the	  protein	  databases	  
frequently	   complicated	   the	   interpretation	   of	   MS	   search	   results.	   This	   was	  
because	   samples	   were	   often	   matched	   to	   different	   truncated	   forms	   of	  
profilaggrin,	   producing	   variable	   MOWSE/MASCOT	   scores	   with	   different	  
percentage	  coverages.	  Logically,	  the	  tryptic-­‐digest	  of	  a	  filaggrin	  sample	  that	  was	  
matched	   to	   the	  complete	  profilaggrin	  sequence	  would	  have	  a	   lower	  score	  and	  
lower	   percentage	   coverage	   than	   if	   it	   were	   matched	   to	   a	   shorter	   (and	  
incomplete)	   profilaggrin	   sequence	   in	   the	   database.	   As	   a	   result,	   direct	  
comparison	  of	  search	  results	  between	  samples	  were	  frequently	  not	  possible.	  
	  
	   Another	   issue	   with	   the	   current	   protein	   databases	   stems	   from	   the	  
significant	  heterogeneity	  of	  filaggrin.	  A	  comparison	  of	  the	  amino	  acid	  sequences	  
of	   the	   10	   filaggrin	   repeats	   from	   RefSeq	   NP_002007	   clearly	   reveals	   the	  
significant	  heterogeneity	  of	  the	  protein.	  To	  illustrate	  this,	  Figure	  6.7	  shows	  the	  
consensus	  sequence	  of	  a	  single	  filaggrin	  repeat	  together	  with	  all	  the	  alternative	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Figure 6.7 Amino acid sequence of human filaggrin which contains 324 amino acids. 
Alternative amino acids (in blue) noted from the comparison of the 10 full filaggrin repeats in 
RefSeq NP_002007 are displayed below the consensus sequence.  
	  
	  
	   As	   the	   alternative	   amino	   acids	   noted	   in	   Figure	   6.7	   are	   from	   only	   one	  
single	  individual,	  it	  is	  highly	  likely	  that	  other	  alternative	  amino	  acids	  exist	  that	  
are	   not	   currently	   reflected	   in	   the	   protein	   databases.	   This	   may	   lead	   to	  
experimental	   filaggrin	   peptides	   with	   alternative	   sequences	   either	   not	   being	  
matched	  to	  filaggrin	  in	  the	  databases,	  or	  matched	  weakly.	  One	  possible	  solution	  
is	  to	  sequence	  the	  FLG	  gene	  in	  a	  large	  cohort	  of	  individuals	  to	  assemble	  a	  more	  
comprehensive	   database	   that	   better	   reflects	   the	   alternative	   sequences	   of	  
filaggrin.	  However,	   the	  present	   technical	  difficulty	   in	   fully	   sequencing	   the	  FLG	  
gene	  due	  to	  its	  large	  size	  and	  repetitive	  nature	  of	  the	  filaggrin	  units	  makes	  this	  
currently	  impractical.	  	  
	  
	   In	  summary,	  this	  structural	  study	  has	  demonstrated	  that	  it	  is	  possible	  to	  
extract	   filaggrin	   using	   tape	   strips	   for	   structural	   studies	   using	   MS	   techniques.	  
The	  use	  of	   tape	   stripping,	  which	   is	   a	  much	   less	   invasive	  method	   compared	   to	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skin	   biopsies,	   will	   make	   it	   more	   feasible	   and	   practicable	   to	   study	   filaggrin	  
protein	  directly	   from	   the	  SC.	   It	   is	  disappointing	   that	   an	   inadequate	  amount	  of	  
filaggrin	  was	  obtained	  from	  all	  the	  AD	  samples	  to	  allow	  for	  any	  comparison	  of	  
filaggrin	   structure	   between	   AD	   and	   non-­‐AD	   samples.	   With	   the	   apparently	  
limited	  amount	  of	   filaggrin	  present	   in	  AD	   skin,	   it	   seems	   that	   the	  only	  ways	  of	  
obtaining	   sufficient	   filaggrin	   from	   AD	   individuals	   would	   be	   to	   either	  
significantly	   increase	   the	   number	   of	   tape	   strips	   used,	   or	   to	   extract	   from	   the	  
large	   amount	   of	   normal	   skin	   following	   breast	   reduction	   procedures	   or	  
abdominoplasties.	   Our	   initial	   strategy	   was	   to	   use	   a	   data	   analysis	   programme	  
called	  Progenesis	   LC-­‐MS	   (NonLinear	  Dynamics)	   that	   can	   reliably	   quantify	   and	  
compare	  the	  peaks	  in	  filaggrin	  tryptic-­‐digest	  samples	  in	  order	  to	  see	  if	  there	  are	  
any	   structural	   differences	   between	   filaggrin	   protein	   found	   in	   AD	   and	   non-­‐AD	  
individuals.	  Preliminary	  runs	  had	  shown	  that	  the	  programme	  could	  rapidly	  and	  
reliably	  identify	  the	  peptide	  peaks	  in	  our	  samples,	  but	  there	  was	  insufficient	  MS	  
data	   in	   any	  of	   the	  AD	   samples	   to	   allow	   for	   accurate	   comparison.	  Nonetheless,	  
this	   study	   has	   confirmed	   the	   heterogeneity	   of	   filaggrin	   protein,	   even	  within	   a	  
single	   individual,	   and	   has	   also	   shown	   that	   filaggrin	   protein	   is	   only	  minimally	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7.0	   GENERAL	  DISCUSSION	  AND	  FUTURE	  PERSPECTIVES	  
	  
	   Clinically,	   the	  most	   striking	   features	   of	   AD	   are	   erythema,	   pruritus	   and	  
inflammation,	  generally	  in	  association	  with	  elevated	  IgE.	  Correspondingly,	  most	  
previous	  research	  on	  AD	  had	  postulated	  immunological	  dysfunction	  as	  the	  key	  
underlying	   aetiological	   factor.	   However	   subsequent	   to	   the	   discovery	   of	   the	  
exceptionally	   strong	   association	   between	  FLG	  mutations	   and	   AD,	   there	  was	   a	  
significant	  shift	  in	  our	  understanding	  of	  the	  aetiology	  of	  the	  disease.	  McLean	  and	  
colleagues	   hypothesize	   that	   the	   absence	   of	   filaggrin	   leads	   to	   a	   defect	   in	   the	  
barrier	   function	  of	  the	  skin,	  and	  that	  this	  secondarily	  allows	  enhanced	  antigen	  
presentation	   to	   the	   immune	   system.	   Therefore,	   according	   to	   this	   'Barrier	  
Hypothesis',	   the	  inflammation	  and	  immunological	  changes	  of	  AD	  (and	  possibly	  
that	  of	  asthma	  and	  hay	  fever)	  are	  consequent	  upon	  this	  antigen	  exposure.	  	  
	  
	   One	   of	   the	  main	   focuses	   of	   this	   thesis	  was	   a	   functional	   study	   aimed	   at	  
determining	   whether	   FLG	   mutations	   correlated	   with	   altered	   skin	   barrier	  
function	  in	  AD	  subjects.	  This	  study	  showed	  that	  FLG	  mutations	  correlated	  with	  
higher	  TEWL	  and	  fewer	  number	  of	  tape	  strips	  required	  to	  abrogate	  skin	  barrier,	  
thus	  providing	  strong	  evidence	  of	  an	  association	  between	  FLG	  variants	  and	  skin	  
barrier	  dysfunction,	  although	  the	  clinical	  relevance	  of	   this	  was	  uncertain	  since	  
FLG	   variants	  were	   not	   found	   to	   be	   associated	  with	   AD	   severity	   in	   this	   study.	  
Nonetheless,	   as	   mentioned	   earlier,	   this	   lack	   of	   association	   between	   FLG	  
mutations	  and	  AD	  severity	  could	  be	  due	  to	  the	  fact	  that	  only	  mild	  and	  moderate	  
AD	   subjects	   were	   recruited	   for	   this	   study.	   Certainly,	   previous	   studies	   had	  
suggested	  that	  filaggrin-­‐related	  AD	  might	  be	  associated	  with	  increased	  severity	  
in	   childhood	   [22,	   120],	   as	   well	   as	   AD	   with	   an	   early	   onset	   that	   persists	   into	  
adulthood	  [31].	  In	  summary,	  the	  results	  from	  this	  study	  suggest	  that	  it	  might	  be	  
possible	   to	   stratify	   AD	   phenotype	   by	   FLG	   genotype,	   with	   filaggrin-­‐related	   AD	  
likely	   to	   exhibit	   poorer	   skin	   barrier	   and	   possibly	   run	   a	   more	   severe	   disease	  
course.	  Thus,	  there	  is	  potentially	  prognostic	  value	  in	  determining	  FLG	  status	  in	  
AD	  patients.	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   There	  was	   also	   a	   secondary	   aim	   in	   this	   functional	   study,	  which	  was	   to	  
test	   the	   hypothesis	   that	   corneocytes	   were	   less	   adherent	   to	   one	   another	   in	  
filaggrin-­‐related	   AD	   compared	   to	   wild-­‐type	   AD	   skin.	   This	   was	   to	   test	   a	  
hypothesis	  developed	  from	  an	  unexpected	  finding	  reported	  by	  Nemoto-­‐Hasebe	  
et	   al	   [244],	  who	   showed	   that	   SC	   thickness	  was	   greater	   in	   filaggrin-­‐related	  AD	  
compared	   to	   wild-­‐type	   AD	   skin.	   To	   possibly	   explain	   this	   finding,	   it	   was	  
hypothesised	   in	   this	   study	   that	   corneocytes	   in	   filaggrin-­‐related	   AD	   skin	  were	  
less	   adherent	   to	   one	   another	   (that	   is,	   less	   densely	   packed),	   which	   should	  
translate	  to	  more	  corneocytes	  (and	  therefore	  more	  protein)	  being	  removed	  by	  
each	   tape	  strip.	   Indeed,	   this	  study	  showed	   that	  significantly	  more	  protein	  was	  
extracted	   from	   filaggrin-­‐related	   AD	   compared	   to	   wild-­‐type	   AD	   skin,	   lending	  
support	  to	  this	  hypothesis.	  This	  was	  also	  consistent	  with	  another	  observation	  in	  
this	  study	  showing	  that	  fewer	  tape	  strips	  were	  required	  to	  abrogate	  skin	  barrier	  
in	   filaggrin-­‐related	  AD	  skin,	  since	   less-­‐adherent	  SC	  cells	  would	  mean	  that	   they	  
would	  be	  easier	   to	  remove	  with	  subsequent	   loss	  of	  skin	  barrier.	  However,	   the	  
sample	  size	  for	  this	  analysis	  was	  small,	  with	  only	  four	  filaggrin-­‐related	  AD	  and	  
four	   wild-­‐type-­‐AD	   samples	   analysed.	   Thus,	   this	   finding	   would	   benefit	   from	  
further	  validation	  by	  extending	  the	  cohort	  size.	  
	  
	   The	   second	   main	   focus	   of	   this	   thesis	   was	   a	   structural	   study	   aimed	   at	  
interrogating	   the	   structure-­‐function	   relation	   of	   filaggrin.	   Up	   to	   about	   half	   of	  
individuals	   with	   AD	   do	   not	   possess	   FLG	   mutations	   and	   it	   is	   not	   known	   if	  
filaggrin	  in	  these	  wild-­‐type	  AD	  subjects	  is	  structurally	  similar	  to	  that	  in	  non-­‐AD	  
individuals.	   Any	   structural	   differences	   between	   the	   two	   groups	   may	   provide	  
insight	  into	  why	  one	  group	  develops	  the	  disease	  while	  the	  other	  does	  not.	  This	  
study	   utilised	   two	   MS	   techniques	   (MALDI-­‐TOF	   MS	   and	   nano	   LC-­‐MS/MS)	   to	  
analyse	   filaggrin	   in	   both	   its	   intact	   and	   tryptic-­‐digest	   states.	   Analysis	   of	   intact	  
filaggrin	   from	  non-­‐AD	  subjects	   confirmed	   the	  heterogeneic	  nature	  of	   filaggrin,	  
even	  within	   a	   single	   individual;	  while	  MS	  analysis	   of	   non-­‐AD	   filaggrin	   tryptic-­‐
digests	  yielded	  good	  mass	  spectra.	  However	  none	  of	  the	  MS	  analysis	  of	  filaggrin	  
from	   AD	   subjects	   yielded	   any	   interpretable	   results,	   with	   the	   mass	   spectra	  
obtained	  by	  both	  MS	  techniques	  suggesting	  that	  filaggrin	  was	  either	  absent	  or	  in	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too	  minute	  an	  amount	  for	  detection.	  This	  was	  confirmed	  by	  immunoblotting	  of	  
the	   initial	   SC	   extracts	   of	   all	   AD	   samples	   (regardless	   of	   their	   genotype)	  which	  
showed	   less	   filaggrin	  extracted	  compared	   to	  non-­‐AD	  samples.	  Additionally,	  no	  
filaggrin	   was	   immunodetected	   in	   any	   of	   the	   final	   purified	   AD	   samples.	   A	  
consequence	  of	  this	  reduced	  amount	  of	  filaggrin	  extracted	  from	  AD	  subjects	  was	  
the	   inability	   to	  make	  any	  structural	   comparison	  between	   the	  protein	   from	  AD	  
and	   non-­‐AD	   skin.	   	   Nonetheless,	   this	   was	   an	   interesting	   finding	   in	   itself,	   and	  
could	   offer	   an	   explanation	   for	   why	   wild-­‐type	   AD	   individuals	   develop	   the	  
disease.	  This	  reduced	  filaggrin	  in	  AD	  skin	  could	  partly	  be	  attributed	  to	  an	  over-­‐
expression	  of	  TH2	  cytokines	  that	  had	  previously	  been	  shown,	  in	  vitro,	  to	  down-­‐
regulate	   filaggrin	   expression	   [115].	  Therefore,	   it	   is	   possible	   that	  wild-­‐type	  AD	  
could	   have	   a	   primary	   immunological	   dysfunction	   that	   secondarily	   result	   in	  
reduced	   filaggrin	   expression	   and	   impaired	   skin	   barrier.	   As	   such,	   the	   clinical	  
phenotype	   of	   AD	   may	   result	   from	   different	   pathophysiological	   mechanisms	   -­‐	  
one	   initiated	   by	   a	   FLG	   defective	   barrier	   failure	   in	   which	   secondary	  
immunological	  changes	  occur,	  and	  the	  other	  a	  predominantly	  immunologically-­‐
mediated	   disease	   in	   which	   cytokines	   released	   into	   the	   skin	   reduce	   barrier	  
function.	  	  
	  
	   Part	  of	  this	  structural	  study	  also	  involved	  developing	  and	  optimising	  the	  
extraction	   and	  purification	   of	   filaggrin,	   as	   sufficient	   amount	   of	   relatively	   pure	  
filaggrin	   was	   required	   for	   MS	   analysis.	   Traditionally,	   discarded	   skin	   from	  
procedures	  such	  as	  breast	  reduction	  surgery	  and	  abdominoplasty	  is	  used	  in	  skin	  
research,	  since	  these	  provide	  a	  large	  amount	  of	  healthy	  skin.	  In	  this	  study,	  tape	  
stripping	  was	   trialled	   for	   the	   first	   time	   as	   a	  mean	  of	   filaggrin	   extraction.	   This	  
was	  a	  minimally-­‐invasive	  and	  quick	  method	  of	  extracting	  SC	  cells,	  and	  has	   the	  
great	  advantage	  of	  allowing	  for	  repeated	  extraction	  from	  the	  same	  individual.	  	  
	  
	   Soon	   after	   commencing	   this	   study,	   it	   became	   clear	   that	   there	   were	  
practical	   benefits	   to	   having	   a	   relatively	   quick	   screening	   test	   to	   detect	   and	  
quantify	  filaggrin	  in	  the	  skin.	  One	  major	  benefit	  of	  such	  a	  test	  was	  the	  obviation	  
of	   expensive	   and	   time-­‐consuming	   genotype	   testing	   for	   individuals	   that	   were	  
	  109	  
unlikely	   to	   possess	   any	   FLG	   mutation.	   In	   the	   absence	   of	   any	   commercially-­‐
available	   filaggrin-­‐specific	  ELISA	  at	   that	   time,	   a	  novel	  one	  was	  developed	   that	  
could	  quantify	  filaggrin	  with	  a	  detection	  sensitivity	  of	  approximately	  30	  ng/ml.	  	  
Given	  more	  time	  and	  resources,	  particularly	  with	  the	  commercial	  availability	  of	  
many	   more	   new	   filaggrin	   antibodies,	   the	   'sandwich'	   ELISA	   that	   was	   initially	  
being	   developed	   could	   be	   made	   more	   specific,	   which	   should	   improve	   the	  
detection	  sensitivity.	  
	  
	   In	   summary,	   this	   study	   has	   provided	   greater	   insight	   into	   the	   role	   of	  
filaggrin	  in	  skin	  barrier	  function	  and	  AD.	  The	  discovery	  of	  mutations	  in	  a	  single	  
gene	  underlying	  up	  to	  around	  half	  of	  AD	  cases	  has	  been	  one	  of	  the	  most	  exciting	  
recent	  genetic	  findings	  in	  dermatology.	  Unsurprisingly,	  this	  has	  generated	  a	  lot	  
of	   research	   interest	   in	   filaggrin.	   Work	   is	   continuing	   in	   this	   lab	   to	   study	   the	  
exceptionally	  strong	  link	  between	  filaggrin	  and	  AD.	  This	  includes	  analysing	  the	  
effects	  of	  FLG	  mutations	  on	  epidermal	  dendritic	  cell	  populations	  as	   these	  cells	  
initiate	  epidermal	   immune	  responses,	  and	  the	  susceptibility	  of	  FLG	  variants	   to	  
irritant	   and	   allergic	   contact	   dermatitis.	   In	   addition,	   as	   there	   have	   been	  
suggestions	   that	   measuring	   baseline	   skin	   barrier	   function	   may	   provide	   an	  
incomplete	  assessment	  of	  barrier	  integrity	  [257],	  future	  work	  will	  analyse	  acute	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